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ABSTRACf 
Successful implantation and placentation during pregnancy depend on the regulated 
expression of trophoblast-associated protease activity. One of the proteolytic mecllanisms 
utilized by trophoblasts is plasmin generation which is thought to be involved in 
trophoblast invasion and control of placental fibrin deposition. In this study., the 
production and regulation of plasminogen activator (PA) activity by human villous 
trophoblasts were investigated 
Primary trophoblast cultures were established from normal human term placentas. 
Highly purified villous cytotrophoblasts were isolated through sequential trypsin-DNase 
digestions of the selected villous tissue.., followed by Percoll density gradient centrifugation 
and subsequent removal of contaminating cells using monoclonal antibodies to 
monomorphic determinants of HLA class I and class II antigens. When placed in culture., 
the isolated cells were characterized as being cytokeratin positive, vimentin, In..A-ABC., 
HLA-DR and CD68 negative. In about 48 hours the majority of the cytotrophoblasts 
transformed into syncytiotrophoblasts. The cultures were functionally viable as assessed 
by their capacity for hCG secretion and reductive cleavage of MTI. No significant 
cytotrophoblast cell proliferation could be demonstrated in 3H-thymidine uptake 
experiments., and trophoblasts at their syncytiotrophoblastic stage did not proliferate at all. 
When the expression of plasminogen activators and their specific inhibitors in vitro 
was compared with m vivo findings7 distinct differences were found. 
Immunocytochemical studies in term placental tissue showed strong syncytial PAI-2 
ii 
immunoreactivity and faint to moderate PAI-l staining. No staining could be 
demonstrated for either u-P A or t-PA. In contrast, the majority of cultured trophoblasts 
expressed u-PA during the first 24 hours of culture. All forms of trophoblast 
(mononuclear trophoblasts, multinuclear aggregates and syncytiotrophoblasts) expressed 
PAI-l, but only occasional syncytiotrophoblasts stained positively for PAI-2 and no t-PA 
im.mtmoreactive trophoblasts were observed. Trophoblast-secreted PAI-l could also be 
detected in conditioned media by ELISA. 
Activation of plasminogen was measured by monitoring the converSion of 
exogenously added Glu-plasminogen to plasmin in serum-free trophoblast cultures, using 
a chromogenic plasmin substrate H-D-V al-Leu-Lys-pNA (S-2251 ). Plasminogen activation 
by trophoblasts followed Michaelis-Menten type kinetics and produced parabolic progress 
curves of pNA accumulation that could be transformed to linear progress curves of 
plasmin generation, the slopes of which yielded constant rates of plasmin generation (i.e. 
PA activity). Trophoblast-associated plasminogen activation was found to originate from 
u-P A but not t-PA, because plasmin generation was markedly reduced in the presence of 
a neutralizing antibody to u-PA but not appreciably in the presence of a neutralizing 
antibody to t-PA. In addition, trophoblasts enhanced plasminogen activation induced by 
exogenous pro-u-PA~ suggesting that cell surface binding of pro-u-PA potentiates the 
generation of plasmin. The basal level of endogenous trophoblast PA activity was 
specifically augmented by a neutralizing antibody to PAI-l, indicating that trophoblast-
secreted PAI-l regulates PA activity in an autocrine manner. Consistent with this fmding~ 
w 
physiological concentrations of exogenous PAI-l and PAI-2 resulted in a dose-dependent 
inhibition of PA activity. 
In order to define modulators of trophoblast-associated PA activity, several types 
of molecules were tested Activated protein C (APC) increase<L whereas thrombin 
decreased PA activity, demonstrating that the coagulation system has the potential to 
modulate trophoblast plasminogen activation. Among growth factors/cytokines., EGF and 
its structural analog TGF-a proved to be potent stimulators. A neutralizing antibody to 
EGF did not have an eff~ suggesting that term trophoblast cultures do not produce a 
sufficient quantity of EGF to modulate PA activity. TGF-~., IGF-11 and IL-lf3 did not 
change PA activity appreciably., nor did LPS, a known stimulator of ll..-1 secretion. With 
respect to hormones., dexamethasone and hCG had an inhibitory effect. Agents that 
elevate intracellular cAMP levels (8-bromo-cAMP and forskolin) inhibited plasminogen 
activation, whereas PMA had no appreciable effect. 
Taken together., this study demonstrates that the human term villous trophoblast 
possesses a highly regulated plasminogen activation system., and various types of 
physiologically important molecules including enzymes, growth factors, steroid and 
peptide hormones modulate the generation of trophoblast-associated plasmin. 
lV 
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CHAPTER.1 
INTRODUCDON: PlASMINOGEN ACfiVATION AND 
THE PlACENTAL TROPHOBLAST 
1.1 THE PlASMINOGEN ACOVATION SYSTEM 
Plasminogen activators (PAs) are serine proteases that convert the inactive 
plasminogen to plasmin. Two types of physiological PAs are known: tissue-type (t-PA) 
and urokinase-type (u-PA). The PAs are involved in a variety of biological processes 
associated with fibrinolysis and/or degradation of the extracellular matrix., such as 
thrombolysis., postlactation involution., ovulation, trophoblast invasion, cell migration, 
inflammation., angiogenesis., tumor invasion and metastasis etc. (Dana et al., 1985; Mayer, 
1990). Plasminogen activation occurs as a result of concerted interactions between the 
components of the plasminogen activation system. The system includes: ( 1) plasminogen 
and plasmin, (2) PAs, (3) inhibitors of plasmin and PAs., and (4) receptors for 
plasmin(ogen) and PAs (Mayer, 1990). 
1.1.1 Plasminogen and plasmin 
Plasminogen is an inactive proenzyme (zymogen) of the fibrinolytic enzyme 
plasmin. It is widely distributed in various extracellular fluids and in plasma where its 
concentration has been found to be about 1.5 to 2 J,LM (Lijnen and Collen .. 1982; Dana et 
al . ., 1985). Plasminogen is primarily produced in the liver (Saito et al . ., 1980; Raum et al., 
1980), albeit other sites for its synthesis have also been reported (Val.insky and Reich, 
1981; Saksela and Vihko, 1986). 
Native human plasminogen (also called Gin-plasminogen after its N-terminal 
2 
glutamic acid) is a single chain glycoprotein with a molecular mass of 92 kDa that 
consists of 791 amino acids (Halkier, 1991 ). It exists in two differently glycosylated forms 
denoted Glu-plasminogen I and Glu-plasminogen II (Castellino and Powell, 1981 ). From 
the N-terminus, Glu-plasminogen is built up of a preactivation peptide, five sequential 
kringle domains, a connecting strand followed by the serine proteinase domain. The 
connecting strand contains the peptide bond Arg561-Val562 cleaved by plasminogen 
activators (t-PA and u-PA) when plasminogen is activated to plasmin (Halkier, 1991~ 
Lijnen et al., 1994 ). The kringle domains possess lysine binding sites (LBS) that mediate 
the binding of plasminogen to lysine residues of fibrin or cell surfaces (Angles-Cano, 
1994 ). During plasminogen activation, Glu-plasminogen may be converted to Lys-
plasm.inogen by plasmin-catalyzed release of the preactivation peptide (Lijnen et al., 
I 994 }. This conversion alters the conformation (Violand et al., 1978) and binding 
characteristics (Lucas et al., 1983) of the native molecule and thus, activation of Lys-
plasminogen to Lys plasmin progresses at a much higher rate than that of Glu-
plasminogen (Hoylaerts et al., 1982}. Glu-plasm.in may also be convened to Lys-plasmin 
by autocatalysis (DmuJ et al., 1985). 
Plasmin is a broad-spectrum trypsin-like serine protease capable of degrading fibrin 
as well as several extracellular matrix and basement membrane proteins such as 
fibronectin, laminin and thrombospondin. Part of its proteolytic effect is exerted through 
activation of other enzymes such as latent metalloproteinases and pro urokinase (PolHinen 
et al., 1991 ). 
3 
Plasmin consists of two polypeptide chains held together by two disulfide bridges. 
The heavy chain or A-chain originating from the N-terminal part of the plasminogen 
molecule contains the kringles with the LBS and therefore is responsible for binding to 
fibrin or cells. The light chain or B-chain corresponding to the C-terminal part of 
plasminogen contains the active site that is composed of His602., Asp645 and Ser740 
(Pollanen et al . ., 1991 ~ Collen., 1980). 
1.1.2 Plasmin inhibitors 
Plasmin is inhibited by several protease inhibitors occurring in plasma Among 
them the most important is ~-antiplasmin (~-plasmin inhibitor), a 67 kDa single chain 
glycoprotein consisting of 452 amino acids (Halkier., 1991 )., which migrates as an ~­
globulin on electrophoresis (Wiman., 1981). It is synthesized in the liver and has a plasma 
concentration of approximately l ~ (Aoki and Harpel., 1984 ). Alph~-antiplasm.in 
belongs to the serine proteinase inhibitor superfamily (serpins). The reactive site of the 
inhibitor is at Arg364-Met365 (Halkier., 1991 ). Alph~-antiplasmin has two forms in 
normal human plasma (Clemmensen et al .• 1981 ): the native form binds plasminogen., 
whereas another modified form does not., because it lacks a C-terminal peptide (Sasaki et 
al... 1986) that contains a second site for interaction with plasmin( ogen) in addition to the 
reactive center. Alph~-antiplasmin establishes stable I: 1 stoichiometric complexes with 
plasmin leading to extremely efficient inhibition. The high inhibition rate is the result of 
interactions between (1) the reactive site of the inhibitor and the active site of plasmin., 
and (2) the carboxy terminal end of ~-antiplasmin and the LBS of kringle 1 of plasmin 
4 
(Angles-Cano~ 1994 ). Due to the latter interaction~ ~-antiplasmin is much less effective 
towards the enzyme in the presence of lysine analogues (Wiman and Collen~ 1978; 
Christensen and Clemmensen 1978). Although ~-antiplasmin rapidly inhibits plasmin in 
solution~ plasmin botm.d to fibrin or cell surfaces appears to be resistant to inhibition. In 
this situation~ the LBS of kringles in plasmin are occupied by lysine residues of fibrin or 
cell membranes preventing ~-antiplasmin from binding to and inhibiting plasmin (Angles-
Cano., 1994 ). Fibrinogen possesses a crosslinking site for ~-antiplasmin . Crosslinking 
occurs between Gln-2 of ~-antiplasmin and a lysine residue of the a-chain offibrin(ogen) 
and is catalyzed by factor Xllla (Kimura and Aoki., 1986). 
Another inhibitor of plasmin is <X.z-macroglobulin. Human ~-macroglobulin is a 
glycoprotein of Mr 725.,000. The purified protein consists of a tetramer of identical 
subunits of Mr -185,000~ each containing approximately 1450 amino acids linked in pairs 
by disulfide bonds. Two pairs associate by noncovalent binding to form the native .. 
tetrameric molecule (Travis and Salvesen~ 1983 ). Alph3:1-macroglobulin is synthesized by 
liver cells, mononuclear phagocytes and fibroblasts (Saksela, 1985). Its plasma 
concentration is 2.5 giL (3 J,LM). It has a very broad specificity. With respect to the 
fibrinolytic syst~ it inactivates tcu-PA~ t-PA, u-P A and plasmin at relatively slow rates 
(Bachmann., 1994a). Alph3:1-macroglobulin is the slower-reacting plasmin inhibitor in 
plasma and is thought to have a significant role in the inactivation of plasmin tmder 
conditions when ~-antiplasmin is depleted (Collen., 1980). 
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1.1.3 Plasminogen activators 
Plasminogen activators are serine proteases that convert the zymogen plasminogen 
to the active protease plasmin. Two types of specific plasminogen activators have been 
defined: urokinase-type (u-P A) and tissue-type (t-PA) plasminogen activators (Dans et al.~ 
1985). 
t-PA has been named tissue plasminogen activator because it was found in tissue 
sections and extracts of various tissues. It has also been identified in blood plasma and 
body fluids (Dana et al.~ 1985 ). t-PA is synthesized as a 72 kDa single-chain 
glycoprotein. From theN-terminus~ the t-PA molecule is composed of a fmger domain~ 
a growth factor domain~ two kringle domains~ a connecting stran~ and a serine protease 
domain with the catalytic site comprised of His47~ Asp96 and Ser203. Conversion of 
single-chain t-PA (sct-PA) to two-chain t-PA (tct-PA) occurs upon plasmin catalyzed 
cleavage at Arg278-lle279 and at Arg3-Ser4. This cleavage results in a 36 kDa heavy 
chain derived from theN-terminus, and a light chain with a molecular mass of 32 kDa 
derived from the carboxy terminal part (Halkier ~ 1991 ). Current evidence indicates that 
unlike most single chain forms of serine proteases, single chain t-PA possesses significant 
catalytic activity {Andreasen et aL, 1991). 
Both forms of t-PA bind to fibrin. This binding is mediated by the second kringle 
and fmger domains oft-PA. There is~ however, disagreement on whether kringle 1 is also 
implicated in fibrin binding, and some authors claim that kringle 1 has a fibrin binding 
capability comparable to that of kringle 2 (Gaffney and Longstaff. 1994). The affmity of 
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t-PA for fibrin increases significantly in the presence of plasminogen. In this situation, 
formation of a ternary complex comprising t-PA, plasminogen and fibrin is likely to occur 
(Hoylaerts et al., 1982~ Collen and Lijnen, 1991 ). 
Fibrin strikingly enhances the activation rate of plasminogen by both single-chain 
and two-chain t-PA (Hoylaerts et al., 1982; Andreasen et al., 1991~ Collen and Lijnen., 
1991 ). Thus., a fast activation can take place on the fibrin clot., while no efficient 
activation occurs in plasma Enhancement of t-PA catalytic activity is not exclusive to 
fibrin., because other compotmds such as fibrin(ogen) fragments, polylysine., heparin and 
some denatured proteins are also able to bind and stimulate t-PA (Mayer, 1990). 
u-P A was discovered first in human urine, but was soon found in other body fluids 
and tissues (Dan0 et al., 1985 ). It is synthesized and secreted as a 50-54 kDa single-chain 
glycoprotein (scu-PA) containing 411 amino acid residues (Halkier, 1991). Scu-PA (also 
called pro-u-P A or pro-urokinase), unlike sct-PA., is considered to be a proenzyme. It 
appears to be the predominant extracellular form of u-P A (Skriver et al.., 1984; Kielberg 
et al . ., 1985), has little or no measurable activity (Gaffney and Longstaff, 1994)., and does 
not react with serine protease inhibitors (Andreasen et al.., 1986) or the active site titrant 
diisopropyl fluorophospbate (DFP) (Gurewich et al., 1984; Pannel and Gurewich, 1986). 
The low but significant intrinsic plasminogen activator activity (0.4% to 6% of the activity 
of two-chain u-P A) and amidolytic activity (ranging 0.1% to 0.4% of that of two-chain 
u-PA) reported by some authors (Gurewich et al., 1984; Pannell and Gurewich, 1986, 
1987; Ellis et al., 1987; Lijnen et al., 1989., 1990) may arise from small amot.mts of two-
7 
chain u-P A generated from scu-PA by traces of contaminating proteases (Husain,. 1991 ). 
The human u-PA gene is 6.4 kb long and located on chromosome 10. Starting 
from theN-terminus,. scu-PA is composed of an epidermal growth factor domain .. a single 
kringle domain,. a connecting peptide,. and a C-terminal serine proteinase domain 
(Bachmann,. 1994a). A low molecular weight variant of scu-PA (32 kDa) is produced by 
a metalloproteinase that cleaves the peptide bond between Glu143-Leu144 while the 
Lys158-lle159 bond remains intact (Stump et aL,. 1986; Marcotte et aL .. 1992). 
Conversion of scu-PA to the active two-chain u-P A (synonyms: tcu-PA or high molecular 
weight (Hl\4W) urokinase) occurs upon cleavage of the peptide bond Lys158-lle159 by 
any of several proteases such as plasmin,. trypsin,. plasma kallikrein,. cathepsin B and L, 
and factor XIIa (Bachmann.. 1994a, 1994b ). HMW urokinase which has a molecular 
weight of about 50-54 kDa (the same as that of scu-PA) possesses a 20 kDa light or A-
chain (residues 1-157) and a 30 kDa heavy orB-chain (residues 159-411) held together 
by a single disulfide bond. The A-chain holds the growth factor and kringle domains,. 
whereas the B-chain contains the serine protease domain with the catalytic triad of the 
active center (His46, Asp97 and Serl98 corresponding to His204,. Asp255 and Ser356 in 
scu-PA) (GOnzler et aL,. 1982; Bachmann, 1984a; Halkier,. 1991; Gaffney and Longstaff, 
1994). Further processing of HlVfW u-P A leads to A-chain terminal heterogeneity: fully 
active HlVfW u-PA in urine and tissue culture contains a C-terminal Phel57 {Giinzler et 
al.,. 1982a; Lenich et al 1991 ). In addition,. plasmin cleavage of HlVfW urokinase at 
Lysl35-Lysl36 results in a low molecular weight form (33 kDa) of two-chain urokinase 
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(LMW urokinase) whose B-chain is identical with that of HMW urokinase (residues 159-
411)~ but the •A-chain no longer contains the amino terminal fragment {ATF~ residues 1-
135) (Giinzler et al., 1982b; Gaffney and Longstaff~ 1994). 
Different molecular forms of u-PA possess distinct differences with respect to 
their activities and binding properties. In contrast to scu-PA~ HMW u-P A and LMW u-P A 
are highly active enzymes, whereas A TF that lacks the serine proteinase domain is 
catalytically inactive. Scu-PA, HMW u-PA and LMW u-PA are all used as therapeutical 
thrombolytics.,. but only scu-PA can induce clot-specific activation of plasminogen. The 
active urokinases have no fibrin specificity and activate fibrin-bound and circulating 
plasminogen relatively indiscriminately (Gurewich.,. 1989; Gaffney and Longstaff.,. 1994). 
The mechanism of clot-specific plasminogen activation by scu-PA is not clear. It is 
known that neither scu-PA nor tcu-PA have an affmity for fibrin. scu-PA, however~ binds 
with high affinity to plasminogen (Longstaff et al., 1992; Gaffney and Longstaff, 1994) 
which, in turn.,. can bind to fibrin. Fibrin enhances scu-PA or tcu-PA induced plasminogen 
activation.,. but this stimulation remains far below that observed for t-PA (Takada et al., 
1989; Liu and Gurewich, 1991 ), the primary plasminogen activator for physiological 
fibrinolysis. All forms of u-PA having the epidermal growth factor domain (scu-PA, 
HMW u-PA and ATF) bind to the cellular u-PA receptor. LMW u-PA, however, has no 
receptor binding capacity due to the lack of this domain (Vassalli et al., 1985; Blasi et al., 
1986). 
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1.1.4 lnbibitors of plasminogen activators 
One way of regulating plasminogen activator enzyme activity is through 
plasminogen activator inhibitors (PAis). The PAls are members of the serpin family of 
proteins (Kruithof,. 1988 ). Currently~ four distinct PAls are known. These include (I) 
plasminogen activator inhibitor type 1 (PAI-I )~ (2) plasminogen activator inhibitor type 
2 (PAI-2)~ (3) plasminogen activator inhibitor type 3 (PAI-3 or protein C inhibitor) and 
(4) protease nexin (Loskutoff et al.,. 1989~ Kruithof,. I988; Schleef and Loskutoff,. 1988). 
PAI-l and PAI-2 are considered to be the most important, highly specific PAis~ whereas 
PAI-3 and protease nexin have broader specificities. 
PAl- I was fust described in endothelial cell culture (Loskutoff and Edgington, 
1977; Loskutoff et al.,. 1983 ). Since then its occurrence has been reponed in numerous cell 
types (Kruithof~ I 988). It is also present in plasma. PAI- I is a Mr- 50 kDa single-chain 
glycoprotein (Ericson et al., I 984; van Mourik et al.~ 1984; Andreasen,. 1986) encoded by 
3.0 and 2.2 kb mRNAs (Ny et al.,. 1986; Ginsburg et al.,. 1986}. The human PAI-l gene 
is 12.2 kb long and located on chromosome 7. The PAI-l molecule contains 379 amino 
acid residues and some heterogeneity may exists at the amino terminus. Its reactive center 
is formed by the Arg346-Met347 bond The presence of methionine in the reactive center 
may explain its wtusual sensitivity to oxidants such as chloramine T,. N-chlorosuccinimide 
and hydrogen peroxide (Lawrence and Loskutoff,. 1986; Loskutoff et al.,. 1989). Another 
important feature is that PAI-I activity can still be detected after SDS-polyacrylamide gel 
electrophoresis wtder reducing conditions (van Mourik et aL. 1984 ). 
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PAI-l is secreted in an active form. Active PAI-l is tmstable and spontaneously 
converted into a stable inactive latent state unless its active conformation is stabilized 
(Loskutoff et al.,. 1989). Vitronectin is a binding protein for PAI-l and appears to 
stabilize PAI-l activity in both the plasma and extracellular matrix (Declerck et al.., 1988; 
Wiman et al., 1988; Mimuro and Loskutoff., 1989). Latent PAI-I can be reactivated with 
denaturants including KSCN., guanidine hydrochloride, SDS and urea (Hekman and 
Loskutoff, 1985). However, oxidatively inactivated PAI-l cannot be converted to active 
PAI-l by treatment with SDS, suggesting that latency does not result from oxidants 
(Lawrence and Loskutoff, 1986; Loskutoff et al ... 1989). PAI-l inhibits sct-PA .. tct-PA and 
tcu-PA by forming I: 1 molar complexes that resist dissociation by SDS, but it does not 
react with scu-PA (Andreasen et al., 1990). 
PAI-2 was discovered originally in placenta It has also been fo\Dld in cells of the 
monocyte/macrophage lineage. High levels of PAI-2 have been detected in pregnancy 
plasma, but it is not present in the circulation under normal conditions. PAI-2 exists in 
two molecular forms. Intracellular PAI-2 is a 47 kDa non-glycosylated protein, whereas 
the secreted form is glycosylated and has a molecular mass of about 60 kDa The PAI-2 
gene is located on chromosome 18 and PAI-2 eDNA encodes a protein consisting of 415 
amino acids. The intracellular and secreted forms have a single mRNA of 2 kb. The 
reactive centre of PAI-2 is formed by Arg380-Thr381. In contrast to PAI-l., PAI-2 is a 
stable inhibitor and has not been shown to occur in a latent inactive form. PAI-2 
primarily inhibits u-P A. It forms covalently bonded equimolar complexes with tcu-PA,. 
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but does not react with scu-PA. PAI-2 also inhibits tct-PA. It is a very poor inhibitor of 
sct-PA (Andreasen et al.J990; Pollanen et al., 1991; Booth,. 1994). 
PAI-3 has been identified in human urine and is also found in plasma It is a 
single-chained 50 kDa glycoprotein that inhibits tcu-PA and thrombin at comparable rates .. 
but reacts very slowly with tct-PA. PAI-3 has been demonstrated to be immunologically 
identical with the heparin dependent inhibitor of activated protein C. It is tmlikely to be 
a relevant physiological plasminogen activator inhibitor. However .. PAI-3 may have a more 
significant function during thrombolytic therapy when the plasma concentration of u-P A 
is high (Kruithof,. 1988~ Loskutoff et aL, 1989~ Pollan en et al.,. 1991 ). 
Protease nexin I is a 45 kDa glycoprotein containing 392 amino acid residues. It 
is produced by many cell types but is not found in plasma. In fact,. it is a broad 
specificity inhibitor of trypsin-like serine proteases rather than a true plasminogen 
activator inhibitor. It inhibits trypsin,. thrombin., u-P A, sct-PA., tct-PA and plasmin while 
forming 1 : 1 complexes with these proteases. Complex formation is promoted by heparin. 
Complexes of protease nexin I with thrombin and u-P A bind to and are internalized by 
fibroblasts. A role for protease nexin I in controlling cell surface protease activity has 
been proposed (Sprengers and Kluft,. 1987; Pollanen et al ... 1991 ). 
1.1.5 Receptors 
Pericellular plasminogen activation is a localized and directed process requiring 
assembly of the components at specific sites on the cell surface. Receptors for 
plasminogen and plasminogen activators play important roles in focusing plasminogen 
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activator activity in a spatially and temporally regulated manner (Pollanen et al.~ 1991 ~ 
Blasi~ 1993 ). 
1.1.5.1 Plasminogen receptors 
Most cells bind plasminogen with very similar characteristics. The binding is of 
low affmity (Kct is approximately 1 JJ.M) and high capacity. The number of plasminogen 
binding sites can exceed 107 sites per cell and more than half of them should be occupied 
if the physiological plasma concentration of plasminogen (2 f!M) is considered 
Plasminogen binding to cells can be inhibited by lysine and lysine analogs ( 6-
aminohexanoic aci~ tranexamic acid). It appears that both the high affinity LBS of kringle 
1 and the low affmity LBS of kringle 5 are involved in the interaction, and this can lead 
to a heterogenous orientation of botmd plasminogen molecules on the cell surface that 
might influence their activation (Plow and Miles, 1990; Plow et al., 1991 ). 
Conflicting data have been reported as to whether Lys-plasminogen and Glu-
plasminogen bind to cells with similar or markedly different affmities. The state of 
glycosylation of plasminogen can also affect affmity, but the data obtained from different 
laboratories are controversial (Plow and Miles, 1990; Plow et al., 1991 ). 
Plasminogen and plasmin bind to the same sites on cells. Some authors found that 
plasmin binds to cells with much higher affinity than plasminogen. This is, however, not 
generally accepted (Plow and Miles, 1990). An important functional consequence of 
plasminogen binding and subsequent cell surface plasmin generation is the protection of 
cell bound plasmin from its inhibitors, ~-antiplasmin and a:z-macroglobulin (Plow et al., 
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1986~ Ellis et al., 1991 ~ Hall et al., 1991; Duval-Jobe and Parmely, 1994 ). 
No single molecule has yet been identified as a plasminogen receptor. Even 
though plasminogen binds to a single class of sites on cells with respect to affmity .. 
considering the very high binding capacity., it is unlikely that a single receptor molecule 
serves as an exclusive receptor. Cell surface proteins with carboxy-term.inallysines that 
bind plasminogen via its LBS may function as plasminogen receptors. Representatives 
of this category of plasminogen receptors are a-enolase and annexin IT. Other plasminogen 
receptor candidates include glutaraldehyde 6-phosphate dehydrogenase, amphoterin., GPIIb-
Illa from platelets., a GPIIb-illa-related molecule from fibroblasts., gangliosides and 
glycosaminoglycans. Thus., both protein and non-protein molecules may ftm.ction as 
plasminogen receptors (Plow et al . ., 1995). 
1.1.5.2 The urokinase receptor 
Specific cell surface receptors for u-PA (u-PAR) were fust reported on human 
blood monocytes and on cells of the monocyte line U937 (Vassalli et al ... 1985~ Stoppelli 
et al.., 1985 ).. and they have been fotmd on various normal and neoplastic cells as well. 
u-PAR is a heavily glycosylated, single-chain protein with an apparent Mr of 55,000 to 
60,000. The Mr has been reduced to 35,000 upon deglycosylation with N-glycanase 
(Nielsen et al. 1988; Behrendt et al.., 1990). The protein sequence has been deduced from 
the structure of eDNA encoding the entire human receptor (Roldan et al ... 1990). The 
nascent molecule contains 313 amino acid residues with five potential attachment sites for 
N-linked carbohydrate. The length of the mature u-PAR protein is somewhat shorter due 
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to COOH-terminal processing (Ploug et al.~ 1991 ). The u-PAR is organized in three 
domains of about 90 amino acids each. The region which is responsible for the specific 
binding of u-P A is located in the ~-terminal domain (Behrendt et al.~ 1991 ). 
u-PAR is an integral membrane protein anchored to the cell membrane by a 
COOH-terminal glycosyl-phosphatidyl.inositol (GPI) moiety (Ploug et al.~ 1991). The GPI 
anchor can be cleaved by bacterial phosphatidylinositol-specific phospholipase C (PI-
PLC)~ thus releasing the receptor. Unoccupied u-PAR released to the medium retains its 
binding capability. Small amounts of water soluble u-PAR can be detected in conditioned 
media of U937 cells even without PI-PLC treatment., suggesting a regulatory action by 
putative human phopholipases. 
u-PAR binds both pro-u-P A and u-P A through their EGF-like domain. The binding 
is of high affmity CKc~ 10-9 to 10-11 M) and low capacity (1000 to 2507000 sites per cell) 
(Blasi7 1988). Catalytic activity of the plasminogen activator is not required for the 
interaction7 because inactivation of u-P A by DFP does not abolish binding (V assalli et al., 
1985). Furthermore, the catalytically inactive A TF has retained its capability for cellular 
binding (Stoppelli et al.7 1985). In contrast~ LMW u-PA7 which is proteolytically active 
but lacks the ~-terminal fragment., cannot bind to the u-PA receptor (Vassalli et al., 
1985). Preformed u-PA/PAI-1 complexes also interact specifically with the receptor and 
require the NH2-terminal fragment of u-P A for binding (Cubellis et al.7 1989). 
Pro-u-PA can be activated to u-PA while bolDld to the receptor (Cubellis et al., 
1986). Bomd u-P A retains its activity (Vassalli et al.7 1985), dissociates very slowly from 
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the cell surface ( Stoppelli et al... 1985) and is neither internalized nor degraded (Cub ellis 
et al ... 1990). Receptor bound u-PA is accessible to and inhibited by PAI-l and PAI-2 
(Cubellis et al ... 1989; Ellis et aL .. 1990~ Pollanen et al ... 1990) .. and u-PA/PAI-1 complexes 
botmd to u-PAR are internalized and degraded ( Cubellis et aL, 1990 ). 
1.1.5.3 t-PA receptors 
In human umbilical vein endothelial cells (HUVEC) high (Kd 28.7 pM) and low 
(Kd 18.1 nM) affinity binding sites for t-PA have been described. Binding of t-PA to 
HUVEC was specific .. saturable .. reversible and did not require lysine binding sites (Hajjar 
et aL, 1987). HUVEC binding sites for t-PA were identified in a plasma membrane 
enriched endothelial cell fraction as a single saturable site (Kd 9 .I nM). Ligand binding 
studies demonstrated a 40 kDa t-PA binding membrane protein that might represent the 
functional t-PA receptor (Hajjar and Hamel .. 1990). A t-PA binding protein isolated from 
detergent extracts of human placenta has been found to be identical with the endothelial 
t-PA receptor. t-PA receptor (t-PAR) is postulated to be a unique dual ligand receptor, 
because it binds specifically both t-PA and plasminogen. The two ligands did not exhibit 
cross-competition.. which suggests that t-PAR assists juxtaposition of t-PA and 
plasminogen thus promoting cell surface plasminogen activation (Hajjar .. 1991 ). Recently. 
it has also been pointed out that the 40 kDa t-PAR is an annexin II related protein (Hajjar 
and Jacovina.. 1993). 
1.2 MAJOR MECHANISMS IN PLASMINOGEN ACOV A TION 
1.2.1 Fibrinolysis 
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Fibrinolysis .. an integral part of hemostasis., involves plasminogen activation at the 
fibrin surface followed by plasmin-catalyzed degradation of the insoluble fibrin clot into 
readily soluble fibrin fragments. Abnormalitites in controlling fibrin degradation may 
have serious pathological consequences including bleeding or thrombosis (Ranby and 
Brandstrom., 1988~ Halkier., 1991 ). 
Plasminogen activators are normally present in the blood., yet very little if any 
plasminogen activation occurs (Collen., 1980~ Pannell and Gurewich., 1986). t-PA., which 
is thought to be the principal plasminogen activator of fibrinolysis, activates plasminogen 
very inefficiently when fibrin is not present. Fibrin has several important roles in 
fibrinolysis. It triggers and regulates its own degradation by enhancing the activation rate 
of plasminogen. Generation of plasmin is focused on and restricted to the fibrin clot 
which provides a solid phase with favorable enzyme kinetics and is also a substrate for 
plasmin. In addition., plasmin generated on the fibrin surface is partly protected from 
inactivation., thus ensuring high-efficiency fibrinolysis (Collen and Lijnen .. 1991~ Angles-
Cane, 1994 ). 
The soluble precursor of fibrin is fibrinogen, a glycoprotein composed of two 
symmetric half molecules, each possessing three polypeptide chains named Aa.., BJ3 and 
y. The two half-molecules are joined in a central amino terminal domain (E domain). 
Formation of a fibrin clot is the fmal phase of blood coagulation. Fibrinogen is converted 
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to fibrin by thrombin which cleaves the Aa and Bf3 chains at specific amino terminal sites 
and releases fibrinopeptide A (FP A) and fibrinopeptide B (FPB) molecules from 
fibrinogen. Fibrin monomers polymerize into a fibrin polymer clot, which subsequently 
undergoes covalent stabilization through crosslinking of monomers by activated factor XIll 
(Mosesson, 1990; Halkier .. 1991). 
Binding of t-PA and plasminogen to fibrin dramatically increases the rate of 
plasminogen activation as compared to catalytic rates obtained in the absence of fibrin. 
Conversion of fibrinogen to fibrin exposes t-PA binding sites and fibrin-boWld sct-PA 
activates fibrin-bound plasminogen. Plasmin initially generated unveils carboxy-terminal 
lysine residues on the surface of partially degraded fibrin that provide additional binding 
sites for both t-PA and plasminogen resulting in the acceleration of plasmin-catalyzed 
fibrinolysis. Initial plasmin degradation is thus an important positive feedback mechanism 
in fibrinolysis (Halkier, 1991; Angles-Cano .. 1994; Lijnen et al ... 1994 ). During fibrin clot 
lysis sct-PA is converted to tct-PA on the fibrin surface by the proteolytic action of 
plasmin (Halkier .. 1991 ). This conversion is .. however .. unlikely to contribute to positive 
feedback amplification of fibrinolysis, because the two forms of t-PA are equally active 
in the presence of both intact and degraded fibrin (Suenson and Petersen, 1986; Uran.o et 
al., 1989; Lijnen et al., 1990; Andreasen et al., 1991). 
The role of u-P A in fibrinolysis is not clearly established In the presence of fibrin 
scu-PA but not tcu-PA induces fibrin-specific proteolysis (Gurewich et al., 1984; 
Zamarron et al., 1984). Scu-PA is not an efficient activator in the presence of intact 
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fibrin~ but it activates plasminogen botmd to partially degraded fibrin with an efficiency 
comparable to that oft-PA (Fleury et al. .. 1993a). Scu-PA which has no affmity for fibrin 
may induce fibrin-specific plasminogen activation by interaction with plasminogen bound 
to carboxy-terminallysine residues of partially digested fibrin (Pannel et al.~ 1988~ Fleury 
et al.~ l993b). 
Whether plasmin-mediated conversion of Glu-plasminogen to Lys-plasminogen 
occurs during fibrinolysis is still debated Lys-plasminogen demonstrates improved fibrin 
binding and activation rate over Glu-plasminogen (Wohl et al.~ 1980; Hoylaerts et al.~ 
1982~ Nesheim et al.'9 1990; Suenson et al.~ 1990) and thus~ formation of Lys-plasminogen 
could theoretically contribute to the positive feedback amplification of fibrinolysis. ~­
antiplasmin might have a role in regulating Lys-plasminogen formation'9 inasmuch as it 
has been shown that in the presence of this plasmin inhibitor Lys-plasminogen is not an 
intermediate in Glu-plasminogen activation (Rouy and Angles-Cano~ 1990)~ whereas the 
absence of ~-antiplasmin permits Lys-plasminogen and Lys-plasmin to form (Rouy and 
Angles-Cano .. 1990). 
Lipoprotein (a) (Lp(a)) .. a plasma lipoprotein appears to attenuate fibrinolysis. The 
human apolipoprotein( a) shows remarkable homology to plasminogen (McLean et al., 
1987). Lp(a) competes with both t-PA and plasminogen for binding sites on fibrin 
(Loscalzo et al., 1990). Furthermore, Lp(a) binding to fibrin is enhanced by plasmin-
mediated partial degradation of the fibrin surface (Harpel et al., 1989). As a result'9 fibrin-
dependent activation of plasminogen by t-PA is inhibited (Loscalzo et al.~ 1990). Elevated 
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concentrations of Lp(a) may thus significantly impair physiological fibrinolysis. 
Fibrinolysis may be inhibited at the level of plasminogen activators or at the level 
of plasmin. The most important inhibitors involved in fibrinolysis are PAI-l and ~­
antiplasmin (Ranby and Brandstrom~ 1988). PAI-l has been shown to bind to fibrin and 
fibrin-bound PAI-l forms SDS-stable complexes with t-PA (Wagner et al .• 1989: Reilly 
and Hutzelmann, 1992). PAI-l bound to fibrin inhibits t-PA mediated fibrinolysis in a 
dose-responsive manner (Reilly and Hutzelmann. 1992). Inactive PAI-1/t-PA complexes 
dissociate from the fibrin matrix and may rebind to fibrin through the rmger and kringle 
2 domains of t-PA. Hence, t-PA/PAI-1 complexes are likely to compete with free t-PA 
for the same binding sites on fibrin leading to further inhibition of t-PA dependent 
fibrinolysis (Wagner et al . ., 1989). Thus, fibrin-bound PAI-l at sites of thrombus 
formation may help prevent thrombi from premature dissolution. However, other data 
indicate that PAI-l fails to inhibit fibrin-bound t-PA significantly (Chmielewska et al., 
1988; Masson and Angles-Cano, 1988). A possible explanation for the divergent results 
may be the difference in the order of appearance and assembly of t-PA and PAI-l on the 
fibrin surface. arising from the different experimental set-ups. 
The physiological plasmin inhibitor, ~-antiplasmin has two modes of action. 
Alph~-antiplasmin in fluid phase is inefficient at inhibiting fibrin bound plasmin. Free 
plasmin dissociated from the clot is, however, rapidly inactivated. This mechanism 
ensures that plasmin remains effective only if bound at the fibrin surface (Wiman and 
Collen, 1978; Collen, 1980; Ranby and Brandstrom., 1988). Contrary to the fluid phase 
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inhibitor? ~-antiplasmin crosslinked to fibrin appears to inhibit bound plasmin since n.:-
antiplasmin deficient plasma clots tmdergo rapid fibrinolysis even if the clot is immersed 
in ~-antiplasmin containing normal plasma (Sakata and Aoki, 1982). Hence, the 
significance of inhibition by crosslinked ~-antiplasmin probably lies in preventing 
premature clot lysis. 
1.2.2 Plasminogen activation at the ceO swface 
It is now realized that many cell types utilize a concerted cascade-like action of 
proteolytic enzymes on or near the cell surface to degrade extracellular matrices (ECM) 
(Moscatelli and Rifkin, 1988~ Chen, 1992). Major ECM degrading cell surface proteases 
include three classes of secreted proteases (serine proteases, cathepsins and matrix 
metalloproteases) and integral membrane proteases (Chen, 1992 ). Assembly of relevant 
proteases and their inhibitors at specific sites on the cell surface provides the cells with 
the potential of a highly efficient and regulated proteolysis that is strictly localized in 
nature. Central to proteolytic mechanisms on the cell surface is plasminogen activation. 
The serine protease plasmin and, to a lesser degree, u-P A are themselves able to degrade 
certain components of ECM proteins (Liotta et al., 1981; Saksela and Rifkin, 1988~ Gold 
et al., 1989). In addition, and perhaps even more importantly, these enzymes can process 
and activate latent metalloproteinases (Matrisian, 1990; Keski-Oja et aL, 1992), which are 
amongst the most powerful ECM degrading enzymes currently known. Thus, the 
plasminogen activation system plays a major part in the regulation of the activity of 
metalloproteinases and in pericellular ECM degradation. 
21 
1.2.2.1 Pericellular distribution of the plasminogen activanon system 
Complex molecular interactions resulting in cellular adhesion are an important part 
of the mechanisms that maintain the normal phenotype of cells. Adhesive interactions 
between the cell surface and extracellular matrix focus on discrete contact sites where 
modulation of such interactions by cell-surface proteolysis can lead to cell migration and 
invasion (Pollanen et al.~ 1991~ Blasi~ 1993). 
In cultures of fibroblasts three types of cell-substratum contact sites are known 
(Chen and Singer~ 1982; Pollan en et al.~ 1991 ): ( 1 ) focal contacts (synonyms: focal 
adhesions or adhesion plaques), (2) close contacts, and (3) fibronexus contacts 
(extracellular matrix contact sites). Focal contacts are the sites of closest apposition 
between the ventral cell surface and growth substratum ( -15 nm). They are frequently seen 
close to the leading edge of moving cells associated with lamellopodia and microspikes. 
Close contacts are adhesions with 30-50 nm spacings between the cell surface and 
substratum, whereas in fibronexus contacts the ventral cell surface is far removed from 
the substratum, though sporadically connected to it by iuamentous aggregates of the 
extracellular matrix. 
In actively growing HT -I 080 fibrosarcoma and human embryonic lung fibroblast 
cultures u-P A has been detected in focal contacts on all parts of the ventral cell surface, 
particularly at leading lamellae, lamellopodia and microspikes. Extracellular u-PA has 
also been found at cell-cell contact sites. By contrast, no u-P A could be demonstrated at 
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close contacts and fibronexus contact sites characteristic of normal stationary fibroblasts 
(PolHinen et al ... 1987 .. 1988~ Vaheri et al ... 1990). 
Distribution of extracellular PAI-l is quite distinct from that of u-P A. It is widely 
distributed on the growth substratum beneath the ventral cell surface (Pollanen et al., 
1987). The extracellular distribution of PAI-l appears identical with that of vitronectin .. 
a binding protein for PAI-L In the vitronectin-PAI-1 complex PAI-l remains active and 
vitronectin retains its cell adhesion properties. Furthermore .. cellular vitronectin receptors 
are known to be localized at focal contacts. Thus .. interactions between vitronectin and 
its receptor may place vitronectin-bol.Dld PAI-l in an appropriate position to inhibit 
receptor botmd u-P A in focal contacts .. further promoting cellular adhesion (Vaheri et al., 
1990~ Pollanen et al ... 1991 ). 
Plasminogen is distributed all over the ventral cell surface, whereas the dorsal 
surface does not bind plasminogen (PolHinen et al... 1991 ). 
1.2.2.2 u-PA dependent cell smface plasminogen activation 
Most cells capable of cell surface plasminogen activation synthesize both scu-PA 
(pro-u-P A) and u-PAR.. but do not usually produce plasminogen. After secretion .. pro-u-
PA binds to u-PAR by autocrine/paracrine mechanisms. Subsequently, activation of 
botmd pro-u-PA to active tcu-PA can take place (Stoppelli et al., 1986; Stephens et al ... 
1989; Blasi .. 1993 ). This process is clearly dependent on cellular binding of the ubiquitous 
plasminogen. Plasminogen binding occurs through interactions with plasminogen 
receptors on the cell surface and is stimulated by interactions between u-PA and its 
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receptor (Plow et al., 1986). The initiating event for pro-u-P A activation is, however, still 
not known (Ellis and Dane, 1991 ). It may be provided by trace amounts of active 
proteases. Plasmin is capable of catalyzing receptor bound pro-u-P A activation (Cubellis 
et al.,. 1986; Stephens et al., 1989) as may be other proteases such as cathepsin B 
(Kobayashi et al.,. 1991 ). Induction of proteolytic activity in pro-u-P A upon binding to 
its receptor has been also proposed as a possible alternative mechanism (Manchanda and 
Schwartz., 1991 ). 
Generation of active u-PA results in rapid activation of cell bo\Uld plasminogen. 
Plasmin formed can leac:L in tum, to further activation of pro-u-P A and plasminogen,. 
enabling more plasmin to form, and so on. Positive feedback regulation resulting in 
progressive increases in the rates of plasmin generation can occur at various levels of the 
plasminogen activation pathway in both solution and in the presence of cells. Conversion 
of pro-u-P A to active u-P A is obviously subject to feedback activation by plasmin. After 
initiation of plasminogen activation increasing concentrations of newly formed plasmin 
enhance the rate of active u-P A generation,. leading to increases in the plasmin generation 
rate (Collen et al., 1986~ Ellis et al.,. 1987,. 1989; Stephens et al.., 1989~ Liu et al.,. 1992). 
Another feedback amplification in plasminogen activation may be initiated at the level of 
conversion of Glu- to Lys-plasminogen. It has been demonstrated that activation of cell-
bound Lys-plasminogen proceeds with more favorable kinetics than that of Glu-
plasminogen (Ellis et al.,. 1991). Moreover, conversion of Glu-plasminogen to Lys-
plasminogen has been detected on the cell surface and this conversion could be inhibited 
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by aprotinin. It is~ therefore~ reasonable to assume that plasmin contributes to the 
feedback amplification of plasminogen activation at yet another level~ by catalyzing Lys-
plasminogen formation. However, conversion of Glu- to Lys-plasminogen was not 
affected by specific inhibitors of plasmin and plasminogen activation, suggesting that 
serine proteases other than plasmin were likely to be involved Still, the involvement of 
plasmin remains a strong possibility. 
It is now well established that plasminogen activation at the cell surface can 
proceed at a much higher rate than in the fluid phase (Ellis et al., 1989, 1991~ Duval-Jobe 
and Parmely ~ 1994 ). Potentiation of plasminogen activation in the presence of cells could 
be abolished by A TF that competes with u-P A binding to u-PAR or lysine analog 
plasminogen binding antagonists (6-aminohexanoic acicL tranexamic acid), thus 
demonstrating the requirement of specific u-PA and plasminogen binding to their 
respective cellular receptors. Cell surface bound u-PA, in fact, activates fluid phase 
plasminogen with kinetics virtually identical with those obtained by u-PA and 
plasminogen in solution. Enhanced feedback activation of pro-u-P A is likely to be the 
most important mechanism of cellular potentiation of plasminogen activation. The 
increase in the rate of two-chain u-P A generation appears to be mediated by cell-bound 
plasmin (Ellis et al., 1989; Duval-Jobe and Parmely, 1994). 
1..2.2.3 t-PA dependent ceU smface plasminogen activation 
While it is abundantly clear that many cell types utilize u-PA dependent cell 
surface plasminogen activation, only a few cases of t-PA induced activation have been 
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reported (Hajjar et al., 1987; Hajjar and Nachmann, 1988; Bizik et al., 1990; Nachmann 
and Hajjar, 1991). 
Intravascular plasminogen activation is controlled to a great extent by vascular 
endothelial cells through their ability to produce plasminogen activators (t-PA and u-P A) 
(van Hinsbergh, 1988) as well as plasminogen activator inhibitors (PAI-l and PAI-2) 
(Scbleef and Loskutoff, 1988). t-PA and PAI-l appear to be the predominant components 
of the vascular plasminogen activation system. They are released into the circulating 
blood (van Hinsbergh et al., 1991 ), but are also found bound to the surface of endothelial 
cells (Bamathan et al., 1988). Both plasminogen (Hajjar et al., 1986; Hajjar and 
Nachman, 1988) and t-PA (Hajjar et al., 1987; Bamathan et aL, 1988) bind specifically 
to HUVEC and furthermore, an endothelial cell t-PA receptor which binds both t-PA and 
Lys-plasminogen has also been identified (Hajjar, 1991). Activation of plasminogen by 
HUVEC botm.d t-PA proceeds with a considerably higher catalytic activity compared to 
fluid phase activation (Hajjar et al., 1987). Enhancement of catalytic efficiency by 
endothelial cells seems to result, at least in part, from the conversion of Glu- to Lys-
plasminogen on the cell surface (Hajjar and Nachman, 1988). t-PA bound to the cell 
surface is protected from PAl -1 (Hajjar et al., 1987), and this is in contrast to the effective 
inhibition of cell surface botm.d u-PA by PAis (Ellis et al., 1990). Lp(a), by competing 
at the endothelial cell surface for plasminogen binding sites down-regulates generation of 
cell-associated plasmin (Nachman and Hajjar, 1991 ). Overall, the above fmdings strongly 
suggest the existence of a powerful endothelial plasminogen activation system whose main 
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role probably lies in controlling physiological non-thrombogenicity at the vascular surface. 
Several human melanoma cell lines also favor t-PA mediated cell surface 
plasminogen activation (Bizik et aL, 1990). These cells produce primarily t-PA and very 
little u-PA. Exogenous t-PA binds to these melanoma cells .. but the binding of u-PA is 
insignificant indicating that functional binding sites for u-P A are poorly expressed In the 
presence of plasminogen .. cell surface bound plasmin activity could be recovered from 
tranexamic acid eluates and was inhibited by an anticatalytic antibody to t-PA, while an 
anticatalytic u-PA antibody had no effect. These findings suggest t-PA mediated cell 
surface plasminogen activation. The reason why some melanoma cell lines employ t-PA 
rather than u-PA to promote cell surface plasmin generation remains unclear and awaits 
further investigation. 
1.2.2.4 Inhibition of cell swface plasminogen activanon 
Inhibition of the plasminogen activation system at the cell surface can occur at the 
level of plasminogen activators or of plasmin. Activation of plasminogen at focal contacts 
is regulated through inhibition of receptor-bound u-P A by PAis. PAI-l freshly secreted 
from cells or bound to vitronectin in the extracellular matrix is active and has the capacity 
to rapidly control cell surface plasminogen activator activity (PolHinen et al. 1991 ). In cell 
culture .. neutralizing antibodies to PAI-l have been shown to increase the amount of active 
u-P A recovered from the cell surface~ indicating that u-P A activity is subject to inhibition 
by endogenous active PAI-l (Stephens et al ... 1989). PAI-2 .. which is not associated with 
the EC~ also has the potential to regulate cell-surface u-PA activity (Ellis et al ... 1990). 
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Exogenous recombinant PAI-2 has been found to bind to and inhibit active u-P A at focal 
adhesion sites (Pollanen et al ... 1990). Because it does not bind to ECM., it is a suitable 
probe for mapping active u-P A sites on the cell surface. 
In U937 promonocyte cultures both PAI-l and PAI-2 inhibited receptor bound u-
PA with association rate constants that were approximately 40% lower in each case when 
compared to solution phase inhibition of unboood active u-PA (Ellis et al.., 1990). These 
constants (4.5 x 106 M-1s-1 and 3.3 x 10' M-1s-1 for PAI-l and PAI-2., respectively)., 
however .. still represent rapid inhibition demonstrating that u-PA bound to its cellular 
receptor remains available for efficient inhibition by PAis. 
Receptor bolm.d active u-PA dissociates slowly and is neither internalized nor 
degraded (Vassalli et al.., 1985; Stoppelli et al . ., 1985; Cubellis et al . ., 1990). However, u-
PA-PAI-1 complexes m1dergo u-PA receptor mediated internalization., followed by 
degradation (Cubellis et al.., 1990; Olson et al . ., 1992) and the internalized receptors are 
recycled back to the cell surface (Conese and Blasi .. 1995). Similarly, u-PA:PAI-2 
complexes are subject to u-PA receptor-dependent internalization and degradation 
(Estreicher et al., 1990). Recently, involvement of the ~-macroglobulin receptor/low 
density lipoprotein receptor-associated protein ( ~-MR) and epithelial glycoprotein 330 
(gp330) in the internalization and degradation of u-PA:PAI-1 complexes has been also 
suggested (Conese and Blasi, 1995). 
While plasmin is readily inhibited in solution., cell-botmd plasmin is protected from 
inactivation by its inhibitors <Xz-antiplasmin and <Xz-macroglobulin (Plow et al . ., 1986; Ellis 
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et al.~ 1991~ Hall et al. .. 1991; Duval Jobe and Parmely~ 1994). Due to the low affinity 
interaction between plasmin and its receptor .. dissociation of plasmin relative to u-P A can 
occur more easily. In serum-containing cultures~ dissociated plasmin is rapidly inhibited 
by its inhibitors, thus confining plasmin activity to the cell surface. In addition, due to 
the presence of inhibitors .. plasmin is not taken up from serum medium onto the cell 
surface, ensuring that cell botmd plasmin results exclusively from activation of botmd 
plasminogen (Stephens et al.., 1989). 
In summary, cell surface plasminogen activation is a highly regulated and localized 
process that requires complex interactions between the components of the plasminogen 
activation system. This process involves a complete cycle of u-PA from synthesis .. 
secretion and autocrine/paracrine binding through cell surface activation and inhibition to 
internalization and degradation. Recycling of u-PAR to the cell surface favors formation 
of new focal adhesion sites required for cell migration and breakdown of physical barriers. 
Thus .. the cell surface can be regarded as being composed of proteolytically active and 
adhesion promoting areas that rearrange continuously in the process of cell migration and 
adhesion (Blasi, 1993 ). 
1.3. REGULATION OF PLASMINOGEN ACilVATION 
Plasmin activity available for various biological fimctions is spatially and 
temporally controlled through regulatory mechanisms acting at several levels of the 
plasminogen activation system. Finely tuned mechanisms exist that regulate the synthesis, 
release, binding characteristics, activity and elimination of several components of the 
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system. Hence., net plasminogen activation is a balance of complex interactions between 
fibrinolytic components each regulated by a variety of mechanisms (For reviews see Dana 
et a1. 7 1985; Saksela and Rifkin., 1988; Loskutoff et al . ., 1989, 1991; Mayer., 1990; Van 
Hinsbergh et al . ., 1991; Plow et al . ., 199 5 ). 
1.4 THE PLACENTAL TROPHOBLAST: INVASIVENESS AND PROTEOLYTIC 
ACI'IVlTY 
1.4.1. Development and structural orgaoizauon of 1be human placenta 
Human development commences at fertilization that normally occurs in the 
ampulla of the uterine tube (Sadler., 1985; Moore., 1988). As the fertilized ovum (zygote) 
passes along the uterine tube it tmdergoes a series of mitotic cell divisions (cleavage) 
resulting in the formation of daughter cells called blastomeres. Approximately three days 
after fertilization a mulberry-shaped mass of 12-16 blastomeres (morula) still surrounded 
by the protective layer zona pellucida enters the uterine cavity. About four days after 
fertilization embryonic development results in a blastocyst consisting of a fluid-filled 
cavity (blastocele) enclosed by a group of centrally located cells (inner cell mass or 
embryoblast), and a flattened outer cell layer known as the trophoblast. The embryoblast 
is the primordium of the embryo., while the trophoblast will eventually give rise to the 
fetal part of the placenta. Initially, the blastocyst floats freely in the uterine secretions, 
and during this period the zona pellucida gradually degenerates and disappears. About 
six days after fertilization the human blastocyst attaches to the endometrial epithelium via 
its embryonic pole (that part of the blastocyst where the embryoblast is located). This 
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attachment marks the begjnnning of the process of implantation., which comprises a series 
of important events (Schlafke and Enders., 1975). Usually., the blastocyst implants in the 
endometrium of the posterior or anterior wall of the body of the uterus. 
The trophoblast at the implanting embryonic pole proliferates rapidly and 
differentiates into two layers: ( 1) an inner cytotrophoblast (cellular trophoblast)., and (2) 
an outer syncytiotrophoblast (syncytium) (Sadler., 1985~ Moore., 1988). The latter is a 
continuous mass of fused trophoblastic cells without cellular botmdaries that has lost its 
capability to divide. The syncytiotrophoblast continues to expand by proliferation and 
subsequent fusion of neighboring cytotrophoblasts. It invades the uterine epithelium and 
endometrial strom~ and the blastocyst slowly embeds itself in the endometrium. 
Meanwhile, stromal cells of the endometrium at the implantation site proliferate and 
enlarge., thus transforming to decidual cells. 
During further development isolated lacunae appear in the syncytium that soon 
communicate with eroded endometrial blood vessels., and thus become ftlled with maternal 
blood (Moore., 1989). By the tenth day after fertilization the blastocyst is completely 
implanted in the superficial compact layer of the endometrium. At this stage the outer 
surface of the blastocyst is completely transformed into syncytiotrophoblast. The 
syncytiotrophoblast lacm1ae soon become partially confluent to form lacunar networks., 
establishing a primitive uteroplacental circulation. Lacuna formation subdivides the 
trophoblast covering of the implanted blastocyst into ( 1) primary chorionic plate., (2) 
lacunar system and (3) trophoblastic shell (Benirsch.ke and Kaufmann, 1990). 
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The primary chorionic plate separates the lacWlar system from the blastocyst 
cavity. Initially., it consists only of cytotrophoblast and syncytiotrophoblast. It becomes 
triple-layered when the extraembryonic mesenchyme spreads over the cytotrophoblastic 
surface of the blastocyst cavity. Toward the lacunae the cytotrophoblast is covered by 
syncytiotrophoblast. The lactmae are separated from each other by trabeculae of the 
syncytiotrophoblast. These trabeculae are invaded longitudinally by cytotrophoblasts 
derived from the primary chorionic plate. Where the peripheral ends of the trabeculae join 
together., they form the trophoblastic shell facing the endometrium (decidua). At the 
beginning, it is purely syncytiotrophoblastic in nature. As soon as .. however., the 
cytotrophoblasts reach the shell it becomes triple-layered, consisting cytotrophoblasts in 
the middle and syncytium on the fetal as well as maternal aspects (Benirschke and 
Kaufmann., 1990 ). 
At the end of the second week increased cytotrophoblastic proliferation and 
syncytial fusion in the trabeculae take place (Moore, 1988~ Benirschke and Kaufmann., 
1990 ). As locally growing cytotrophoblast masses extend into the syncytiotrophoblast 
primary chorionic villi protruding into the lactmae (henceforth called intervillous space) 
are formed. These villi consist of a core of cytotrophoblasts surrotmded by an outer layer 
of syncytiotrophoblast. Branching of the primary villi initiate the development of villous 
trees, the stems of which are derived from the former trabeculae. When the stem villi 
keep their contact with the trophoblastic shell they are called anchoring villi. Villi that 
do not contact the trophoblastic shell are free (floating) villi. At arotmd day 15 
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mesenchymal cells derived from the extraembryonic mesoderm of the primary chorionic 
plate grow into the primary chorionic villi transforming them to secondary villi. These 
villi have a core of mesoderm covered by a single layer of cytotrophoblastic cells~ which .. 
in tum .. are surrotmded by the outer syncytium. After blood vessels have appeared in the 
villi they are called tertiary chorionic villi. Capillaries in tertiary villi come into contact 
with vessels in the mesoderm of the chorionic plate and in the connecting stalk that later 
develops into the umbilical cord, forming the connection between placenta and embryo. 
By the end of the third week embryonic blood begins to circulate through the capillaries 
of the chorionic villi. Until about the eighth week villi cover the entire surface of the 
chorion. As development advances .. villi at the embryonic pole continue to expand giving 
rise to the villous chorion (chorion frondosum ). Chorionic villi at the abembryonic pole 
degenerate and disappear. This villous-free part of the chorion is called the smooth 
chorion (chorion laeve ). The ftmctional layer of the gravid endometrium known as 
decidua is found at three locations: ( 1) over the villous chorion (decidua basalis) .. (2) over 
the abembryonic pole (decidua capsularis ) .. and (3) on the surface of the uterus opposite 
to the growing embryo (decidua parietalis ). 
The placenta has two components: ( 1) a fetal portion .. and (2) a maternal portion 
(Moore.. 1988). The fetal portion is formed by the villous chorion .. consisting of the 
chorionic plate and the villi. The latter project into the intervillous spaces containing 
maternal blood. The maternal portion is formed by the decidua basalis. 
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Development of the chorionic plate begins with the formation of the primary 
chorionic plate (Benirschke and Kaufmann .. 1990). When the amnion comes into close 
contact with and attaches to the primary chorionic plate the .. the latter is transformed to 
the defmitive (mature) chorionic plate. It serves as the base from which the villous trees 
are suspended into the intervillous space. The mature chorionic plate is composed of 
several layers. At the fetal aspect three layers of the amnion are found.. i.e. amnionic 
epithelium .. compact layer consisting of a lattice of collagen fibers .. and amnionic 
mesoderm. Underneath the latter there is a spongy layer .. separating the amnion and the 
chorionic mesoderm. The next layer consists of primary cytotrophoblasts (remnants of the 
original cytotrophoblast layer of the blastocyst) .. which rests on the subjacent Langhans 
fibrinoid. This layer contains X cells which are derived from either primary chorionic 
cytotrophoblasts or villous cytotrophoblasts of peripheral villi attached to and encased by 
the fibrinoid. Finally.. the intervillous surface of the chorionic plate is covered by 
remnants of the syncytiotrophoblast. 
The placental (chorionic) villi exhibit a characteristic cellular organization. They 
possess a central mesenchymal core (stroma) covered by an outer layer of 
syncytiotrophoblast and mononuclear cytotrophoblasts (Langhans' cells) underneath. The 
syncytiotrophoblast (syncytium) is a continuous multinucleated trophoblastic layer without 
separating cell borders. It lines the intervillous space and thus faces the maternal blood 
directly. The Langhans' cells which form the inner layer of the trophoblastic covering of 
the placental villi are joined to each other and the syncytium by desmosomes and tight 
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jmctions. The basal surface of the Langhans' cells rest on the trophoblastic basal lamina 
that separates the trophoblast from the villous core. At the sites where the Langhans' 
layer becomes discontinuous the syncytium establishes direct contact with the basal 
lamina. Villous cytotrophoblasts fimction as stem cells that proliferate and subsequently 
differentiate into villous syncytiotrophoblast by fusion. During early pregnancy., villous 
cytotrophoblasts form a nearly complete layer which later becomes discontinuous., and at 
term these cells are found beneath only about 20% of the syncytiotrophoblast (Moore., 
1988~ Benirschke and Kaufmann., 1990). 
The stroma of the placental villi consists of fibroblasts., macrophages., fetal vessels 
and connective tissue fibers. 
The villi serve as the site where the exchange of materials between fetus and 
mother takes place. Oxygenated maternal blood enters the intervillous space via the 
eroded ends of decidual spiral arteries., while deoxygenated maternal blood leaves through 
endometrial veins. Fetal deoxygenated blood reaches the placenta in two umbilical 
arteries that divide into numerous branches in the chorionic plate before entering the villi. 
The blood vessels form an extensive arterio-capillary-venous network in the villi. 
Oxygenated fetal blood leaves the placenta via the umbilical vein. The maternal and fetal 
circulations are separated by the placental membrane (barrier) consisting of (I) syncytium., 
(2) cytotrophoblast., (3) trophoblastic basal lamin~ (4) connective tissue., and (5) fetal 
endothelium surrounded by its basal lamina As pregnancy advances the syncytium 
becomes thinner., the number of cytotrophoblasts is diminished and the fetal capillaries 
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come closer to the villous surface. Consequently, the barrier becomes significantly 
reduced in thickness, and in many places it encompasses only syncytium., fused 
trophoblastic and capillary basal lamina., and fetal capillary endothelium (Moore, 1988~ 
Benirschke and Kaufmann, 1990 ). 
On the maternal aspect of the delivered placenta the basal plate borders on the 
intervillous space. The term basal plate is applied to the fused contact zone between the 
trophoblastic shell and the decidua basalis, where cytotrophoblasts derived from the 
trophoblastic shell in vade and intermingle with the endometrial stroma so that the border 
separating trophoblastic shell and decidua can no longer be defined. The deeper tissue 
layers of the placental site that remain in utero after placental separation are referred to 
as the placental bed. In situ the basal plate and placental bed are collectively called the 
jWlctional zone, which include all admixed fetal and maternal tissues basal to the 
intervillous space. The mature basal plate is about 100 J.lm to 1.5 mm in thickness. Its 
inner surface facing the intervillous space is covered with focal residues of the 
syncytiotrophoblast of the former trophoblastic shell. Where the syncytiotrophoblast is 
absent it is replaced by Rohr's fibrinoid believed to result at least from tissue necrosis. 
The syncytiotrophoblast rests on an inconsistent connective tissue layer followed by the 
principal layer of the basal plate consisting of a mixture of decidual cells, extravillous 
cytotrophoblasts, fibrinoid and remnants of buried villi and cell columns. The next layer 
is called the Nitabuch' fibrinoid. Separation of placenta from the placental bed usually 
takes place just below this layer (Benirschke and Kaufmann, 1990). 
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During early stages of pregnancy anchoring villi are attached to the intervillous 
surface of the basal plate via cytotrophoblastic cell columns. The cell columns are 
composed of a multilayered core of extravillous cytotrophoblasts demarcated sharply by 
a basal lamina from the adjacent stroma of the anchoring villi. Invasion of the basal plate 
by columnar cytotrophoblasts is accompanied by cellular differentiation. Cytotrophoblast 
stem cells located near the basal lamina proliferate and either fuse to form the 
syncytiotrophoblast covering of the anchoring villi or invade., and thus extensively 
colonize the basal plate and placental bed During later stages of pregnancy the cell 
columns are not conspicuous but rather exist incorporated into the basal plate at the base 
of the anchoring villi (Benirschke and Kaufmann., 1990 ). 
The basal plate is protruded into the intervillous space in the form of placental 
septa which divide the fetal part of the placenta into several cotyledons. Characteristic 
cellular elements of these septa are decidual cells and extravillous cytotrophoblasts. 
Similar to placental septa., cell islands are also non-villous parts of the placenta connected 
to villous tips or the chorionic plate. They are composed of mainly extravillous 
cytotrophoblasts encased in fibrinoid {Benirschke and Kaufmann, 1990). 
1.4.2 Pathways of trophoblast differennanon: heterogeneity of the trophoblast 
During the villous stage of placental development trophoblasts are found in the 
chorionic villi and at extravillous locations (Benirschke and Kaufmann, 1990). The 
villous syncytiotrophoblast forms the superficial layer of the villi, overlying the inner 
cytotrophoblasts (Langhans' cells). The remaining extravillous trophoblast., classified into 
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extravillous cytotrophoblast and extravillous syncytiotrophoblast., is present outside of the 
villi at several locations, such as ( 1) chorionic plate, (2) chorion laeve., (3) marginal zone, 
(4) trophoblastic shell and basal plate, (5) cell columns, (6) cell islands and (8) placental 
bed . Various forms of extravillous trophoblast have been described and designated as 
extravillous cytotrophoblast., interstitial trophobl~ intravascular trophoblast., en do vascular 
trophoblast .. intraarterial trophoblast., placental site giant cell., multinucleated trophoblastic 
giant cell., X cell, primary extravillous cytotrophoblast., secondary extravillous 
cytotrophoblast., primary chorionic cytotrophoblast, primary and secondary basal 
trophoblast etc. This diversity of designations suggests that., despite different 
morphological features and special localizations, some of the different names may 
represent identical or similar differentiation stages of the trophoblast. 
Recently .. an alternative classification distinguishing three types of trophoblast has 
been proposed (Kurman et al., 1984; Yeh and Kurman, 1989; Kurman., 1991). According 
to the authors .. there exist a transitional form of trophoblast (intermediate trophoblast) in 
addition to the clearly defmed cytotrophoblast and syncytiotrophoblast. The intermediate 
trophoblast is believed to represent an intermediate stage of differentiation between 
cytotrophoblast and syncytiotrophoblast., and is characterized by distinctive biochemical 
features and a diverse morphological expression. This cell type occurs at both villous and 
extravillous locations.. and thus it cannot be simply identified as being extravillous 
cytotrophoblast. On the other hand., extravillous trophoblast is often recognized as a 
particular location of the intermediate trophoblast. Some authorities believe, however .. that 
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the extravillous cytotrophoblast population is heterogenous (Benirschke and Kaufmann., 
1990). 
The trophoblast tmdergoes different pathways of differentiation dependent on the 
anatomical location and the gestational age. All forms of trophoblast derive from the 
blastocystic trophobl~ the outer mononuclear cell layer of the preimplantation blastocyst 
(Hamilton and Boyd, 1960). During early stages of implantation the blastocystic 
trophoblast differentiates into primitive mononuclear cytotrophoblast and 
syncytiotrophoblast. The former acts as a stem cell by proliferating and subsequently 
fusing with the overlying syncytiotrophoblast. Over the course of the lactmar and villous 
stages of placental development further differentiation of the trophoblast takes place., 
resulting in various trophoblast subpopulations. Soon after lactmae appear in the primitive 
syncytium the cytotrophoblasts grow into the syncytiotrophoblastic trabeculae and 
ultimately give rise to highly invasive intermediate trophoblasts of the trophoblastic shell. 
Intermediate trophoblasts deriving from the shell subsequently invade the decidua and 
myometrium. During the villous stage of placental development two different pathways 
of trophoblast differentiation exi~ which give rise to villous and extravillous trophoblast 
populations (Kurman et al.7 1984~ Yeh and Kurman~ 1989~ Kurman~ 1991~ Damsky et al . ., 
1992). In floating chorionic villi cytotrophoblast stem cells that are mononuclear7 
1.mdifferentiated trophoblasts displaying proliferating activity fuse into syncytiotrophoblast 
covering the entire villous surface. The villous syncytiotrophoblast (syncytium) represents 
a terminally differentiated noninvasive state. In anchoring chorionic villi cytotrophoblast 
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stem cells enter both differentiation pathways. Again, some stem cells fuse into 
syncytium. Others break through the syncytium at the tips of the villi and differentiate 
into intermediate cells of cell columns attached to the uterine wall. Intermediate 
trophoblasts emanating from the cell columns deeply invade the uterus and display such 
morphological and functional expressions as interstitial trophoblasts and intravascular 
trophoblasts. Intermediate trophoblasts may also fuse and form binucleate~ trinucleate and 
multinucleated cells. The latter is also referred to as syncytiotrophoblastic giant cells. 
1.4.3 Trophoblast invasion during implantation and placental development 
The placenta is a fetomatemal organ developed primarily for an exchange of 
molecules between fetus and mother. To achieve this goal fetal and maternal circulations 
are brought into a close proximity by fetal trophoblast invasion of the uterus. The degree 
of trophoblast invasion, differing widely in extent among various mammalian orders, 
determines the complexity of the placental barrier separating the two circulations. 
Epitheliochorial placentas (e.g. in m1gulates) are non-invasive, the chorionic trophoblast 
remains closely attached to the intact endometrial epithelium. In the syndesmochorial type 
placentas of sheep and goats trophoblast invasion is arrested after destruction of the 
uterine epithelium. Deeper invasion resulting in the erosion of the endometrial connective 
tissue establishes the endotheliochorial type placenta characteristic of carnivores. Finally, 
when the maternal vessels are also eroded and destroyed by the invasive trophoblast, the 
hemochorial placenta is developed. In this case, the maternal blood is in direct contact 
with the trophoblast. This relationship occurs for instance in rodents and higher primates 
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including the human (Benirsch.ke and Kaufmann, 1990). 
Trophoblast invasion begins with implantation of the blastocyst. In different 
mammals implantation varies with regard to the nature of the in volvem.ent of the uterine 
epithelium. Accordingly, three types of implantation can be distinguished: ( 1) intrusive 
implantation, characterized by trophoblast penetration between intact uterine epithelial 
cells, (2) displacement implantation, in which large areas of epithelium are displaced from 
the tmderlying basal lamin~ and (3) fusion implantation.. where the invading 
syncytiotrophoblast is fused with epithelial cells during penetration of the uterine 
epithelium (Schlafke and Enders.. 1975). In the implantation of the human blastocyst, a 
combination of the fusion and intrusive types are likely to be involved (Denker7 1990). 
After penetration of the luminal endometrial epithelium the expanding 
syncytiotrophoblast continues to invade the epithelial basal lamina and underlying 
maternal tissues. Due to the invasive activity of the syncytiotrophoblast .. some maternal 
capillaries become eroded and may be incorporated into the syncytial lactmar system. At 
this stage.. however, there is no communication with the endometrial spiral arteries. 
During the first month of pregnancy proliferating cytotrophoblasts of the emerging 
trophoblastic shell extend the implantation site and start to invade the decidua where they 
are referred to as intersitial cytotrophoblasts. At the same time, the decidual segments of 
spiral arteries are breached as a result of the fust wave of endovascular trophoblast 
migration. The endovascular trophoblasts appear to be derived from the trophoblastic 
shell, and migrate in the lumen of decidual spiral arteries. However, they do not cross 
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the decidual-myometrial junction in the first few months of pregnancy (Pijnenborg, 1990). 
At 4-6 weeks the trophoblastic shell begins to regress7 but proliferating 
cytotrophoblasts remain at the tips of the anchoring villi (cell columns) (Pijnenborg, 
1990). From 8 weeks these cells migrate into the decid~ and start to invade the inner 
myometrium (interstitial invasion). The myometrial segments of spiral arteries develop 
regressive changes7 such as endothelial swelling, internal vacuolation7 appearance of 
hypertropied basophilic cells and disruption of the media Disintegration of the spiral 
arterial wall is positively correlated with the emergence of perivascular interstitial cells7 
and hence the regressive changes may be viewed as a preparation by interstitial 
trophoblasts for the second wave of endovascular trophoblast invasion7 which affects the 
myometrial segments of spiral arteries7 starts at 14-15 weeks and ends by about 18-20 
weeks. The endovascular trophoblasts replace the endotheli~ and destroy the muscular 
and elastic elements of the vessel wall. Eventually~ the spiral arteries are converted into 
widened tubes, the walls of which are composed of trophoblasts embedded in an 
amorphous fibrinoid material. Due to the absence of normal muscular elements, these 
transformed spiral arteries (also called uteroplacental vessels) can passively accomodate 
the greatly augmented blood flow as pregnancy advances. Although the primary role has 
been assigned here to the endovascular trophoblast, some claim that invasion of the spiral 
arteries is initiated by interstitial trophoblasts from outside the vessels (Kurman et aL, 
1984). 
After 1 0 weeks of gestation a growing number of multinucleated trophoblastic 
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giant cells have also been observed in the decidua and myometrium. These cells appear 
to develop by fusion of interstitial trophoblasts, and probably represent a rmal noninvasive 
stage of cytotrophoblastic differentiation (Pijnenborg, 1990). 
1.4.4 Trophoblast invasiveness: involvement of proteases and protease inhibitors 
During implantation and placental development human trophoblasts invade the 
uterus and come in direct contact with the maternal circulation. Trophoblast invasion 
normally continues tm.til about the fourth month of pregnancy and is restricted to the 
maternal endometrium and the inner third of the myometrium. Various steps of 
trophoblast invasion, including attachment to and detachment from basement membranes 
followed by degradation of basement membrane components, utilize mechanisms very 
similar to those evolved in invasive tumor cells (Lala and Graham., 1990; Graham and 
Lal~ 1992). Yet .. the invasive behavior oftrophoblasts is markedly different from that of 
tumor cells, considering that trophoblast invasion is a temporally and spatially regulated 
process as opposed to the tmcontrolled invasiveness of tumors that lead to the malignant 
destruction of adjacent and distant tissues. 
Trophoblast differentiation along the invasive pathway involves the coordinated 
expression of several classes of molecules, including adhesion receptors, ECM 
components, HLA-G, matrix degrading proteases and their inhibitors etc. Acquisition of 
the appropriate adhesion phenotype is critical to trophoblast invasiveness. Trophoblasts 
express various integrin adhesion receptors for interaction with basement membrane 
constituents such as laminin, collagen type IV and fibronectin. Human rust trimester 
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cytotrophoblast stem cells in the villi express a6J34 integrin~ a receptor for lam in in. As 
these cells enter the cytotrophoblast cell columns., they downregulate the a6p.4 integrin., 
and express primarily the fibronectin receptor a5J31. Cytotrophoblasts in the uterine wall 
express a5~1 and al~l integrins. The latter serves as a receptor for laminin and type IV 
collagen (Damsky et al . ., 1992 ). First trimester cytotrophoblasts differentiating along the 
invasive pathway in vitro recapitulate the pattern of their integrin switching observed in 
situ. Term cytotrophoblasts~ however., which display greatly reduced invasive potential .. 
are unable to up regulate their a 1 J3 1 expression .. suggesting that this molecule is essential 
for trophoblast invasion. Invasion assays involving antibodies to integrin receptors or their 
ECM ligands indicated that interactions between laminin or collagen type IV and their 
a 1 J3 1 receptor promote, whereas fibronectin-a5 J3 1 interactions inhibit trophoblast invasion 
(Damsky et al . ., 1994 ). The observation that laminin-trophoblast interactions promote 
invasion is consistent with laminin stimulation of trophoblast type IV collagenolytic 
activity (Emonard et al ... 1990)., which is known to be necessary for trophoblast 
invasiveness (Graham and Lala., 1992). Pathological evidence for the involvement of 
interactions between trophoblast integrin receptors and ECM components in trophoblast 
invasion has been obtained by Zhou et al. ( 1993) who demonstrated that up regulation of 
a 1 P 1 integrin by invasive cytotrophoblasts fails to occur in preeclampsia, a condition 
characterized by decreased trophoblast invasion. 
The distribution pattern of ECM ligands is also tightly regulated during trophoblast 
invasion (Damsky et al., 1992), and this, along with the coordinated expression of integrin 
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receptors provides a means for trophoblasts to up-., and downregulate their invasive 
potential. Trophoblasts themselves synthesize fibronectin (Queenan et al.~ 1987)., laminin 
and type IV collagen (Autio-Harmainen et al . ., 1991 )., and during their migration they may 
even contribute to the formation of maternal cell-associated ECM., thus facilitating 
trophoblast-ECM interactions. 
By analogy to tumor cells, trophoblasts appear to detach from basement 
membranes by reducing their adhesion to ECM components. Both tumor cells and 
invasive frrst-trimester trophoblasts express f31-6 branched Asn-linked oligosaccharides 
on the cell surface., which serve to reduce adhesive cell-ECM interactions and thereby 
facilitate invasion. Hence expression of branched oligosaccharides is likely to be an 
important part of the invasive trophoblast phenotype (Yagel et al . ., 1989, 1990~ Graham 
and Lal~ 1992 ). 
Another molecule linked to differentiation of cytotrophoblasts along the invasive 
pathway is HLA-G (McMaster et aL, 1995). Expression of HLA-G in vivo is confined 
to invasive cytotrophoblasts of the cell columns and uterine wall. Consistent with this 
observation, In.A-G was exclusively produced by isolated cytotrophoblasts that invaded 
Matrigel (Collaborative Research Inc., Bedford., MA)., an ECM substrate, in an in vitro 
invasion model. In addition., cytotrophoblasts purified from frrst-., second-, and third-
trimester placentas respectively upregulated their lll..A-G production when cultured on a 
thin layer of Matrigel, but the mRNA levels remained lDl.changed all over the culture 
period suggesting postranscriptional regulation. High levels of HLA-G m.RNA were 
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detected in rust- and second trimester cytotrophoblasts, whereas only trace amounts were 
found in term cytotrophoblasts committed at least in vivo to the noninvasive pathway of 
differentiation. 
Breakdown of ECM barriers during trophoblast invasion depends on trophoblast-
secreted proteolytic enzymes. In particular, urokinase-type plasminogen activator (u-P A) 
and matrix-degrading metalloproteinases appear to endow trophoblasts with degradative 
properties necessary for invasiveness (Graham and Lala, 1992). u-PA may cleave ECM 
components., including fibronectin (Gold et al.., 1989}., but it is not considered to be an 
efficient direct mediator of matrix degradation. By activating plasminogen., however, it 
can trigger a proteolytic cascade leading to the activation of metalloproteinases that 
directly degrade numerous matrix components (Matrisian~ 1992 ). Moreover., it may 
proteolyti.cally process the 72 kDa type IV collagenase (Keski-Oja et al.., 1992). Plasmin 
may also degrade a variety of matrix proteins., includin fibronectin.,laminin., proteoglycans 
and type IV collagen (Liotta et al.., 1981; Goldfarb et al . ., 1986~ MacKay et al.., 1990). 
Also. it can activate metalloproteinases.. including interstitial procollagenase and 
prostromelysin (Matrisian~ 1992 ). The matrix-degrading metalloproteinase (MMP) family 
plays important roles in processes requiring extensive ECM remodelling, such as 
embryonic development or tumor invasion (Matrisian., 1990 ). On the basis of substrate 
specificity metalloproteinases can be divided into three groups: the collagenases, 
gelatinases, and stromelysins (Matrisian, 1992 ). The collagenase group includes the 
interstitial collagenase (MMP-1) and neutrophil collagenase (MMP-5). While both 
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collagenases share the ability to degrade collagens I~ IT~ and m .. interstitial collagenase has 
somewhat wider specificity as it can also cleave collagens vn and X. Gelatinases are 
specific for denatured collagens (gelatins)~ elastin and collagen types IV and V. The 
gelatinase group has two members that have been designated tmder various names: ( 1) 
gelatinase A also known as 72 kDa type IV collagenase or l\.fl\.1P-2~ and (2) gelatinase B 
(92 kDa type IV collagenase, "MMP-9). The third group is the stromelysins that include 
stromelysin 1 (MMP-3 ), stromelysin 2 (MMP-1 0 )7 and matrilysin (MMP-7). They all 
degrade a number of substrates~ such as proteoglycans~ fibronectin., laminin., gelatins., 
elastin and collagen IV. 
1.4.4.1 Mattix degradauon by die periimplantafion blastocyst 
It has long been known that blastocyst-associated proteases are essential for the 
success of implantation (Denker., 1977). Cultured mouse blastocysts and trophoblasts have 
been shown to secrete plasminogen activator., with a pattern of enzymatic activity that 
corresponds closely with the limited period of trophoblast invasiveness in vivo (Strickland 
et al . ., 1976). Trophoblast outgrowth by mouse blastocysts cultmed on monolayers of 
decidual cells could be inhibited by plasminogen-depleted serum or nitrophen.ol-p-
guanidino benzoate (NPGB) that prevented trophoblast plasminogen activation (Kubo et 
al . ., 1981 ). It has also been reported that implantation-defective mouse blastocysts produce 
less fibrinolytic activity than control blastocysts (AxelrocL 1985). Zymographic and 
Northern blot analyses of extracts of trophoblasts isolated from cultured blastocysts 
identified u-P A as the exclusive plasminogen activator synthesized by mouse trophoblasts 
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in vitro., and furthermore., expression of the u-P A gene has been demonstrated by invasive 
trophoblast cells in vivo (Sapino et al., 1989). The accumulated results thus appear to 
suggest that activation of plasminogen by trophoblasts is implicated in the process of 
implantation. Other reports9 in tum., do not support the view that trophoblast-secreted u-
PA has a major role in ECM degradation. Matrix degradation by mouse trophoblast 
outgrowths has not been significantly affected by plasminogen depleted serum or 
inhibitors of plasminogen activation (Glass et aL., 1983: Behrendson et al.~ 1992), and in 
addition, u-PA and u-PAR deficient mice can apparently implant normally (Carmeliet et 
al.., 1994~ Bugge et al . ., 1995). 
Recently, cultured mouse blastocysts have been shown to express matrix-degrading 
metalloproteinases, including 92-kD gelatinase and stromelysin, and tissue inhibitors of 
metalloproteinases (TThfP-1,-2.,-3) (Brenner et al., 1989; Behrendtsen et al.9 1992; Harvey 
et al . ., 1995). Degradation of ECM by trophoblast outgrowths in blastocyst culture was 
inhibited by neutralizing antibodies to 92-kD gelatinase., and TIMP (Behrendtsen et al., 
1992 ). These findings point to metalloproteinases as essential mediators of matrix 
degradation by trophoblast cells. 
1.4.4.2 Expression of matrix-degrading proteinases and their inhibitors by human 
tro pho blasts 
Martin and Arias (1982) demonstrated the secretion of plasminogen activator by 
cultures of human ftrst trimester trophoblasts., and Queenan et al. ( 1987) reported that the 
plasminogen activator activity measured in term trophoblast cultures was originated from 
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u-PA production. Zini et al. (1992) provided immunocytochemical evidence for the 
expression of u-P A by cultured term trophoblasts't and detected secreted u-PA't PAI-l and 
PAI-2 antigens in trophoblast conditioned media Furthermore, synthesis of PAI-l and 
PAI-2 by cultured trophoblasts have been confumed by immunocytochemistry and 
Northern blot hybridization (Feinberg et al., 1989). Cellular localization of plasminogen 
activator inhibitors have also been studied in vivo. PAI-l was primarily localized in 
trophoblasts invading the decidua and myometrium't while only weak imnu.moreactivity 
was found in the villous syncytiotrophobl~ and cytotrophoblasts did not stain. PAI-2 
staining was characteristic of the syncyti~ but there was no obvious staining in villous 
cytotrophoblasts and extravillous invading trophoblasts. It thus appears that PAI-l is a 
marker of invasive extravillous (intermediate) trophoblasts in vivo (Feinberg et al., 1989). 
Differentiation of cytotrophoblasts into syncytiotrophoblasts in culture is associated with 
gradually declining u-PA secretion, u-PAR mRNA expression and u-PA binding. 
Urokinase receptors on cultured trophoblasts are saturated with endogenous prourokinase't 
which is converted into active two-chain urokinase by a mechanism largely, but perhaps 
not exclusively, dependent on the presence of plasminogen. First-trimester 
cytotrophoblasts express more urokinase receptors than cytotrophoblasts isolated from term 
placentas. In addition, the ability of frrst trimester cytotrophoblasts to generate plasmin 
appears to exceed that of term cytotrophoblasts (Zini et al., 1992 ). Urokinase receptors 
in vivo are strongly expressed by villous cytotrophoblasts and syncytiotrophoblast in the 
frrst and second trimesters, whereas their expression is markedly diminished at term. 
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Extravillous cytotrophoblasts expressed u-PAR predominantly at their leading edge 
consistent with a role for u-PA in directing plasminogen activation during trophoblast 
invasion (Multhaupt et al.~ 1994). In conclusion., these findings taken together indicate 
that human trophoblasts express several elements of the plasminogen activation system in 
a developmentally regulated manner. 
Several cell-associated and secreted gelatin-degrading metalloproteinases have been 
detected by zymographic analysis of human trophoblast cultures. Cytotrophoblasts derived 
from early or term placentas differed in their ability to express distinct types of these 
proteases. First trimester trophoblasts produced a complex array of metalloproteinases 
(Fisher et al.., 1989; Bischof et al . ., 1991 )., whereas second- and third trimester trophoblasts 
displayed a simple pattern of expression (Fisher et al.~ 1989). Furthermore~ fust trimester 
trophoblasts produced significant 92 kD and 72 kD type IV collagenolytic activities. At 
term., the synthesis of the 92 kD type IV collagenase was greatly reducecL and only 
minimal 72 kD activity was detectable (Fisher et al . ., 1989; Shimonovitz et al.~ 1994 ). 
Secretion of the 92 kD type IV collagenase antigen (Librach et aL., 1991) and the mRNA 
expression of both type IV collagenases (Shimonovitz et al.~ 1994) followed similar 
temporal pattern. There was also a fairly good correlation between the production of these 
gelatinases and temporal expression of invasiveness in vivo, suggesting that the 72 kD and 
92 kD type IV collagenases are needed for trophoblast invasion. Distribution of 
metalloproteinases and their inhibitors has been recently mapped in the human placenta. 
Interstitial collagenase (Moll and Lane~ 1990) and 72 kD type IV collagenase (Fernandez 
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et al.,. 1992) were localized in first-trimester trophoblasts of both villous and extravillous 
(intermediate) types. Palette et al. (1994) documented the expression of gelatinase A and 
B and their inhibitors by immlDlohistochemistry., North em blot analysis and in situ 
hybridization. Gelatinase A (72 kD type IV collagenase) was primarily present in first-
trimester intermediate trophoblasts. Gelatinase B was also expressed in villous 
trophoblasts of floating villi where it was found codistributed with TIMP-2. In term 
placentas .. gelatinase B was no longer detectecL whereas TIMP-2 expression continued 
tm.til term. 
1.4.4.3 Degradation and invasion of extraceUular matrices by human cytotrophoblasts 
Fisher et al. ( 1985) demonstrated that cytotrophoblast outgrowths of isolated frrst-
trimester placental villi degraded extracellular matrices containing basement membrane 
proteins. By contrast,. no evidence of matrix degradation was obtained if second- or third-
trimester villi were tested. Consistent with these findings., isolated first trimester 
cytotrophoblasts also degraded the matrices on which they were cultured (Fisher et al.,. 
1989; Bischof et al ... 1991 }. but again degradation was not observed by cytotrophoblasts 
prepared from second- or third-trimester placentas (Fisher et al.,. 1989). Kliman and 
Feinberg (1990) reportecL however., that both fust- and third-trimester cytotrophoblasts 
displayed degradative activity depending on the ECM thickness. 
Several authors assayed trophoblast invasiveness,. employing in vitro invasion 
models, based on the ability of cytotrophoblasts to invade natural and artificial basement 
membranes (Yagel et al., 1988; Kliman and Feinberg, 1990; Librach et al., 1991; Graham 
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and Lala, 1991; Shimonovitz et al., 1994). The in vitro invasive capability of 
cytotrophoblasts isolated from placentas of various gestational ages is a question that has 
given rise to some controversy. While it is abundantly clear that first-trimester 
cytotrophoblasts are highly invasive (Kliman and Feinberg, 1990; Librach et al. 1991 ~ 
Shimonovitz et al., 1994 ), there is no agreement on whether term cytotrophoblasts retain 
their invasive capacity in vitro. Librach et al. (1991) showed that term cytotrophoblasts 
did not penetrate an artificial basement membrane (Matrigel), whereas others pointed out 
that isolated cytotrophoblasts at term possess some invasive potential (Kliman and 
Feinberg~ 1990~ Graham and Lala, 1992~ Shimonovitz et al., 1994). 
Considerable progress has been made towards elucidation of the proteolytic 
mechanisms utilized by trophoblasts to invade basement membranes (Yagel et al., 1988; 
Lala and Graham, 1990; Librach et al., 1991; Graham and Lala, 1992). Yagel et al. 
( 1988) examined the role of serine and metal.loproteinases in mediating the invasiveness 
of the malignant human JAR choriocarcinoma and murine B16F10 melanoma lines and 
of normal trophoblast lines established from rust-trimester human placentas. Normal 
trophoblasts and metastatic malignant cells demonstrated similar capacity for the invasion 
of an epithelium-free human amniotic membrane and had some invasion-promoting 
proteolytic mechanisms in common. Inhibitors of metalloproteinases ( 1,1 0-phenanthroline, 
TIMP) or serine proteases ( aprotinin, epsilon aminocaproic acid, and an antiplasminogen 
antibody) almost completely blocked the invasiveness of both the normal trophoblast and 
malignant cell lines. The collagenase activator Mersalyl (Sigma, St. Louis., MO) enhanced 
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the invasion by all the three lines investigatecL and this effect could not be prevented by 
simultaneous administration of aprotinin. Lala et al. ( 1990) also reported that collagenase 
activity was reduced in trophoblast cultures grown in plasminogen-deficient (serum-free) 
media and inhibited by aprotinin in the presence of serum. 
Librach et al. ( 1991) showed that metalloproteinase inhibitors (TIMP and TIMP-2) 
and a neutralizing antibody to the 92 kD type IV collagenase completely abrogated the 
ability of frrst-trimester cytotrophoblasts to invade Matrigel. In contr~ an antibody that 
inhibits interstitial collagenase had no effect on cytotrophoblast invasiveness. 
Plasminogen activator inhibitors (PAI-l and PAI-2), a neutralizing antibody to u-P A and 
aprotinin only partially (20-40%) inhibited invasion .. whilst ~-antiplasmin had negligible 
effect. These results contrast those of Yagel et al. ( 1988) who reported a nearly complete 
blockade of cytotrophoblast invasion by inhibitors of the plasminogen activation system. 
In a review on the mechanisms of trophoblast invasion .. Graham and Lala ( 1992) proposed 
that serum-free media lacking plasminogen may account for the moderate anti-invasive 
effect observed in the Matrigel system of of Librach et al. ( 1991 ). In this case, small 
amotmts ofplasmin(ogen) remaining associated with the trophoblast membrane could only 
take part in the proteinase cascade. 
Overall .. the above studies suggest that a proteinase cascade involving metallo- and 
serine proteinases mediate trophoblast invasiveness and the 92 kD type IV collagenase is 
rate-limiting for invasion. Serine proteinases appear to play a role by turning on 
metalloproteinase activation .. although direct stimulation of invasiveness by plasmin or u-
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PA cannot be completely ruled out either. 
1.4.4.4 Control of trophoblast invasiveness: role of facton modulating trophoblast 
proteinase activity 
Mouse trophoblasts turned out to be more invasive when developed in non-
pregnant uteri or extrauterine sites than in pregnant or pseudopregnant decidualized uteri 
(Kirby, 1965 ). Similarly, placenta accreta or ectopic pregnancy in humans~ conditions 
with little or no decidual tissue, are associated with increased trophoblast invasion 
(Billington, 1971 ). These fmdings indicate that trophoblasts are intrinsically invasive and 
their invasiveness is tmder decidual control. 
Conditioned media from fust trimester human decidual cells (DCM) inhibited 
trophoblast invasiveness in vitro (Graham and Lala, 1991; Graham et al., 1993). This 
inhibition was completely prevented by either a neutralizing antibody to TGF-f3 or TIMP-
1, and reproduced by TGF-f31 alone. The same antibodies also stimulated invasiveness 
above control levels .. suggesting that the decidua controls trophoblast invasiveness by 
producing TGF-(3 and TIMP-1 which are also elaboratecl however, by trophoblasts 
themselves. Results from another laboratory (Bass et aL. 1994) are in apparent contrast 
to those just quoted. Accordingly, TGF-J31 had no effect in a Matrigel invasion assay. 
The reason for the lack of effect may lie in the relatively high TGF-J3 content of Matrigel 
(Vukicevic et al., 1992 ). TGF-f3 activity measurements demonstrated that decidual cells 
release latent TGF-f3, while trophoblasts produce this growth factor in the active form. 
TGF-131 reduced collagenase type IV activity, and anti-TGF-13 resulted in a significant 
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decrease in TIMP mRNA level as well as activity in f'rrst trimester trophoblast cultures. 
Moreover~ TIMP activity was completely abrogated by addition of anti-TGF-~ to decidual 
cultures. Thus~ decidua and trophoblast derived TGF-~ inhibits trophoblast invasion by 
inducing TIMP-1 production in both decidual cells and trophoblasts. TIMP-1 ~ in tum., can 
directly inhibit type IV collagenases that are critical to trophoblast invasion. Consistent 
with these findings., TGF -~1 upregulated the levels of both TIMP-1 and the 3.5 kb TIMP-2 
messages in normal first trimester trophoblasts (Graham et al.~ 1994 ). 
An additional mechanism through which TGF-~ can exert its anti-invasive effect 
ts downregulation of u-PA activity, as demonstrated by casein zymography of first 
trimester trophoblast-conditioned media (Graham et al.~ 1993, 1994). Whether this effect 
is due to upregulation of PAI-l activity or downregulation of u-P A synthesis remains to 
be investigated. Moreover, the trophoblast plasminogen activation system may turn on 
the TGF-J}-dependent., invasion-inhibiting pathway by plasmin-mediated activation of the 
decidua-derived latent TGF-~ (Graham and Lala, 1992; Strickland and Richards, 1992). 
This may be one way by which trophoblasts can possibly interact with decidual cells to 
control their own invasiveness. Autocrine inhibition of invasion via production of 
endogenous TGF-131 also remains a possibility (Lala and Graham., 1990). TGF-~ also 
inhibits trophoblast invasiveness by other mechanisms, including increased differentiation 
of invasive mononuclear trophoblasts into non-invasive multinuclear cells (Graham et al., 
1992 ), and reduction of trophoblast migration via modulation of cell surface integrin 
expression (Irving and Lala, 1995). Whether these mechanisms are independent of the 
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TGF-J3-induced downregulation of of u-PA and type IV collagenase activities are not 
known and therefore await clarification. 
In additon to TGF-~, several other maternally and fetally derived molecules have 
been shown to regulate trophoblast protease activity as well as invasiveness. Librach et 
al. ( 1994) reported that ll..-1 13 stimulated :MMP-9 (92 kDa type IV collagenase) protein 
production and activity by fust-trimester human cytotrophoblasts. It also enhanced 
cytotrophoblast invasion. LPS, which upregulated cytotrophoblast production of ll..-1 J3, 
mimicked these effects. Conversely, dexamethasone and cortisol decreased IL-l J3 
production and inhibited MMP-9 secretion and trophoblast invasiveness. These results 
suggest that trophoblast-derived ll..-113 may act as an autocrine mediator in controlling 
trophoblast invasiveness via modulation of pericellular metalloproteinase activity. As 
decidual production of IL-113 is known (Romero et al., 1989~ Kauma et al., 1990), 
paracrine stimulation of trophoblast invasiveness by IL-113 is also highly probable. 
During early murine development u-PA and MMP-9 are strongly expressed by 
invasive trophoblasts (Strickland et al., 1976; Sappino et al., 1989~ Behrendtsen et al.., 
1992~ Harvey et al., 1995). Trophoblast outgrowths of cultured mouse blastocysts on day 
7 of development., which coincides with the period of trophoblast invasion of the uterus 
in vivo, responded to EGF or leukaemia inhibitory factor (LIF) stimulation by increased 
production of both u-P A and l\1MP-9 activities (Harvey et al., 1995). Uterine expression 
of EGF and LIF is triggered by maternal estrogen at the time of implantation (Huet-
Hudson et al., 1990~ Bhatt et al., 1991 ~ Cross et al., 1994 ). It thus appears that the uterus 
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controls trophoblast proteinase expression and invasiveness by estrogen dependent 
secretion of LIF and EGF. This mechanism may tum out to be critical to implantation~ 
considering that blastocysts of mice lacking a ftmctional LIF gene fail to implant (Stewart 
et aL, 1992)~ and mouse blastocysts having no EGF receptors die shortly after initiation 
of implantation (Harvey et al.~ 1995). 
hCG treatment of human trophoblast cultures has been reported to suppress 
urokinase and general serine protease as well as the 92 kDa collagenase activities in 
conditioned media (Milwidsky et al., 1993; Y agel et al.~ 1993 ). In addition, 
nonphysiologically high concentrations ofhCG or FSIL a structurally related glycoprotein 
hormone, also caused a partial direct inhibition of purified urokinase preparations. hCG-
mediated inhibiton of neither u-PA nor collagenase activities could be ascribed to a 
decreased synthesis of these enzymes or an increase in the synthesis of metalloproteinase 
inhibitors~ because hCG had no effect on u-P A~ collagenase or TIMP m.RNAs and TIMP 
protein secretion. As hCG did not inhibit collagenase IV or plasmin preparations either, 
it has been suggested that hCG controls trophoblast metalloproteinase activity via a 
urokinase-mediated cascade that involves the generation of plasmin. In accordance with 
the proposed role of proteinases in invasiveness (Mignatti and Rifkin, 1993)~ hCG 
downregulation of enzyme activities was accompanied by inhibition of trophoblast 
invasion through amniotic basement membranes (Yagel et al., 1993). 
Dexamethasone that inhibits trophoblast invasion and :MMP-9 activity (Libracb. et 
al.~ 1994) also caused a dose-dependent decrease in plasminogen activator production by 
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first-trimester human trophoblast cultures (Martin and Arias, 1982). Therefore, plasmin-
dependent control of trophoblast metalloproteinase activity and invasion by maternal 
glucocorticoids is a possible scenario in vivo. 
Extracellular matrix (ECM) components are also involved in regulating trophoblast 
protease activity. Laminin and fibronectin are effective stimulators of uP A production in 
cultured mouse blastocysts., suggesting that trophoblast-ECM interactions may control 
trophoblast invasion by regulating PA activity (Zhang et al . ., 1996). Moreover., both 
malignant and normal first-trimester human trophoblasts increased their expression of 
interstitial and type IV collagenase activities when cultured on type I collagen or Matrigel 
containing various ECM proteins. Laminin., however., selectively increased type IV 
collagenase activity without having any effect on interstitial collagenase activity (Emonard 
et al . ., 1990 ). 
1.4.5 Plasminogen activation in normal and preedampeic pregnancy: role of the 
trophoblast 
Plasma fibrinolytic activity decreases progressively during normal pregnancy, and 
is barely detectable at term (Bonnar et al... 1990; Astedt., 1993 ). It rapidly returns., 
however, to non-pregnant values shortly after separation of the placent~ which suggests 
that this organ is essential for maintaining the depressed fibrinolytic activity in pregnancy 
plasma. A marked elevation in PAl activity, involving increased secretion of both PAI-l 
and PAI-2, has been shown to account for this condition. The pregnancy-induced 
suppression of fibrinolytic activity may be viewed as a physiologic adaptation which., 
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however~ contributes to the increased risk of venous thromboembolism in pregnancy. 
Exaggerated suppression of fibrinolytic activity has been found in preeclampsia 
(Bonnar et aL .. 1971~ Yoshimura et aL. 1985}. a common pregnancy-induced syndrome 
that endangers the lives of both the mother and fetus. Although it is recognized primarily 
by maternal hypertension and protein uri~ various maternal abnormalities~ including those 
of the liver .. brain .. blood vessels .. coagulation and fibrinolytic system., render the disesase 
polymorphic (Weiner., 1988; Roberts.. 1989; Bonnar et al . ., 1990; Redman., 1990 ). 
Preeclampsia occurs with high frequency in hydatidiform mole in which the uterus 
contains only disordered placental tissue. Removal of the placental tissue cures the 
disease. This implies that the fetus is not necessary for the disease to develop and 
suggests that preeclampsia is a trophoblastic disorder with secondary maternal 
manifestations (Redman~ 1990., 1993 ). According to the current perception the most likely 
factor underlying the pathogenesis of preeclampsia is placental ischaemia secondary to 
structural abnormalities of maternal spiral arteries (Redman.. 1993 ). In preeclampsia 
trophoblast invasion of the myometrial segments of the spiral arteries does not occur 
(Brosens et al.~ 1972; Gerretsen et al . ., 1981) or is deficient (Meekins et al... 1994 ). 
Trophoblast invasion may be incomplete in some decidual spiral arteries as well (Khong 
et al.~ 1986; Meekins et al... 1994 ). The partial failure in the conversion of the spiral 
arteries to uteroplacental vessels is believed to be a major cause of the reduced blood flow 
to the placenta in preeclampsia (Redman, 1993). The reason for this failure is obscure. 
It is known., however, that several components of the proteolytic cascade mediating 
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trophoblast invasiveness is abnormally altered in preeclampsia Plasminogen activator 
activity is reduced in placental tissue (Yoshimura et al.~ 1985) and plasma (Bonnar et al.~ 
1971) of women with preeclampsia Furthermore~ trophoblasts purified from placentas of 
preeclamptic patients secrete less activated 1\lflviP-9 and express reduced cell surface-
associated PA activity compared to trophoblasts from normal placentas (Graham and 
McCrae, 1996). The diminished expression of trophoblast-associated protease activity 
may restrict trophoblast invasion and is likely to contribute to the widespread fibrin 
deposition seen in spiral arteries (Bonnar et al . ., 1990) and the placental villous tissue 
(Kanfer et al . ., 1996) in preeclampsia. Excess fibrin deposition may also reduce the 
uteroplacental blood flow thus causing placental ischaemia Elevated PAI-l activity and 
antigen levels have been fol.Dld in both the plasma and placental extracts from women 
with preeclampsia (Estelles et al . ., 1989, 1994; Bonnar et al.~ 1990; Reith et al.~ 1993 ), 
suggesting that increased PAI-l secretion is responsible for the excessive suppression of 
fibrinolytic activity. By contrast, plasma PAI-2 antigenic levels in preeclampsia are 
significantly lower than those in normal pregnancy (Reith et al.., 1993; Estelles et aL .. 
1994). In preeclampsi~ increased production of PAI-l has been localized in villous 
syncytiotrophoblasts which produced significantly less PAI-2 compared to 
syncytiotrophoblasts of placentas from normal pregnancies (Estelles et al.., 1994 ). The 
reason for the altered synthesis of PAI is, at present., totally unknown. Elucidation of the 
mechanisms leading to abnormal regulation of the plasminogen activation system in 
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preeclampsia may bring us one step closer to understanding the pathogenesis of this severe 
disorder. 
l.S RATIONALE AND OBJECI1VES 
The ability of human trophoblasts to invade the uterine wall and possibly regulate 
fibrin deposition at the sites of invasion and in the placental intervillous spaces appears 
to be linked to their plasmin generation. Plasminogen activation by trophoblasts must be 
exquisitely regulated to ensure proper realization of the trophoblast proteolytic potential 
critical to normal placental development and function. Abnormal regulation of trophoblast 
plasminogen activation may lead to disordered placentation such as in preeclampsia. 
Hence, a clear tmderstanding of the normal fmlction as well as regulation of trophoblast 
plasminogen activation is not only of physiological importance7 but may also provide 
potential clues to elucidating the pathogenesis of this disorder. It is hypothesized that 
autocrine, paracrine and endocrine regulatory influences control the activation of 
plasminogen by trophoblasts. 
The primary objectives of this thesis are: 
( 1) to purify and culture a pure population of human term villous cytotrophoblasts that 
allows studying trophoblast plasminogen activation in the absence of contaminating cells, 
(2) to examine the expression of plasminogen activators and their inhibitors by 
trophoblasts in vivo and in culture, and 
(3) to define modulators of trophoblast plasminogen activation in vitro. 
2.1 MATERIALS 
CHAPrERl 
MATERIALS AND METHODS 
2.1.1 Materials for ceO culture 
Trypsin .. DNase and bovine serum albumin (BSA) were purchased from Sigma 
Chemical Company (St. Louis .. Missouri). Dulbecco's Modified Eagle Media.. Dulbecco's 
Phosphate-Buffered Saline .. Hanks' Balanced Salt Solutions (HBSS) .. HEPES .. penicillin .. 
streptomycin .. kanamycin .. and Fungizone were purchased from Gibco (Burlington .. 
Ontario). Fetal bovine serum was obtained from Cansera (Rexdale .. Ontario). A 
microcarrier spinner flask and magnetic stirrer were obtained from Bellco (Vineland.. New 
Jersey). A stainless steel sieve (I 04 Jlill) and 40 fJ.I11 nylon mesh for vacuum ftltration 
were supplied by Sigma Chemical Company (St. Louis .. Missouri) and Small Parts Inc. 
(Miami Lakes .. Florida), respectively. Percoll, density marker beads and peristaltic pump 
were supplied by Pharmacia (Baie D'urfe, Quebec). Tissue culture plates .. dishes, tubes 
and Thermanox coverslips were from Nunc (distributed by Gibco .. Burlington, Ontario). 
Square and round glass coverslips .. and culture slides were supplied by Fisher (Dartmouth, 
Nova Scotia). 
2.1.2 Antibodies 
Monoclonal mouse antibodies to cytokeratin, vimentin, CD68 .. In..A-ABC, IaA-
DR, and negative control mouse lgG 1 and lgG2a were purchased from DAKO (distributed 
by Dimension Laboratories .. Mississauga, Ontario). Swine anti-rabbit im.mtm.oglobulins .. 
rabbit PAP .. normal rabbit immunoglobulins as well as polyclonal rabbit antibodies to 
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alpha-1-antichymotrypsin (ACT),. beta-2-microglobulin,. human placental lactogen (hPL),. 
and human chorionic gonadotropin (hCG) were also supplied by DAKO (distributed by 
Dimension Laboratories., Mississauga,. Ontario). Normal horse serum .. biotinylated anti-
mouse IgG., biotinylated anti-rabbit IgG .. avidin., and biotinylated HR.P were from Vector 
Laboratories (distributed by Dimension Laboratories., Mississauga., Ontario). Normal goat 
immunoglobulin .. antibodies to PAI-I. PAI-2 .. UK .. t-PA were provided by American 
Diagnostica (Greenwich., Connecticut) and Biopool (Burlington., Ontario). Anti-human 
EGF neutralizing antibody was obtained from R&D Systems Inc. (Minneapolis., MN). 
Dynabeads M-450 coated with goat anti-mouse lgG was purchased from Dynal 
(distributed by Harlan Bioproducts for Science Inc ... Indianapolis .. Indiana). 
2.1.3 Fibrinolysis and coagulation products 
Pro-urokinase (scu-PA) .. activated human protein C (APC) .. recombinant PAI-l .. 
recombinant PAI-2., and Imubind PAI-l ELISA kits were purchased from American 
Diagn.ostica (Greenwich., Connecticut). Human Glu-plasminogen was obtained from 
Biopool (Burlington, Ontario). H-0-Valyl-L-Leucyl-L-Lysin-p-Nitroanilin (S-2251) was 
supplied by Helena Laboratories (Mississauga., Ontario). Human a-thrombin was 
purchased from Sigma Chemical Company (St. Louis., Missouri). 
2.1.4 MisceUaneous chemicals 
Human recombinant transforming growth factor-a (TGF-a) and insulin-like growth 
factor II were obtained from Gibco (Burlington .. Ontario). Human recombinant interleukin 
I beta (IL-l rl) .. transforming growth factor beta 1 (TGF-rl1) were purchased from R&D 
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Systems Inc. (Minneapolis., Minnesota). Epidermal growth factor (EGF)., phorbol 12-
myristate 13-acetate (PMA)., dexamethasone .. human chorionic gonadotropin (hCG)., 8-
bromoadenosine3:5'-cyclicmonophosphate(8-bromo-cAMP).,forskolin,lipopolysaccharide 
(LPS) from E. coli 0 Ill :B4., 3-( 4,5-dimethylthiazol-2-yl)-2 .. 5-diphenyltetrazolium bromide 
(MIT) .. and protease type XIV were supplied by Sigma Chemical Company (St. Louis., 
Missouri). hCG MAIAclone kits were purchased from Serono (distributed by NCS 
Diagnostics Inc . ., Etobicoke., Ontario). Tritiated methyl-thymidine was obtained from ICN 
(Mississauga., Ontario). Filters for cell harvesting were supplied by Skatron (Sterling, 
Virginia}. Liquid scintillation cocktail (Ready Protein+) was purchased from Beckman 
(Mississauga., Ontario). 
2..2 ME'IHODS 
2.2.1 Isolation and culture of cytotrophoblasu 
2.2.1.1 Mecbauical processing of the placental ussue 
Fifty-six normal human term placentas were obtained from uncomplicated Cesarean 
sections or occasional vaginal deliveries. Small blocks of villous tissue dissected from 
the softest, thickest portions of cotelydons .. carefully avoiding the chorionic plate., decidua 
basalis and fibrous areas, were gently pressed and washed in D-PBS several times to 
remove as much blood as possible. Finally, the tissue blocks were coarsely chopped into 
3-5 mm pieces. 
2.2.1.2 Enzymatic disaggregauon 
Digestion of the chopped villous tissue was performed using the procedure of 
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Kliman et al. (1986) to which some minor modifications were added About 80 g of 
chopped tissue was transferred into a micro carrier spinner flask (Bellco) with 300 ml of 
Caz.t- and M~ free HBSS, containing 25 mM HEPES, pH 7 .4~ 100 units/mL penicillin, 
100 J.Lg/mL streptomycin, 100 iJg/mL kanamycin~ 2.5 iJg/mL Ftmgizone, 13000 tmits/mL 
trypsin, and 300 Kunitz units/mL DNase. The mixture was incubated at 37 oc for 30 min 
tmder continuous stirring at 40 rpm on a Bellco J.L-carrier magnetic stirrer. An additional 
30000 Kunitz units of DNase were added after the initial 10 min incubation. After tissue 
fragments were allowed to settle for 1 min, the supernatant was carefully decanted into 
50 mL plastic centrifuge tubes containing 5 mL FCS and mixed by inversion. The tissue 
fragments were resuspended in 100 mL of HBSS, and the supernatant was obtained as 
before. Next., the supernatants were centrifuged at 1000 x g for 10 min. Finally, the 
pellet was resuspended in Dl\tfEM containing 20% FCS and allowed to stand tmtil the 
remaining two digestions were completed. The technique of the second and third 
digestions was essentially the same as that described above, except that the volume of the 
trypsin/DNase mixture was adjusted to 200 and 150 mL, respectively .. and no extra DNase 
was admixed following the initial 10 min incubation. The resuspended pellets from all 
three digestions were rtltered through a 104 J,Lm stainless steel sieve {Sigma) and then 
through a 40 J.lm nylon mesh (Small Parts Incorporation) by vacuum ftltration. 
2.2.1.3 Percoll density gradient centrifuganon 
Separation of cytotrophoblasts at their buoyant densities was performed as reported 
by Kliman et al. ( 1986). The placental cell suspension obtained by enzymatic 
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disaggregation was sptm at 1000 g for 10 min. The pellet was resuspended in HBSS to 
a final volume of 8 m.L and then the suspension was divided into two 4 mL aliquots. Each 
aliquot was carefully loaded onto a preforme~ discontinuous Percoll gradient in a 50 m.L 
plastic tube. The gradient was prepared by layering, using a peristaltic pump, 3 mL each 
of 70% to 5% Percoll diluted with HBSS from 90% Percoll (9 parts (v/v) ofPercoll mixed 
with 1 part (v/v) lOx HBSS) in S % gradations. The gradients loaded with the cell 
suspension were centrifuged at 1200 x g for 20 min and the cells forming a band at 
densities between 1.051 and 1.063 g/m.L were collected. Densities were determined by 
running an identical gradient loaded with color-coded density marker beads. The collected 
cells were diluted 5 times in culture medium (D:MEM supplemented with 100 units/m.L 
penicillin, 1 00 J.Lg/mL streptomycin, 100 J.Lg/mL kanamycin, 2.5 J.Lg/mL Ftmgizone and 
20% FCS) and pelleted at 1 000 g. The cells were washed once more and kept 
resuspended in culture medium until further purification. 
2.2.1.4 Immunomagneuc separauon of villous cytotrophoblasts 
Percoll-purified cytotrophoblasts were further purified by imm.l.Ulomagnetic cell 
separation using a modification of the method of Douglas and King (1989). Non-
trophoblastic elements were removed by incubating the cells with anti-HLA antibodies 
boWld to secondary antibody-coated magnetic beads. Briefly, to a mixture of 10 J.1L (0.94 
J.Lg) of monoclonal anti-HLA-ABC (DAKO) and 20 J.LL ( 1.06 J.L8) of anti-HLA-DR 
(DAKO) antibodies 40 f.lL (1.6 x 107 beads) Dynabeads M-450 Goat anti-Mouse IgG 
(DYNAL) were added in sterile microcentrifuge tubes. Control tubes received 9.4 J,LL 
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(0.94 J,lg) mouse IgG2a (DAKO) and 10.6 J..LL (1.06 J.l8) mouse IgGI (DAKO) negative 
control antibodies in place of the anti-Fn..A antibodies. The antibody mixtures were 
incubated for 4 hours at room temperature under rotation for even mixing. The beads 
were collected with a Dynal Magnetic Particle Concentrator and then washed 4 times for 
30 min with Cal+ and M~ free HBSS supplemented with 100 units/mL penicillin~ 100 
j.tg/mL streptomycin, 1 00 J,tg/mL kanamycin, 2.5 JJg/mL Fungizone and I% heat-
inactivated FCS (complete HBSS). The preformed antibody-bead complexes were stored 
in 250 JJL of complete HBSS at 4 oc until use. Percoll-purified cytotrophoblasts were 
washed once with cold complete HBSS and the cell concentration was adjusted to 1. 7 x 
1 0 7 /mL. Two htmdred and fifty J.LL ( 4 x 1 06 ) cells were then mixed with 250 J.lL 
preformed antibody-bead complexes ( 4:1 bead to cell ratio) and incubated on ice for 45 
min under occasional gentle mixing by inversion. Villous cytotrophoblasts were collected 
by aspirating the supernatant while the microcentrifuge tubes were in the Magnetic 
Particle Concentrator. Finally, the cells were spl.ttl at 400 x g and resuspended in culture 
medium. 
2.2.1.5 Primary trophoblast culture 
Cytotrophoblasts were plated out at various densities into 96-well Ntm.clon plates, 
24-well Nunclon plates with or without Thermanox coverslips/12 mm round glass 
coverslips (Fishei"), 35 m.m Ntmclon culture dishes with 22 x 22 mm glass coverslips or 
Fisher SuperCell Culture Slides. The cells were cultured in Dl\AEM supplemented with 
1 00 tm.its/mL penicillin, 100 f.!g/mL streptomycin, 1 00 IJg/mL kanamycin, 2.5 J..Lg/mL 
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Fungizone and 20% FCS in humidified 5% C02 - 95% air at 37 oc for up to 14 days. 
The culture medium was replaced every 24 hours. 
2.2.2 Immunocytochemical procedures 
2.2.2.1 Immunocytochemical staining of placental tissue secnons and trophoblast cell 
pellets 
Small pieces of intact or trypsin/DNase digested placental tissue as well as pellets 
of Percoll-purified cytotrophoblasts were fixed in 4% paraformaldehyde with 0.2% picric 
acid in 0.1 M sodium phosphate buffer [pH 7.4) or Bouin's fluid (75 m.L I% picric acid, 
25 mL formalin., 5 mL glacial acetic acid) for 48 hours at 4 °C. After intensive washing 
in 0.1 M sodium phosphate buffer [pH 7.4], the specimens were dehyrated and embedded 
in paraffm. Sections cut at 4-5 J.lm thicknesses were deparaffmized and hydrated through 
decreasing concentrations of ethanol to deionized water prior to immunocytochemistry. 
Cryostat sections were cut at 5 f.Uil from placental tissue snap frozen in petroleum ether 
in a bath of acetone cooled with solid carbon dioxide. After thawing, sections were fixed 
in acetone for 5 min at room temperature (RT)., washed in PBS and then subjected to 
immtmocytochemistry. 
For single immunolabelling, sections were stained using the avidin-biotin complex 
(ABC) immunoperoxidase technique (Hsu et al., 1981 ). Endogenous peroxidase was 
inhibited by treating sections with 0.6% ~02 in methanol for 15 min at RT. After 
washing several times in PBS {0.01 M sodium phosphate buffer containing 0.9% NaCI 
[pH 7.4]), dependent on the antigen to be localized, the staining intensity and number of 
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labelled cells were increased by incubation with 0.025% protease type XIV (Sigma) for 
15 min at RT. Subsequently, sections were washed and incubated with 5% normal serum., 
obtained from the species in which the secondary antibody was raised., for 30 min at RT 
to block nonspecific binding of imnnmoglobulins. After blotting excess serum., sections 
were incubated with the primary antibody .. diluted in PBS containing 1% normal serum., 
for 60 min at RT or 24-48 hours at 4 °C. Sections were washed again and incubated with 
5 J.lg/mL biotinylated secondary antibody for 30 min at RT, followed by the Vectastain 
ABC reagent (Vector) for 60 min at RT. The ABC reagent was prepared by mixing 
reagent A (avidin) with reagent B (biotinylated HRP) as suggested by the manufacturer. 
After washing, the peroxidase reaction was developed with 0.05 M Tris-buffered saline 
[pH 7.6] containing 0.02-0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB), 0.04% 
nickel chloride and 0.01% ~02. This technique produced a strong blue/black precipitate. 
To obtain a different brown reaction product the nickel chloride component was omitted 
from the substrate solution. Finally, sections were washed in deionized water., 
counterstained for 15 min with 0.25% methyl green when necessary., dehydrated, cleared 
in xylene and mounted in Permom1t. 
For double immunocytochemistry., the first antigen was localized by means of the 
ABC imml.Dloperoxidase method, as described above, employing monoclonal mouse 
primary antibodies. DAB-Ni was used as peroxidase substrate. After washing in 
deionized water, the second antigen was detected with the peroxidase-antiperoxidase 
(PAP) method (Steinberger, 1974) as follows. First, peroxidase activity was quenched 
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with 0.6% ~01 in methanol for 15 min at RT. Sections were then incubated for 30 min 
with 5% normal serum obtained from the species in which the secondary antibody was 
raised. After blotting excess s~ sections were incubated with rabbit primary antibody~ 
diluted in PBS containing 1% normal s~ for 60 min at RT or 24 to 48 hours at 4 °C. 
N e~ sections were washed in PBS and incubated with the secondary antibody in large 
excess for 3 0 min. After washing, sections were incubated with the peroxidase-
antiperoxidase (PAP) complex diluted at 1 : 1 00 in PBS containing l% normal serum. 
After sections had been washed, the peroxidase reaction was developed as before., using 
DAB as chromogen. Finally., sections were washed in deionized water, cotmterstained 
with 0.25o/o methyl green for 15 min., dehydrated in n-butanol., cleared in xylene and 
mounted in Permo\Dlt. 
In all cases., imm.tmocytohemical control experiments included replacement of the 
primary antibody with normal imm.tm.oglobulin of the same isotype and concentration, 
using adjacent sections. For double imnn.mocytochemistry, several additional controls 
were employed to determine if false positive double labelling had occured., due to 
nonspecific color mixing or cross-rections between the I st and 2nd reaction sequences. 
These included ( 1) incubation of sections with methano~02, followed by DAB~01 
after the rust reaction had been completed; this sequence had been designed to exclude 
the possibility that some peroxidase activity remained available before starting the second 
reaction, (2) testing the possibility that the 2nd secondary antibody cross-reacts with the 
1st primary antibody; to this end., sections were sequentially incubated with the 1st 
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primary antibody, 2nd secondary antibody, PAP and DAB~02, (3) testing if cross-
reactivity exists between the 2nd primary antibody and 1st secondary, by sequentially 
incubating with the 2nd primary antibody, 1st secondary antibody, ABC reagent, 
DAB~02, ( 4) testing the possibility of cross reactions between the secondary antibodies 
as well as between the 1st secondary antibody and PAP; this was performed by 
incubating in the order: 1st primary antibody, 1st secondary antibody, 2nd secondary 
antibody, PAP, DAB~02, and (5) sequential incubations by the 1st primary antibody .. 
2nd secondary antibody, PAP and DAB~02 to exclude possible cross-reactivity between 
the 2nd secondary antibody and PAP. 
2.2.2.2 Immunocytochemical staining of trophoblast cultures 
Trophoblast cultures were washed twice in PBS and fixed in either 
acetone/methanol ( 1:1) for 10 min at RT or Bollin's fluid for 24 hours at 4 °C. After 
washing several times in PBS, acetone/methanol fixed cultures were treated with 0.6% 
~02 in PBS for 15 min to block endogenous peroxidase. Cultures fixed in Bouin's fluid 
were first permeabilized with 0.2% (v/v) Triton X-100 in PBS for 10 min, washed again 
and subsequently exposed to 0.6% ~02 in PBS for 15 min. All cultures were 
immunostained by means of the ABC method as described earlier. Co·unterstaining was 
performed using 0.25% methyl-green or Mayer's hematoxylin for 15 min. Finally, cultures 
were washed, dehydrated, cleared in xylene and mounted in Permount. Control 
experiments were done as described before. 
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l.l.l.J Ul1ras11Uctural immunocytochemistry 
Placental tissue samples were fixed in 4% paraformaldehyde, 0.2% glutaraldehyde 
in 0.1 M sodium phosphate buffer [pH 7.4], washed several times with O.I M sodium 
phosphate buffer [pH 7.4], dehydrated in graded alcohols and embedded in Lowicryl. 
Ultrathin sections were motmted on nickel grids, washed in PBS and incubated with 5% 
normal goat serum in PBS for 15 min. Grids were then transferred onto drops of the 
primary antibody diluted in PBS containing I% normal goat serum and incubated 
overnight at 4 °C. After washing, sections were incubated for 60 min at RT with goat 
anti-mouse lgG labelled with colloidal gold particles I 0 run in size. Sections were washed 
again, exposed to osmium vapor, contrasted with uranyl acetate and lead citrate and 
viewed under a Philips EM300 electron microscope. 
2.2.3 [~thymidine incorporation 
Cytotrophoblasts (1.6 x 104 in 200 ~ aliquots) were cultured in Ntmc 96-well flat-
bottomed plates for various periods of time. The culture medium was changed every 24 
hours. Six hours before concluding the assay, 10 J.lL culture medium containing I J.lCi 
[methyl-3H]thymidine (ICN) was added to each well. At the end of the incubation the 
cultures were washed with Cal+ and M~ free HBSS and then incubated with 0.25% 
trypsin-lmM EDTA at 37 oc for 30 min. Cells were harvested on microglass filters 
(Skatron) using a Skatron cell harvester. The filters were airdried at room temperature for 
a minimum of 2 hours and placed in Beckman Mini Poly-Q vials. To each vial, 5 mL of 
scintillation cocktail (Ready Protein+, Beckman) was added. Finally, radioactivity was 
cotmted on a Beckman LS3801 liquid scintillation cotmter. 
2.2.4 MTf assay 
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This was based on the method originally described by Mosmann ( 1983) and 
developed further by Denizot and Lang ( 1986) and Hansen et al. ( 1989 ). Cytotrophoblasts 
were cultured at 2x 1 O' /1 00 J,IL/well in 96-well culture plates as described above. The 
cultures were washed twice with indicator-free DrvtEM containing I 00 units/mL penicillin .. 
100 J.Lg/m.L streptomycin., I 00 J.Lg/mL kanamycin, 2.5 J.lg/m.L Fungizone and I mg/m.L 
BSA. To each well, I 00 f..lL of the same medium and then 25 J.LL of MTI (3-( 4 .. 5-
dimethylthiazol-2-yl)-2.,5-diphenyltettazolium bromide) dissolved in PBS (0.01 M sodium 
phosphate (pH 7.4], 0.9% NaCl) at 5 mglm.L were added and the cultures were incubated 
for 2 hours. After washing with PBS .. each well received 100 J.LL of lysis buffer (20% 
(v/v) SDS in a mixture of 50% (v/v) of each DMF and deionized water (pH 4. 7]). The 
MTI formazan reaction product was completely solubilized by incubating the plates 
overnight at 37 °C. Absorbances were measured at 595 nm using an automated microplate 
reader (Bio-Rad). 
2.2.5 Quantitatioo of bCG 
Supernatants of trophoblast cultures were assayed for hCG using Serono hCG 
MAlA clone kits. Briefly., 50 IlL of hCG standards and appropriately diluted supernatant 
samples were pipetted into 12 x 75 mm round-bottom polystyrene tubes (Falcon). To 
each tube .. 500 IlL of 1131 anti-hCG Reagent containing fluorescein and iod.ine-125 labelled 
mouse monoclonal antibodies to hCG was added and the tubes were incubated at 37 oc 
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for 15 min. Subsequently, 200 J.lL of sheep antiserum to fluorescein covalently bound to 
magnetic particles were added. After 5 min incubation at room temperature7 the hCG-
monoclonal antibody-second antibody complex was sedimented in a MAlA Magnetic 
Separator, washed once and the radioactivity of the bound fraction was measured for 1 
min in a gamma counter (LKB 1277 Gammamaster). Results were obtained in miU/m.L7 
using the automated data reduction program provided for the gamma counter. 
2.2.6 Measurement of PAI-l anagen 
The concentration of PAI-l in trophoblast conditioned medium were measured by 
ELISA, using Imubind PAI-l ELISA kits (American Diagnostica). This ELISA utilizes 
two different monoclonal antibodies for capture and detection, respectively. The assay 
was performed as suggested by the manufacturer. Briefly, flat-bottomed Nunc Maxisorp 
microtitre plates were ftrst incubated with (1) a monoclonal mouse antibody to PAI-l. 
This and all subsequent incubations were followed by washing to remove excess unreacted 
reagents. After further incubations with (2) conditioned medium, (3) biotinylated 
monoclonal mouse anti-human PAI-I (detection antibody) and ( 4) horseradish peroxidase 
conjugated streptavidin., the peroxidase reaction was developed by 
orthophenilenediamin~O:z substrate solution. The reaction was stopped by I M R:zS04 . 
Absorbance was read at 492 nm., using an automated microplate reader (Bio-Rad). 
2.2.7 Measurement of trophoblast-associated plasminogen ac1ivation 
2.2.7.1 Plasminogen acovation assay 
Trophoblast-mediated activation of plasminogen was measured using an adaptation 
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of the method of Zini et al. ( 1992 ). Villous cytotrophoblasts were plated at 2 x I O' into 
Nunc 96-well plates and cultured in Dfvf:EM supplemented with I 00 units/mL penicillin~ 
100 (.lg/mL each of streptomycin and kanamycin~ 2.5 J.lg/m.L Fungizone and 20% FCS. 
Trophoblast cultures at 36 to 72 hours were then washed twice with indicator- and serum-
free DMEM containing 1 mglmL BSA as well as antibiotics and Fmgizone (hereafter 
called serum-free medium) at concentrations indicated above. Hydrolysis of S-2251 was 
determined in quadruplicate under various conditions. All reagents were diluted in serum-
free medium prior to the assay and filter-sterilized For measurement of total trophoblast-
mediated hydrolysis of S-2251, each well received (I) 50 flL of serum-free medium with 
or without modulator~ (2) 100 f,lL of 0.8 mM S-2251, and (3) 50 J..LL of 100 f.1g/mL Glu-
plasm.inogen. For measurement of trophoblast-mediated plasminogen-independent 
hydrolysis of S-2251 .. each well received ( 1) 50 J.LL of serum-free medium with or without 
modulator, (2) 100 J.LL of 0.8 m.M S-2251~ and (3) 50 JlL of serum-free medium. 
Spontaneous hydrolysis of S-2251 was determined by adding into empty wells (I) 100 ~ 
of serum-free medium .. followed by (2) 100 (.1L of 0.8 mM S-2251. To assess plasmin 
activity contaminating the purified plasminogen preparation .. empty wells received (I) 50 
J,.LL of serum-free medium, (2) 100 J,.LL of 0.8 mM S-2251, and (3) 50 J.LL of 100 (.lg/mL 
Glu-plasminogen. After plasminogen activation had been initiated by adding plasminogen 
(time zero), cells were continued to culture mder assay conditions up to an additional48 
hours in humidified 5% C02 - 95% air at 37 °C. Absorbance readings (at 405 nm) were 
taken regularly at 4 to 8 hours using an automated microplate reader (Bio-Rad). 
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2.2. 7.2 Analysis and kineuc treatment of data 
The absorbance value representing plasminogen-dependent hydrolysis of S-2251 
(catalyzed by plasmin generated during activation of exogenous plasminogen) was 
calculated by subtracting the absorbance due to plasminogen-independent (catalyzed by 
various trophoblast-secreted proteases and by plasmin present at time zero) hydrolysis and 
plasmin contamination of the plasminogen preparation from the total hydrolysis measured. 
Subtraction of the absorbance resulting from plasminogen-independent hydrolysis is based 
on the assumption that plasminogen activation and plasminogen-independent hydrolysis 
of S-2251 are simply independent and additive. 
In the plasminogen activation assay, pNA is produced through a cascade of 
reactions., consisting of conversion of plasminogen to plasmin by the trophoblast 
plasminogen activator (PA) and plasmin-catalyzed hydrolysis of S-2251. 
PA 
~ P1ac;minogen ----->~Plasmin 
(Pig) k_, K. (Pin) 
H-0-Val-Leu-Lys-pNA ---~-->~Peptide+ pNA 
(S-2251) k'cc, K'. 
Assuming that both reactions above obey Michaelis-Menten kinetics, rate equations for 
plasmin ( 1) and pNA (2) are described as follows: 
(I ) d[Pln] ;: 
dt 
kcat[PA] 
K 
+-·-[Pig] 
d[pNA] k:J_Pln] (2) =----
dt K' 
1 + --"'-[S-2251] 
ff [S-2251] » K·., equation (2) can be writte.n as 
(3) dfp:] = k~ [Pin] 
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Equation (3) demonstrates that plasmin concentration is directly proportional to the initial 
rate of hydrolysis of S-2251~ i.e. plasmin activity. The rate of plasmin generation 
(plasminogen activation rate), in tum~ is proportional to the acceleration of the appearance 
of pNA as shown by 
(4) d
2fpNA] = k' d[Pln] 
dt2 CQt dt 
Integration of equation (I) yields 
kc:JPA] 
(S) [Pin] = --K- t + [PlnoJ 
1 + -"'-[Plg] 
where [Pln0] is the concentration of plasmin at time zero. Substituting [Pin] from equation 
( 5) into equation (3) gives 
(6) d[pNA] 
dt 
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= kdc..J.;A] t + k:m [PlnJ 
1 + --"'-[Plg] 
On integrating equation (6)., concentration of pNA is obtained at any time as shown by 
(7) [pN.A] -= kdccm£PA] 
K 
2(1 + -"'-) [Plg] 
where [pNA0] is the concentration of pNA at time zero. 
When analyzing the experimental~ progress curves (time-absorbance curves) 
of pNA accumulation were constructed by fitting polynomials (degrees l to 6) to sets of 
experimental data representing the mean and S.E. of quadruplicate cultures., using a non-
linear curve fitting computer program (Sigmaplot., Jande!). Curve fitting was performed 
only on early datapoints obtained before depletion of the substrates became significant. 
Plasmin concentrations (plasmin activities) were given as the first time derivative of the 
absorbance (dA/dt). The rates of plasmin generation {equivalent to PA activity) were 
calculated as the second time derivative of the absorbance ( d2 A/dr) and expressed as 
percentage of the rate in control cultures. In all cases, the results shown were from one 
placenta and are representative of similar experiments performed in cultures from two or 
three placentas. 
CHAPfER3 
ISOLATION, CHARACfERIZADON AND CULTIJRE OF Vll.LOUS 
CYTO'IROPHOBIAS1S FROM HUMAN TERM PLACENTAS 
3.1 INTRODUCTION 
Trophoblast cell cultures obtained by disaggregation of placental tissue provide the 
potential of manipulating homogenous trophoblast populations. Although a variety of 
techniques have claimed success in isolation of human cytotrophoblasts (reviewed later 
in this chapter)~ the purification procedures employed often suggest that a heterogenous 
cell population was isolatec:L which contained not only cytotrophoblasts but also non-
trophoblastic contaminating cells. An additional problem is that the isolated 
cytotrophoblasts themselves are also likely to be heterogenous in nature. Cellular 
contamination and heterogeneity of purified cytotrophoblast populations may lead to 
erroneous assignments of specific trophoblast ftm.ctions. 
The objective was to develop a procedure for purification and culture of a pure 
population of human villous cytotrophoblasts. Non-trophoblastic contaminants, such as 
macrophages, fibroblasts and endothelial cells, are known to produce constituents of the 
plasminogen activation system as well as various biologically important molecules, 
including ECM components~ cytokines and growth factors., which may potentially obscure 
the evaluation of plasminogen activation by trophoblasts. It was thus felt imperative to 
eliminate contaminating cells as much as possible. Human villous cytotrophoblasts were 
obtained using a modification of the method of Klim.an et al. (1986} and Douglas and 
King (1989)., respectively. As described in Chapter 2., cytotrophoblasts were isolated from 
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human term placentas by mechanical and enzymatic dissociation of the placental tissue~ 
followed by Percoll density gradient centrifugation and immunomagnetic separation 
employing monoclonal antibodies to monomorphic determinants of HLA class I and class 
II antigens. 
3.2 RESULTS 
3.2.1 Immunocytochemical identification of various cell types in tbe placenta 
A variety of antigens were localized in the chorionic villous tissue. Table 3.1 
summarizes the imm\Dlocytochemical characteristics of various cell types in human term 
placental villi A monoclonal antibody to low molecular weight cytokeratins labelled both 
the syncytium and cytotrophoblasts of placental villi. The staining intensity was 
significantly increased by protease XIV pretreatment. In addition to the trophoblast 
epithelium in the placental villi~ numerous cytokeratin positive extravillous 
cytotrophoblasts were observed in cell islands connected to the villous tree. Furthermore~ 
the wall of larger blood vessels and some stromal elements in stem villi were also stained 
(Fig. 3.la, b, c). 
Distribution of vimentin immunoreactivity was in sharp contrast to that of 
cytokeratin positive cells. Virtually all cells in the central mesencymal core of the 
placental villi were immunoreactive., including vascular endothelial and smooth muscle 
cells~ and placental macrophages (Hofbauer cells). The trophoblastic epithelium., however~ 
remained completely devoid of staining (Fig. 3 .2a., b). 
Immunocytochemical staining for HLA antigens demonstrated that all villous 
Table 3.1. Immunocytochemical characterization of various cell types in placental villi 
Syncytium Cyto- Endothelial Smooth Macrophage 
trophoblast cell muscle cell 
Cytokeratin + + ± 
Vimentin + + + 
HLA-ABC + + + 
fl-2-micro-
globulin + + + 
HLA-DR + 
hCG + 
hPL + 
ACT ± + 
CD68 + 
+ positive, - negative, ± inconsistently positive 
00 
0 
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stromal cells expressed lll..A-ABC and beta-2-microglobulin~ whereas Ifl..A-DR 
immunoreactivity was localized only in Hofbauer cells. The trophoblast epithelium did 
not display any staining (Fig. 3.3 ). 
Most of the syncytium displayed hCG imnumoreactivity, but the staining intensity 
varied to a great extent (Fig. 3 .4~ b). A strong uniform syncytial staining was obtained 
using a polyclonal antibody to hPL (Fig. 3.5a). No staining was observed for either hCG 
or hPL in cytotrophoblasts and the villous stroma 
A polyclonal antibody to a-1-antichymotrypsin (ACT) reacted strongly with 
Hofbauer cells (Fig. 3.6~ b). The apical surface of the syncytium was usually positive 
as well. Another macrophage associated antigen (CD68) was localized exclusively in 
Hofbauer cells (Fig. 3. 7 ~ b), using two different monoclonal antibodies to CD68. Both 
antibody KPl (Pulford et al., 1989) and EBM/11 (Kelly et al., 1988) reacted weakly and 
inconsistently with Hofbauer cells. However,. the number and staining intensity of KPI 
labelled cells increased dramatically after protease XIV treatment of paraftm sections. 
Protease pretreatment did not appreciably improve staining results obtained by antibody 
EBM/11. CD68 imml.Uloreactivity in Hofbauer cells was also studied at the electron 
microscopic level, using immunogold technique. These studies revealed that CD68 is 
associated with lysosomal-like intracytoplasmic granules in these cells (Fig. 3.8). Finally,. 
double imml.Dlocytochemistry demonstrated that CD68 and ACT are colocalized in the 
same macrophage population (Fig. 3.9). Some cells,. however, stained positively only for 
ACT. 
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3.2.2 <llaracterizadon of Percoll purified ceUs 
Immunocytochemical hPL staining of the fmely chopped chorionic villous tissue 
revealed that the trophoblast epithelium of the placental villi almost completely dissociated 
30 min after trypsin-DNase treatment (Fig. 3.5b). The denuded appearance of the villi 
suggested that both cytotrophoblasts and mesenchymal elements were released 
Following enzymatic disaggregation~ the resultant placental cell suspension was 
subjected to discontinuous Percoll density gradient centrifugation. Three major bands 
were obtained in the gradients (Fig. 3 .I 0). A wide band containing cellular debris but not 
viable cells was located at the top of the gradients. Another band containing red blood 
cells was invaribly found at the bottom. In the middle of the gradient (between densities 
1.051 and 1.063 g!mL)~ there was a band containing 5 x 107-2 x 101 cells/SO g villous 
tissue. Cells obtained from this band were 90-95% viable as assessed by trypan blue 
exclusion. 
lmmtmocytochemical analysis of the cells collected from the middle band was 
performed on sections prepared from paraffm embedded cell pellets. Approximately 80-
90% of these cells stained positively with an antibody to low molecular weight 
cytokeratins (Fig. 3 .I d) and were considered as being mostly cytotrophoblasts. No 
specific staining was observed in pellets incubated with normal isotype control IgG (Fig 
3.le). A small percentage (2-4%) ofPercoll purified cells were positively stained for hCG 
(Fig. 3.4c) or hPL (Fig. 3.5c). These cells were thought to be remnants of the syncytium 
which lysed during trypsin/DNase digestion. Vimentin (Fig. 3.2c), ACT (Fig. 3.6c) and 
Fig. 3.1. lmmunostaining for cytokeratin in placenta and Percoll purified ceUs. A 
monoclonal antibody to low molecular weight cytokeratins strongly labelled the 
trophoblastic epithelium of all chorionic villi { ~ b~ and c }. blood vessels and some stromal 
cells in stem villi {b)., and extravillous cytotrophoblasts in cell islands (c). The majority 
of Percoll purified cells were mononuclear and displayed cytokeratin immWloreactivity. 
Occasional syncytial remnants (arrow) were also cytokeratin positive (d). Percoll purified 
cells did not exhibit staining when the antibody to cytokeratin was replaced with normal 
isotype control IgG (e). (All sections were lightly counterstained with methyl green. 
Magnification: ~ x 100; b., x 200; c., x 100; ~ x 410; e., x 410) 
J4 
Fig. 3 .2. lmmunostaining for vimentin in placenta and Percoll purified cells. Cytokeratin 
immunoreactivity was distributed all over the central mesenchymal core of chorionic villi, 
whereas the trophoblastic epithelium remained completely devoid of staining (arrowheads, 
b) (a and b). Note intense labelling of vascular endothelial cells (thin arrow) and placental 
macrophages (thick arrow) (b). A few Percoll purified cells stained positively for 
vimentin (c). (Magnification: a, x 200; b, x 400~ c, x 400.) 
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Fig. 3.3. Localizaeion of HLA anngeos in the placenta. Acetone-fixed cryostat sections 
were stained with a poly clonal antibody to beta-2-microglobulin (a)~ the monoclonal 
antibody W6/32 that recognizes a monomorphic determinant common to lll.A-A~ B, C~ 
and G antigens (b), and a monoclonal antibody to a monomorphic determinant on Ill.A-
DR/a (c). Both beta-2-microglobulin and lll.A-ABC were widely distributed in the 
stroma of placental villi, whereas HLA-DR was found only in some sparsely scattered 
stromal cells (most likely macrophages). None of the above antibodies stained the 
trophoblastic epithelium (arrowheads). (Magnification: x 410). 
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Fig. 3.4. Immunostaining for hCG in placenta and PercoU purified cells. The syncytium 
displayed hCG imm.t.m.oreacti.vity of variable intensity in the majority of chorionic villi. 
Some villi .. however, remained strikingly unreactive (a and b). A few Percoll purified 
cells stained positively for hCG (c). (All sections were cotm.terstained with methyl green. 
Magnification: ~ x 100~ b, x 200; c, 410.) 
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Fig. 3.5. Immunostaining for bPL in placenta and Peftoll pwified cells. The syncytium 
of chorionic villi was positively stained for hPL~ whereas the villous core remained 
tmreactive (a). Imnumostaining of the finely minced and trypsin-DNase digested chorionic 
villous tissue demonstrated that the syncytium was almost completely dissociated after 30 
min treatment (b). Only occasional Percoll purified cells were found to be hPL 
immunoreactive (c). (All sections are lightly COWlterstained with methy 1 green. 
Magnification: ~ x 200; b~ x 100; c~ 410.) 
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Fig. 3.6. Immunostaining for Acr in placenta and PercoU purified ceUs. Numerous 
macrophages were labelled in the core of placental villi. The apical surface of villi were 
also stained to a variable degree (a and b). A significant number of Percoll purified cells 
di~played ACT-like immtmoreactivity (c). (Magnification: ~ x 200~ b~ x 410; c~ x 410.) 
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Fig. 3.7. Immunostaining for CD68 in placenta and PercoU purified ceUs. Placental 
macrophages (Hofbauer cells) were strongly labelled with a monoclonal antibody to CD68 
(KP 1 ) in the villous core of chorionic villi Note the lack of staining on the surface of 
syncytium (a and b). A few Percoll purified cells were CD68 immunoreactive (c). (All 
sections were lightly cotmterstained with methyl green. Magnification: ~ x 200~ b~ x 410; 
c~ 41 0.) 
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Fig. 3.8. lntrastructural localization of CD68 immunoreactivity in Hofbauer ceUs. 
Ultrathin sections of term placentae were incubated with a monoclonal antibody to CD68 
(KPI ). The sites of CD68 immunoreactivity were then visualized using goat anti-mouse 
lgG labelled with colloidal gold particles. Labelling was predominantly seen m 
lysosomal-like granules of Hofbauer cells. Magnification: x 60~000. 

Fig. 3.9. Double immunocytochemical staining of placental sections for CD68 and Acr. 
First, CD68 was localized by means of the ABC immlDloperoxidase methocL using the 
antibody KPI. Subsequently, ACT was detected with the PAP method. In these 
micrographs the dark black areas represent the intense bluish-black DAB-Ni precipitate 
of the CD68 staining., while the lighter black ones show the localization of the less 
intensive brown DAB reaction product produced by the ACT i.mm\Dlostaining. The two 
antigens were found to be codistributed in the cytoplasm of most placental macrophages 
(Hofbauer cells) (a and b). Some cells., however .. exhibited only ACT staining (arrow). 
Note the strong granular appearance of the cytoplasmic staining for CD68 as distinct from 
the diffuse ACT immunoreactivity. (Section a was lightly co\Dlterstained with methyl 
green. Magnification: a.. x 410; b., x 1020.) 
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Fig. 3 .I 0. Separatton of cytotrophoblasts by density gradient cen1rifugatton. A 4 mL 
aliquot of placental cell suspension obtained by enzymatic disaggregation was layered onto 
a preformed discontinuous Percoll gradient in a 50 mL plastic tube (on the left). The 
gradient was centrifuged at 1200 x g for 20 min. Densities were determined by nmning 
an identical gradient loaded with color-coded density marker beads (right tube). 
Cytotrophoblasts were banded in the middle of the tube (arrow) between densities 1.05 I 
and 1. 063 g/m.L. 
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CD68 (Fig. 3. 7c) im.ml.Dloreactive cells were identified as nontrophoblastic contaminants., 
such as endothelial cells., smooth muscle cells., fibroblasts or macrophages. They each 
accotmted for about l 0-20% of all Percoll purified cells. Since many of the vim en tin 
positive cells were ACT and CD68 positive in vivo., these numbers are also an 
approximate estimate for the proportion of all nontrophoblastic contaminating cells in the 
Percoll purified fraction., the majority of which appear to be macrophage. 
Percoll purified cytotrophoblasts demonstrated little replicative activity. No 
significant 3H thymidine uptake was revealed when these cells were cultured in the 
presence of 20% fetal calf serum (Fig. 3.11 ). 
3.1.3 Characteristics and culture of purified villous cytotrophoblasts 
When Percoll purified cytotrophoblasts were cultured in the presence of fetal calf 
serum., three main cell types., i.e. single mononuclear cells, multinucleated aggregates and 
syncytial units could be observed in 24-36 hours (Fig. 3.12a. c). In the multinucleated 
aggregates, the outlines of aggregated cells were still visible .. whereas the syncytial units 
did not possess recognizable cell borders. Occasionally .. bi- and trinucleated cells were 
also seen. The multinucleated aggregates and syncytial structures were trophoblastic in 
nature and thus stained positively for cytokeratin (Fig. 3 .12a. c) but were not labelled with 
monoclonal antibodies recognizing vimentin (Fig. 3.13a., c), CD68 (Fig. 3.14c) or 
monomorphic determinants on IaA class I (HLA-ABC) (Fig. 3.15a., c) and class II (HLA-
DR) (Fig. 3.14a) antigens. Some of the single mononuclear cells were also cytokeratin 
imnumoreactive (Fig. 3.12a, c) suggesting that they are trophoblastic in origin. Variable 
Fig. 3.1 I. Time course of ~-metbyl-Chymidine uptake by trophoblast cultures. 
Cytotrophoblasts were plated at 1.6 x 1 05/well into 96-well flat-bottom Ntmclon culture 
plates and cultured in DMEM supplemented with l 00 units/m.L penicillin., l 00 J.lg/mL 
streptomycin, l 00 J..Lg/m.L kanamycin~ 2.5 J.lg/mL Ftmgizone and 20% FCS. The culture 
medium was replaced daily with 200 J.1L of fresh medium. 3H-methyl-thymidine ( 1 JJ.Ci) 
was added to each well 6 h before concluding the assays. At the designated times the 
cultures were washed twice with Ca++ -Mg++ free HBSS., treated with 0.25% trypsin.., I mM 
EDT A for 3 0 min at 3 7 oc and harvested on micro glass filters using a Skatron cell 
harvester. Radioactivity of the filters was measured by liquid scintillation 
spectrophotometry. Data shown are the mean and S.E. from quadruplicate cultures. 
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numbers of mononuclear., bi- and trinucleated cells were immunoreactive for vimentin 
(Fig. 3.13~ c), CD68 (Fig. 3.14c), ~A class I (Fig. 3.15a, c) or class IT (Fig. 3.14a) 
antigens. On the basis of their immunoreactivity., these cells were classified as non-
trophoblastic contaminating cells such as fibroblasts, endothelial cells and macrophages. 
The relative proportion of contaminating cells was progressively increased as the cultures 
grew older. 
To obtain pure villous cytotrophoblasts, it was necessary to eliminate 
contaminating cells. This was accomplished using a mixture of the same anti-ID..A-ABC 
and an.ti-HLA-DR antibodies that had been previously shown in immunocytochemistry to 
react with nontrophoblastic stromal elements but not villous trophoblasts (Fig. 3.3 ). 
Preformed complexes of these antibodies with goat anti-mouse IgG coupled to magnetic 
microspheres were incubated with Percoll purified cells, and the cells rosetted with 
microspheres were removed by a magnet. The proportion of rosette forming 
contaminating cells varied between 10-40% of the total number of purified cells. The 
specificity of rosette formation was tested by replacing the anti-Ifi..A antibodies with a 
mixture of negative isotype controls of the same antibody concentrations. In this case, the 
number of rosetted cells was less than 0.5o/o. Cell viability with trypan blue exclusion was 
fotmd to be about 85-90%, and the overall number of viable villous cytotrophoblasts 
obtained from 80 g of chorionic villous tissue ranged between 2 x 107 and 1.3 x 101. 
When placed in culture, villous cytotrophoblasts., obtained using Percoll density 
gradient centrifugation followed by immunomagnetic purification, formed cytokeratin 
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im.mtmoreacti ve multinucleated trophoblast aggregates and sycytiotrophoblasts. Occasional 
round mononuclear cells were in variably cytokeratin positive (Fig. 3 .12b .. d). No vim en tin 
(Fig. 3.13b, d) or CD68 (Fig. 3.14d) positive cells were found in these cultures. All 
cultures were HLA-ABC (Fig. 3.1Sb .. d) and HLA-DR (Fig. 3.14b) negative at 24 h but 
some syncytiotrophoblasts became :En.A-ABC positive after several days of incubation 
(not shown). The cultures were also shown to secrete immunoreactive hCG into the 
culture medilllll, and the hCG secretion could be stimulated by 8-Br-cAMP (Figs. 3.16 and 
3 .I 7) .. suggesting that the cultures were fimctionally viable. Viability was also confirmed 
by demonstrating the ability of cultured trophoblasts to cleave MTI (Fig. 3.18). 
3.3 DISCUSSION 
Human placental fmlctions have been extensively studied in organ .. explant and cell 
cultures (Lake .. 1983; Ringler and Strauss .. 1990; Contractor and Sooranna.. 1993 ). Organ 
culture is a method whereby a small piece of tissue is maintained in its characteristic 
morphological and functional state. An essential difference between organ and explant 
cultures is that intensive cellular proliferation .. migration and differentiation can only occur 
in explant culture (Freshney.. 1987). Both placental organ and explant cultures have 
proved valuable in elucidating placental flmctions but suffered from the problem of 
cellular heterogeneity. By contrast., placental cell cultures offer the potential of 
manipulating defined cell populations and thereby the possibility of a less ambiguous 
assignment of cellular ftmctions (Ringler and Strauss.. 1990; Contractor and Sooranna.. 
1993). 
Fig. 3.12. Micrographs of trophoblast cultures immunostained for cytokeratin. Cells 
isolated by Percoll density gradient centrifugation (a and c) or Percoll density gradient 
centrifugation followed by immunomagnetic separation (b and d) were cultured for 24 
hours (a and b)~ 96 hours (c) or 120 hours (d). All forms of trophoblast (single 
mononuclear trophoblasts~ multinucleated aggregates, and syncytial units) stained for 
cytokeratin (a, b, c, and d), while contaminating nontrophoblastic cells remained tmstained 
(arrowheads .. a and c). No cytokeratin negative cells were observed in cultures obtained 
using Percoll as well as immunomagnetic separation (b and d). Mononuclear trophoblasts 
and multinucleated aggregates (a, c~ and d) exhibited stronger immunoreactivity than the 
flattened syncytial structures. The outlines of aggregated cells were invariably discernible 
in multinucleated aggregates (a, c,. and d) as distinct from syncytial mtits in which cell 
borders could not be recognized any longer. In syncytial units numerous nuclei 
surrounded by vacuoles were concentrated at distinct sites of the cytoplasm. At the 
periphery of these units cytokeratin positive mononuclear cells were usually seen as 
possibly being incorporated into the syncytium (arrows., b and c). (All cultures were 
lightly counterstained with hematoxylin. Magnification: x 200.) 
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Fig. 3.13. 1\ficrograpbs of trophoblast cultures immunostained for vimentin. Cells 
isolated by Percoll density gradient centrifugation (a and c) or Percoll density gradient 
centrifugation followed by immunomagnetic separation (b and d) were cultured for 24 
hours (a and b) and 120 hours ( c and d)~ respectively. Numerous rotm.d or elongated 
fibroblast-like vimentin immunoreactive cells were observed in cultures obtained using 
Percoll purification only (a and c)~ whereas no vimentin positive cells were present in 
cultures after combined Percoll and immunomagnetic purification (b and d). Note that 
multinucleated trophoblast aggregates (a, b~ c~ and d)~ syncytial structures (c and d)~ and 
mono- and binucleated trophoblast cells were vimentin negative. (All cultures were 
counterstained with hematoxylin. Magnification: ~ x 100; h~ x 100; c~ x 200; ~ x 200.) 
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Fig. 3.14. Immunostaining of trophoblast cultures for m.A-DR and CD68. Cells isolated 
by Percoll density gradient centrifugation (a and c) or Percell density gradient 
centrifugation followed by immunomagnetic separation (b and d) were cultured for 24 
hours (a and b) and 120 hours (c and d)., respectively. A monoclonal antibody to a 
monomorphic determinant on laA-DR/a stained some nontrophoblastic cells (most likely 
macrophages) (a)., while trophoblasts remained unstained (a and b). Similarly., 
macrophages (c) but not trophoblasts displayed CD68 imm1Dloreactivity ( c and d). Note 
that trophoblast cultures established from villous cytotrophoblasts isolated by combined 
Percoll and immunomagnetic separation are completely devoid of Ill..A-DR/a (b) and 
CD68 positive cells (d). (All cultures were counterstained with hematoxylin. 
Magnification: x 200.) 
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Fig. 3.15. Immunocytochemical staining of trophoblast cultures for class I HLA antigens. 
Cells isolated by Percell density gradient centrifugation (a and c) or Percoll density 
gradient centrifugation followed by immunomagnetic separation (b and d) were cultured 
for 24 hours (a and b) and 120 hours (c and d)., respectively. The monoclonal antibody 
W6/32 that recognizes a monomorphic determinant common to 1ll..A-A~ B., C., and G 
antigens stained nontrophoblastic contaminating cells (a and c)~ but did not label 
mononuclear trophoblasts., multinucleated trophoblast aggregates or syncytia (a., b., c., and 
d). Note the complete absence of contaminating cells from cultures obtained after 
combined Percoll and immunomagnetic purification (b and d). (All cultures were 
cotmterstained with hematoxylin. Magnification: x 200.) 
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Fig. 3.16. Stimulation of hCG secre,on by 8-bromo-cAMP in trophoblast culture. 
Cytotrophoblasts were cultured at 8 x 1 05 /mL in Dl\tffiM supplemented with 1 00 tmits/mL 
penicillin, 1 00 J.tg/mL streptomycin., 100 J.Lg/mL kanamycin., 2.5 J.tg/mL Fungizone and 
20% FCS in 24-well Nunclon culture plates in the presence or absence of 1.5 mM 8-
bromo-cAMP. Culture medium was collected every 24 h and replaced with fresh medium. 
After centrifugation, the supernatants were stored at -20 oc until assayed for hCG using 
Serono hCG MAIAclone kits. The data shown are the mean and S.E. from quadruplicate 
cultures. 
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Fig. 3.1 7. Dose-dependent sumulaaon of bCG secretion by 8-bromo-cAMP in trophoblast 
culture. Villous trophoblasts cultured in the presence of 20% FCS were washed and 
incubated in serum-free medium alone (control) or serum-free medium containing 
increasing concentrations of 8-bromo-cAMP (0.001-3.2 m.M). After 24 h conditioned 
media were collected, centrifuged and the supernatants were assayed for hCG. The data 
shown represent the mean± S.E. from quadruplicate cultures. 
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Fig. 3 .18. MIT cleavage by cultured trophoblasu. Cytotrophoblasts were cultured at 
2xiO'/IOO J,LL/well in 96-well culture plates in the presence of 20% FCS for 72 h. The 
cultures were then washed twice and further incubated in indicator-free medium. At the 
indicated times~ the cultures were incubated with MIT for 2 h. After solubilization the 
absorbance of the blue formazan was measured at 595 nm. The data shown are the mean 
and S.E. from 8 wells. 
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Isolation and culture of cytotrophoblasts have been reported from many laboratories 
(for reviews see Loke~ 1983; Ringler and Strauss~ 1990; Contractor and Soorann~ 1993). 
A variety of methods involve mechanical and enzymatic (usually trypsiniDNase) 
disaggregation of the chorionic villous tissue, resulting in trophoblast preparations more 
or less contaminated with non-trophoblastic placental cells. The majority of 
cytotrophoblasts are mononuclear cytotrophoblasts~ because the syncytium being very 
sensitive to enzymatic treatment is only recovered as occasional remnants. Currently. the 
most widely used method for purification of cytotrophoblasts is the one reported by 
Kliman et al. ( 1986). In this metb.o~ contaminating cells are removed through Percoll 
density gradient centrifugation. This technique is known to yield trophoblast preparations 
containing at least 90-95% cytotrophoblasts (Douglas and King7 I 989; Zini et al., 1992), 
although considerably less purity (80%) has been also reported (Contractor and Soorann~ 
1993). 
Further purification of Percoll-purified cytotrophoblasts has been achieved by 
positive or negative immunoselection using monoclonal antibodies that bind to 
cytotrophoblasts or nontrophoblastic cells~ respectively. Contractor and Sooranna ( 1988) 
used a panning technique to separate cytotrophoblasts from a heterogenous mixture of 
placental cells obtained by enzymatic treatment. Their procedure involved incubation of 
placental cells with a trophoblast-specific antibody followed by absorption of labelled cells 
in plates coated with anti-mouse IgG. Kawata et al. ( 1984) developed a method to isolate 
cytotrophoblasts from human placental cell suspensions using trophoblast- and faA-
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specific antibodies~ and fluorescence-activated cell sorting. Douglas and King (1989) 
employed imm.un.omagnetic beads coated with anti-mouse IgG to separate villous 
cytotrophoblasts from nontrophoblastic cells labelled with mouse monoclonal antibodies 
against class I and class IT HLA antigens. Expression of CD9 antigen by placental 
stromal cells but not by villous and extravillous trophoblasts has also been utilized to 
obtain pure cytotrophoblast preparations. CD9 expressing cells were removed by either 
imnnmomagnetic separation (Morrish et al.~ 1991) or second antibody-conjugated glass 
bead columns (Yui et aL~ 1994 ). Isolation of first-trimester extravillous trophoblasts has 
been reported by Loke et al. (1989). Their approach is based on selective binding of 
extravillous trophoblasts to lam in in. Extravillous cytotrophoblasts isolated by attachment 
to laminin-coated magnetic beads are W6/32 and cytokeratin positive, and some but not 
all display hCG~ hPL or SPI im.mtm.oreactivity. This phenotype corresponds to that of 
intermediate trophoblasts described by Kurman et al. ( 1984 ). A monoclonal antibody 
specific for a framework determinant of In..A-B was used by Shorter et al. ( 1990). This 
antibody labelled all cell types present in the amniochorion and decidua, but did not bind 
to chorionic cytotrophoblasts. Hence~ sorting the negative population by flow cytometry 
yielded extravillous cytotrophoblasts. 
We have been successful in isolating and culturing pure villous cytotrophoblasts 
from human term placentas~ using a modification of the methods of Kl.iman et al. (1986) 
and Douglas and King ( 1989)~ respectively. Our procedure consists of sequential trypsin-
DNase digestions of the carefully selected chorionic villous tissue~ discontinuous Percoll 
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density gradient centrifugation, and immunomagnetic removal of contaminating cells 
bearing lll..A class I and class II antigens. Characterization and identification of the cells 
obtained after Percoll centrifugation and imml.Dlomagnetic separation, respectively, relied 
on their imm.tm.ocytochemical staining characteristics in vivo. Differential expression of 
cytoskeletal proteins, HLA antigens and hormones by various cellular constituents of the 
chorionic villous tissue was utilized to determine the identity of the isolated cells. 
Intermediate filaments are fibrous structures that form part of the cytoskeleton. 
Intermediate f'tlam.ent proteins display cell-type specific expression, which helps 
distuinguish cells of various origin. In particular~ expression of cytokeratins is 
characteristic of epithelial cells, whereas vimentin is a cytoskeletal component of cells of 
mesenchymal origin. Although a rare occurrence, coexpression of cytokeratin and 
vimentin has been also reported (Moll et al., 1982; Osborn and Weber., 1983 ). We fol.Dld 
that both the syncytium md cytotrophoblasts of placental villi and extravillous 
cytotrophoblasts in cell islands are cytokeratin positive. Moreover., some mesenchymal 
elements in the vessel walls of larger villi were also stained Our fmdings are in 
agreement with those reported earlier (Loke and Butterworth., 1987: Beham et al . ., 1988: 
Daya and Sabet, 1991) and confirm that cytokeratin is a reliable trophoblast marker. 
However., the fact that some mesenchymal elements in larger villi may also express 
cytokeratin suggests that cytokeratin positivity is a necessary., but not a sufficient 
condition for the identification of trophoblasts. Approximately 80-90% cells were 
cytokeratin positive in our Percoll purified preparations. We estimate that the actual 
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proportion of villous cytotrophoblasts is somewhat less than that, considering the possible 
contamination with cytokeratin positive extravillous cytotrophoblasts and mesenchymal 
elements. 
Vimentin imm1.m.oreactivity was observed in practically all cellular components of 
the central core of placental villi. including vascular endothelial cells~ smooth muscle cells 
of blood vessels~ stromal mesenchymal cells and macrophages. The trophoblast covering 
of the placental layer~ however, remained tmstained. It should be mentione<L however, 
that extravillous cytotrophoblasts may stain for vimentin (Loke and Butterworth, 1987). 
Therefore~ the estimated I 0-20% vimentin positive cells detected in our Percoll purified 
preparations represent villous mesenchymal elements and some extravillous trophoblasts. 
Our immunocytochemical investigations also confirmed previous results that villous 
cytotrophoblasts and syncytium express neither class I nor class II major 
histocompatibility complex (rviHC) antigens (Faulk and Temple, 1976; Sunderland et al., 
1981 ~ Loke and Butterworth, 1987; Johnson, 1993 ). By contrast, all cellular components 
of the villous stroma were stained with the monoclonal antibody W6132 that reacts Y4-ith 
a monomorphic determinant common to m..A-A, B and C antigens (Barnstable et al., 
1978), and In..A-DR was detected on Hofbauer cells. Although villous trophoblasts do 
not express MHC molecules, various forms of extravillous trophoblasts have been shown 
to react with the monoclonal antibody W6/32 (Loke and Butterworth, 1987). However., 
they failed to bind to antibodies directed at ffi..A-A or l:ll..A-B polymorpic determinants 
of the fetal phenotype (Redman et al . ., 1984 ). Subsequent investigations revealed that the 
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trophoblast HLA antigen immunoprecipitated by W6/32 is identical with HLA-G, a 
nonclassical, nonpolymorphic class I 1\fiiC molecule (Ellis et al., 1986, 1990~ Kovats et 
al., 1990). 
Our immunocytochemical investigations performed on smears of Percoll purified 
cells revealed 20-30% each of In..A-ABC and lfl.A-DR immunoreactive cells. These 
numbers are close to those obtained for the percentage of rosette forming cells ( 1 0-40%) 
that reacted with the same anti-HLA-ABC and anti-HLA-DR antibodies during the 
imm.unomagnetic purification of villous cytotrophoblasts. The high proportion of HLA-
ABC and HLA-DR positive cells suggest that our Percoll purified preparations were 
significantly contaminated with stromal cells, especially macrophages. 
Placental macrophages were stained with antibodies to a-1-antichymotrypsin (ACT) 
and CD68. It appears that CD68 is a more specific marker for placental macrophages 
than ACT, because ACT staining was also seen on the luminal surface of the syncytium, 
whereas similar staining has never been observed using antibodies to CD68. Our electron 
microscopic findings corraborated that CD68 is exclusively localized in placental 
macrophages, and the predominant sites of CD68 imnumoreactivity are intracytoplasmic 
lysosomal-like bodies. By double immmocytochemistry, we found that ACT and CD68 
were codistributed in the villous stroma Our finding provides evidence that both antigens 
are present in the same macrophage population, and CD68 is not expressed in stromal 
cells negative for ACT. Although the expression of CD68 is macrophage specific in the 
placental villi, other cell types may express this antigen in other organs (Pulford et al., 
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1990). 
In our Percoll purified preparations about I 0-20o/o of cells were stained with the 
antibody to KP1. This is consistent with the proportion obtained for the HLA-DR positive 
ceUs and again points to considerable macrophage contamination. 
Our immunocytochemical studies demonstrated that hCG and hPL are localized 
exclusively in the syncytium of placental villi. Percoll purified cytotrophoblasts were 
negative for both hCG and hPL. Only occasional (2-4%) isolated syncytial fragments 
were immunoreactive. This confirms that syncytial contamination of our Percell purified 
preparations is not significant. These results support the findings reported earlier by 
several investigators (Kliman et al.,. 1986). 
It is implicitly accepted by investigators that Percoll fractionation of placental cell 
suspensions as described by Kliman et al. (1986) yields pure cytotrophoblasts of the 
villous variety. However9 in view of the relatively high number of vimentin positive 
extravillous cytotrophoblasts observed in cell islands~ we believe that some extravillous 
cytotrophoblasts are also present in these preparations,. because these cells cannot be 
completely avoided during selection of the villous tissue. Furthermore,. we are not aware 
of any evidence that villous cytotrophoblasts separate at buoyant densities different from 
those of extravillous cytotrophoblasts. 
In our hands,. the method of Kliman et al. ( 1986) did not produce consistently pure 
cytotrophoblasts. Variations in the architecture and digestibility of the placental tissue as 
well as small Wlavoidable inconsistencies in the selection and mincing of the villous 
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material are likely to contribute significantly to this problem. In addition~ there is always 
some subjectivity in determining the borders of the band in which the cytotrophoblasts are 
sedimented. Taking wider bands usually results in higher proportions of cellular 
contamination. In contrast to methods relying exclusively on a single Percoll purification 
step~ the method used in this thesis yields villous cytotrophoblasts not contaminated by 
mesenchymal cells or extravillous cytotrophoblasts. Separation of villous cytotrophoblasts 
has been achieved by a one-step incubation employing complexes of anti-HLA antibodies 
and anti-mouse IgG coupled with magnetic microspheres. This procedure requires less 
time., is more convenient and less damaging to cytotrophoblasts than the indirect technique 
of Douglas and King ( 1989) that involves two incubations and repeated centrifugations. 
CHAPfER4 
ACI1V ATION OF PLASMINOGEN BY HUMAN TERM TROPHOBLASTS 
4.1 INTRODUCUON 
It is now well-known that the plasminogen activation system undergoes extensive 
alterations in pregnancy (see Chapter 1 ). The placental trophoblast appears to be critically 
involved in developing the suppressed fibrinolytic activity seen in both the maternal 
plasma and placenta during normal and preeclamptic pregnancies in particular. In 
addition., several studies suggest that the plasminogen activation system of trophoblasts 
is essential for mediating trophoblast invasiveness. Both trophoblast underinvasion and 
overinvasion of the maternal uterus in preeclampsia and choriocarcinoma., respectively,. 
have been suspected of being associated with abnormal regulation of the trophoblast 
plasminogen activation cascade (Estelles et al., 1994; Graham et al. 1994 ). At present,. 
however .. little information is available on the factors that regulate the activation of 
plasminogen by trophoblasts with either normal or disturbed invasiveness. In this study, 
an attempt has been made to extend our ooderstanding of the trophoblast plasminogen 
activation system. The emphasis was placed on testing various compounds .. known or 
suspected to be important in trophoblast development and ftmction .. for their ability to 
modulate plasmin generation by trophoblasts. 
4.2 RESULTS 
4.2.1 Expression of plasminogen activators and their inhibitors by trophoblasts in vivo 
and in vitro 
Immunohistochemical investigation of tissue sections from term placentas could 
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not demonstrate any staining for either u-PA or t-PA in the trophoblast lining of 
chorionic villi. Only occasional placental macrophages were found to be u-PA 
immunoreactive (Fig. 4.ld). In contras~ most trophoblasts expressed u-PA (Fig. 4.2a) but 
not t-PA (not shown) during the first 24 hours of culture. The most intense staining was 
observed in mononuclear trophoblasts and multinuclear aggregates~ The syncytium 
showed patchy staining~ the intensity of which diminished with advancing time in culture. 
Light to moderate PAI-l staining was observed in the syncytium of the villi (Fig. 4.1 a). 
Some placental macrophages were also labeled (Fig. 4.1 b). All forms of trophoblasts 
showed moderate to strong diffuse as well as punctate PAI-l staining in culture (Fig. 
4.2b), and PAI-l was also detected in trophoblast conditioned medium by ELISA (Fig. 
4.3 ). The syncytium was strongly PAI-2 immunoreactive in vivo~ and occasional 
placental macrophages were also imm.tmostained (Fig. 4.lc). By contrast~ only occasional 
syncytial units demonstrated light PAI-2 staining in culture whilst the majority of cultured 
trophoblasts remained unstained (Fig.4.2c). 
4.2.2 Kinetics of plasminogen activation by cultured trophoblas1S 
Villous cytotrophoblasts obtained from human term placentas were cultured at 
various densities for 36-72 hours in the presence of fetal calf serum. During this perio~ 
cytotrophoblasts formed multinuclear aggregates and fused into syncytial units. 
Trophoblasts were then washed and cultured in serum-free medium containing S-2251 in 
the presence or absence of Glu-plasminogen. Hydrolysis of S-2251 was measured by 
recording the appearance of pNA. Fig. 4.4A shows parabolic progress curves of pNA 
Fig. 4.1. Immunosmining for PAis and u-P A in the placenta. The syncytium of chorionic 
villi showed light to moderate PAI-l staining (a). Some blood vessels and macrophage-
like cells in the stroma were also stained (b). PAI-2 immunoreactivity was found in the 
syncytium (c). Occasional stromal cells (probably macrophages) displayed 
inmnmoreactivity for u-PA .. but the trophoblastic epithelium were not labelled (d). 
(Sections a.. b .. and d were lightly counterstained with methyl green. Magnification: a.. b .. 
and d x 40; c .. 20 x.) 
~32 
a 
Fig. 4.2. Immunocytochemical staining of trophoblast cultures for u-PA and PAis. 
Cultured trophoblasts were positively stained for u-P A (a) and PAI-l (b). Note the diffuse 
u-P A staining as distinct from the mainly punctate distribution of PAI-l immunoreactivity. 
Weak PAI-2 staining was observed in a few syncytial tmits,. whereas the majority of 
trophoblasts remained unstained (c). (In culture a hematoxylin cotm.terstaining was used. 
Magnification: x 410.) 
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Fig. 4.3. Secretion of PAI-l by cultured tropboblasts. Cytotrophoblasts were cultured at 
8 x 1 05 /m.L in DJ\,!EM supplemented with 100 units/mL penicillin, I 00 IJ.g/mL 
streptomycin, I 00 Jlg/mL kanamycin, 2.5 JJg/mL Ftmgizone and 20% FCS in 24-well 
Ntmclon culture plates. Culture medium was collected and replaced with fresh medium 
every 24 h. After centrifugation, the supernatants were stored at -20 oc tmtil assayed for 
PAI-l using Imubind PAI-l ELISA kits (American Diagnostica). Results shown are the 
mean and S.E. from quadruplicate cultures. 
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formation., resulting from plasminogen-dependent hydrolysis of S-2251. These curves 
were obtained by non-linear curve-fitting and represent the best fit to the experimental 
data In each case, the progress curve for pNA formation could be described by a 
quadratic polynomial (y=a+bx+c~), which had been predicted from the expected kinetics 
of plasmin generation and S-2251 hydrolysis (see Chapter 2). Plasmin activity, which is 
proportional to plasmin concentration, was calculated as the first derivative of these 
quadratics (y•=b+2cx). Thus., a linear increase in plasmin activity with time was obtained 
(Fig. 4.4B ). Computation of the rates of plasmin generation as the second derivative of 
the quadratic equations describing the progress of plasminogen-dependent pNA formation 
yielded a constant (y,.=2c) at each seeding density. The constant rate of plasmin 
generation implies that cultured villous trophoblasts maintain their PA activity at a 
constant level over the time investigated Fig. 4.4C demonstrates that at a ftxed 
plasminogen concentration (0.28 J,LM) .. the rate of plasmin formation plotted as a function 
of seeding density is approximately linear in the range between 1.5 and 3.0 x 10.5 
cytotrophoblasts/well. 
Fig. 4.5 shows the progress curve of S-2251 hydrolysis in the absence of 
plasminogen. A non-linear increase in pNA accumulation with time was obtained. The 
results obtained indicate the presence of trophoblast secreted proteases that are capable of 
hydrolyzing S-2251 in the absence of plasminogen. However, the magnitude of 
absorbance values arising from plasminogen independent cleveage of S-2251 was always 
much smaller than that observed in the presence of plasminogen. 
Fig. 4.4. Effect of seed cell deosity on plasminogen activation by trophoblases. Villous 
cytotrophoblasts were plated at varying densities and cultured in the presence of 20% FCS 
for 48 h. Trophoblast cultures were then washed and incubated in serum-free medium 
containing 0.4 mM S-2251 in the presence or absence of 0.28 J.LM Glu-plasminogen. 
Hydrolysis of S-2251 was measured by recording the appearance of pNA at 405 nm. 
Plasminogen-dependent hydrolysis of S-2251 was calculated as the difference between 
absorbances measured in the presence and absence of plasminogen. Progress curves of 
plasminogen-dependent pNA generation (A) were drawn by fitting quadratics to the 
experimental points representing the mean and S.E. of quadruplicate cultures. Plasmin 
activities (B) were obtained by taking the first derivative of the quadratic equations. The 
rates of plasmin generation (C) were obtained from the second derivative of these 
equations. 
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Fig. 4.5. Plasminogen-independent hydrolysis of S-2.251 by trophoblasu. Villous 
cytotrophoblasts were plated at varying densities and cultured in the presence of 20% FCS 
for 48 h. Trophoblast cultures were then washed and incubated in serum-free medium 
containing 0.4 mM S-2251. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm. The data shown are the mean and S.E. from quadruplicate 
cultures. 
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Plasmin generation by trophoblasts was also dependent on exogenously added 
plasminogen. Progress curves of pNA accumulation in the presence of varying 
concentration of Glu-plasminogen are shown in Fig. 4.6A. A plot of the initial rate of 
plasmin generation against Glu-plasminogen concentration resulted in a rectangular 
hyperbola (Fig. 4.6B). The hyperbola was transformed to a linear relationship when the 
variables were plotted in a double reciprocal manner (Lineweaver-Burk plot) (Fig. 4.6B., 
inset). This indicates that activation of plasminogen by cultured trophoblasts obeys 
Michaelis-Menten kinetics. 
Plasminogen-dependent accumulation of pNA was completely abolished by the 
addition of the plasmin inhibitor aprotinin (Fig. 4. 7)., confirming that it entirely results 
from plasmin-catalyzed hydrolysis of S-2251. 
4.2.3 Characterizaoon of trophoblast PA activity 
To determine which of the two known types of physiological plasminogen 
activators are responsible for the PA activity measured in villous trophoblast cultures, we 
examined the effect of neutralizing anticatalytic antibodies to u-P A and t-PA respectively 
on trophoblast plasminogen activation. The basal rate of plasmin generation was dose-
dependently reduced by the antibody to u-PA., and the highest antibody concentration 
resulted in nearly complete inhibition (Fig. 4.8). By contr~ the antibody to t-PA did not 
inhibit the activation of plasminogen (Fig. 4.9). Likewise, normal goat lgG that served 
as negative control for both the anti-u-PA and anti-t-PA IgGs had no effect (Fig. 4.10). 
The results therefore indicate that PA activity of human villous trophoblasts results from 
Fig. 4.6. Kinetics of Glu-plasminogen activation by trophoblasa .. Cultured trophoblasts 
(2 xiO'/well) were washed twice and incubated in serum-free medium containing 0.4 mM 
S-2251 and Glu-plasminogen at varying concentrations. Hydrolysis of S-2251 was 
measured by recording the appearance of pNA at 405 nm. Plasminogen-dependent 
hydrolysis of S-2251 was calculated as the difference between absorbances measured in 
the presence and absence of plasminogen. Progress curves of plasminogen-dependent 
pNA generation (A) were constructed by fitting quadratics to the experimental points 
representing the mean and S .E. of quadruplicate cultures. The rates of plasmin generation 
were obtained from the second derivative of these curves and plotted against the 
plasminogen concentration (B). The inset shows the data replotted in a double reciprocal 
manner. The value of Km was found to be 0.42 J,LM. 
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Fig. 4. 7. Inhibition of trophoblast-associated plasminogen acuvaaon by aprotinin. 
Cultured villous trophoblasts (2 x 10' per well) were washed and incubated in serum-free 
medium containing 0.4 mM S-2251 and aprotinin (Trasylol) at varying concentrations., in 
the presence or absence of 0.28 J.1M Glu-plasminogen. Hydrolysis of S-2251 was 
measured by recording the appearance of pNA at 405 nm. Plasminogen-dependent 
hydrolysis of S-2251 was calculated as the difference between absorbances measured in 
the presence and absence of plasminogen. Progress curves of plasminogen-dependent 
pNA generation were constructed by fitting quadratics to the experimental points 
representing the mean and S.E. of quadruplicate cultures. The rates of plasmin generation 
(inset) were obtained from the second derivative of these curves and expressed as 
percentage of the rate in control cultures with no aprotinin added. 
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Fig. 4.8. Inbibiuon of trophoblast plasminogen activauon by a neutralizing anttbody to 
u-PA. Cultured villous trophoblasts (2 x 105 per well) were washed and incubated in 
serum-free medium containing 0.4 mM S-2251 and anti-u-PA at varying concentrations~ 
in the presence or absence of 0.28 f,.lM Glu-plasminogen. Hydrolysis of S-2251 was 
measured by recording the appearance of pNA at 405 nm. Plasminogen-dependent 
hydrolysis of S-2251 was calculated as the difference between absorbances measured in 
the presence and absence of plasminogen. Progress curves of plasminogen-dependent 
pNA generation were constructed by fitting quadratics to the experimental points 
representing the mean and S.E. of quadruplicate cultures. The rates of plasmin generation 
(inset) were obtained from the second derivative of these curves and expressed as 
percentage of the rate in control cultures with no antibody addition. 
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Fig. 4.9. Effect of a neutraliziog antibody to t-PA on plasminogen acuvation by 
trophoblasts. Cultured villous trophoblasts (2 x 10' per well) were washed and incubated 
in serum-free medium containing 0.4 mM S-2251 and anti-t-PA at varying concentrations., 
in the presence or absence of 0.28 J..LM Glu-plasminogen. Hydrolysis of S-2251 was 
measured by recording the appearance of pNA at 405 nm. Plasminogen-dependent 
hydrolysis of S-2251 was calculated as the difference between absorbances measured in 
the presence and absence of plasminogen. Progress curves of plasminogen-dependent 
pNA generation were constructed by fitting quadratics to the experimental points 
representing the mean and S.E. of quadruplicate cultures. The rates of plasmin generation 
(inset) were obtained from the second derivative of these curves and expressed as 
percentage of the rate in control cultures with no antibody addition. 
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Fig. 4.1 0. Effect of normal goat lgG on plasminogen activation by trophoblasa. Cultured 
villous trophoblasts (2 x 10' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and normal goat IgG at varying concentrations, in the presence 
or absence of 0.28 f,.lM Glu-plasm.inogen. Hydrolysis of S-2251 was measured by 
recording the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-
2251 was calculated as the difference between absorbances measured in the presence and 
absence of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no antibody addition. 
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u-PA but not t-PA. 
4.2.4 Trophoblast! enhance plasminogen acuvauon iniuated by single-chain u-P A (pro-u-
P A) 
Cell surface binding of pro-u-PA and plasminogen is thought to enhance 
plasminogen activation through an increased plasmin mediated feedback activation of pro-
u-P A (Ellis et al., 1989; Duval-Jobe and Parmely .. 1994). Human term trophoblasts 
possess u-P A receptors, and the generation of plasmin initiated by trophoblast-botmd pro-
u-P A is accompanied by an accelerated conversion of pro-u-PA to u-PA (Zini et al., 
1992 ). We therefore sought to investigate whether activation of plasminogen is increased 
in the presence of trophoblasts. In these experiments, cultured trophoblasts were treated 
with aprotinin followed by acid treatment to inhibit trophoblast associated serine 
proteinases and remove cell-bound u-P A, respectively. After neutralizing the acidic 
buffer, the cultures were washed and cultured in serum-free medium containing 
plasminogen, S-225C and scu-PA. Plasminogen activation was simultaneously measured 
in the absence of trophoblasts, using the same concentrations of plasminogen, S-2251 and 
scu-PA. As shown in Fig. 4.11, scu-PA (0.1 nM) induced plasminogen activation is 
enhanced in the presence of trophoblasts as compared to fluid phase activation in the 
absence of trophoblasts. High (presumably saturating) concentrations of scu-PA did not 
accelerate plasminogen activation (data are not shown). No significant plasmin generation 
was detected in cultures treated with aprotinin and acidic buffer, indicating that 
endogenous u-P A or plasmin entrapped on the trophoblast surface during serum culture 
Fig. 4.11. Effect of trophoblasa on exogenous pro-u-P A induced plasminogen activation. 
Cultured villous trophoblasts (2 x 10' per well) were washed twice in indicator-free 
medium~ and the cultures were treated with 1000 K.I.U./m.L aprotinin (Trasylol) for 15 
min to inhibit trophoblast associated serine proteinases. Subsequently., the cells were 
incubated with 50 mM glycine-HCI buffer containing 0.1 M NaCI (pH 3.0) for 5 min to 
remove u-PA from the trophoblast surface. After neutralization with 0.5 M HEPES., 0.1 
M NaCl (pH 7.3) for 1 min followed by two washes with indicator-free medi~ pro-u-P A 
(0.1 nM) and S-2251 (0.4 mM) were added to the cultures. Hydrolysis of S-2251 was 
measured in the presence or absence of 0.28 J,LM Glu-plasminogen. Pro-u-PA induced 
hydrolysis of S-2251 was simultaneously measured in the absence of trophoblasts as well. 
Plasminogen-dependent hydrolysis of S-2251 was calculated as the difference between 
absorbances measured in the presence and absence of plasminogen. The data shown are 
the mean and S.E. from quadruplicate wells. 
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are not implicated in trophoblast-mediated enhancement of plasminogen activation. 
4.2.5 Inhibition of trophoblast PA activity by PAis 
156 
We demonstrated earlier in this chapter that cultured villous trophoblasts express 
both PAI-l and PAI-2. Here we show that exogenous PAis are efficient inhibitors of 
trophoblast-associated u-P A activity. Fig. 4.12 demonstrates the inhibition of trophoblast 
plasminogen activation by varying concentrations of recombinant PAI-l. The dose-
dependent inhibition of plasminogen activation by recombinant PAI-2 is shown in Fig. 
4.13. 
4.2.6 Regulation of trophoblast PA adivity by endogenous PAis 
Next .. we examined whether trophoblast u-P A activity is regulated by endogenously 
secreted PAis. Fig. 4.14 demonstrates that a neutralizing polyclonal antibody to PAI-l 
increases trophoblast PA activity in a dose dependent manner. An approximately sixfold 
enhancement was reached at 200 JJ.g/mL of antibody concentration. Normal goat IgG that 
served as negative control had no effect on PA activity of trophoblasts at the same 
concentrations (Fig. 4.10) The results again point to the capacity of human villous 
trophoblasts to produce PAI-l and indicate that the basal level of trophoblast PA activity 
is under autocrine control of PAI-l. 
We were tmable to obtain evidence for the regulation of trophoblast PA activity 
by PAI-2. Neither of the two different antibodies to PAI-2 tested increased trophoblast 
PA activity (Fig. 4.15) .. suggesting that these cultures may not secrete significant amount 
of PAI-2. 
Fig. 4.12. Inhibition of trophoblast plasminogen activadon by PAI-l. Cultured villous 
trophoblasts (2 x 105 per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and PAI-l at varying concentrations~ in the presence or 
absence of 0.28 JiM Glu-plasminogen. Hydrolysis of S-225 1 was measured by recording 
the appearance of pNA at 405 run. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no PAl -1 addition. 
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Fig. 4.13. Inhibition of trophoblast plaslllinogen activation by PAI-2. Cultured villous 
trophoblasts (2 x 10' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and PAI-2 at varying concentrations, in the presence or 
absence of 0.28 1-1M Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no PAI-2 addition. 
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Fig. 4.14. Enhancement of trophoblast plasminogen activation by anti-PAI-l. Cultured 
villous trophoblasts (2 x 10" per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and anti-PAI-l at varying concentrations~ in the presence or 
absence of 0.28 ~ Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no antibody addition. 
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Fig. 4.15. Effect of anti-PAI-2 on plasminogen acuvation by trophoblasts. Cultured 
villous trophoblasts (2 x I O' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and anti-PAI-2 at varying concentrations, in the presence or 
absence of 0.28 J,LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no antibody addition. 
c: 
0.8 c ·a 
... 
u-
=-
...-.. ~g 
II") 
.5 5 0 e u 
~ 0.6 a'O < "5.~ 
'-" 
--c 
< 1.) z ii ~ 
c. 
~ 0.4 0 
c 
0 
·-(U 
""" 0.2 C1) c 
C1) 
0 
0.0 
0 
200 
150 
100 
so 
0 
5 
10 100 
Anti-PAl-2(~gl~) 
10 15 20 25 30 35 
Time (hr) 
164 
Anti-PAI-2 
(Jlg/mL) 
• 50 
0 25 
• 12.5 
0 6.25 
.. 3.13 
A 1.56 
• 0.78 
v Control 
165 
4.2. 7 Modulauon of trophoblast PA activity by various compounds 
To defme modulators of trophoblast plasminogen activation., various substances 
known to be important in trophoblast development and invasiveness have been tested for 
their ability to alter the rate of plasmin generation in trophoblast cultures. 
4.2.7.1 Effects of c:ompoaena of the blood coagulation system 
Thrombin and activated protein C (APC) have been shown to modulate PA activity 
m endothelial cell cultures (Loskutoff,. 1979~ Sakata et al . ., 1985 ). As it has been 
suggested that these proteases may be involved in the pathogenesis of preeclampsia (Amar 
et al.,. 1986; de Boer et al.,. 1989; Espana et aL. 1991} where disturbed plasminogen 
activation occurs,. we have examined whether they also modulate PA activity in 
trophoblasts. Thrombin caused a dose dependent inhibition of trophoblast plasminogen 
activation,. which was complete at very low concentrations (Fig. 4.16). APC increased the 
plasminogen-dependent hydrolysis of S-2251 (Fig. 4.17). However., when the rates of 
plasmin generation were calculated,. no increased rates were obtained In fact,. at the 
highest concentration tested ( 16 nM) the time course of pNA generation was 
approximately linear, thus resulting in a zero rate of plasmin generation. This suggest a 
mechanism involving an initial stimulation of plasminogen activation (during the initial 
4-hour time interval when pNA accumulation is too low to be detected)., accompanied by 
later inhibition. 
4.2. 7.2 Effects of growdl facton/cytokines 
As shown in Fig. 4.18, EGF stimulated plasminogen activation in a dose dependent 
Fig. 4.16. Inbibition of trophoblast plasminogen activadon by thrombin. Cultured villous 
trophoblasts (2 x 105 per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and thrombin at varying concentrations~ in the presence or 
absence of 0.28 J.1M Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no thrombin addition. 
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Fig. 4.17. Effect of APC on plasminogen activadon by trophoblasCs. Cultured villous 
trophoblasts (2 x 10' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and APC at varying concentrations~ in the presence or absence 
of 0.28 J.lM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no APC addition. 
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manner. As little as I ng/m.L of EGF induced an increase in the rate of plasmin 
generation.. and maximal stimulation was reached at I 0 ng/mL. Likewise.. TGF -a.. a 
structural analog of EGF caused a dose dependent stimulation of PA activity (Fig. 4.19). 
We also sought to determine whether the EGF induced stimulation of trophoblast 
PA activity is accompanied by cellular proliferation and/or increased metabolic activity. 
To this en<L the MTI reductive cleavage of trophoblast cultures was determined following 
the measurement of PA activity in the presence of EGF. Fig. 4.20 shows that EGF does 
not appreciably change the capacity of trophoblasts to cleave MTI,. indicating that EGF 
stimulation of trophoblast PA activity is not connected to proliferation/increased metabolic 
capacity. 
To determine whether endogenous secretion of EGF has a role in regulating the 
basal level of PA activity .. trophoblasts were cultured in serum-free medium alone or with 
increasing doses of a neutralizing antibody to EGF. Fig. 4.21 shows that the antibody did 
not cause a decrease in plasminogen activation. This result suggests that term villous 
trophoblast cultures do not produce sufficient amount of EGF to modulate PA activity. 
Alternatively, EGF may be produced in a precursor form not recognized by the antibody. 
TGF-f3 has been reported to inhibit trophoblast PA activity in first trimester 
trophoblasts (Graham et aL. 1993,. 1994). Our experiments suggest,. however,. that similar 
inhibition does not occur in primary cultures of term villous trophoblasts. As 
demonstrated in Fig. 4.22,. TGF-f31 does not affect plasminogen activation in our cultures. 
Our results suggest that IGF-II (Fig. 4.23) and IL-1(3 (Fig. 4.24) have no 
Fig. 4.18. Stimulation of trophoblast plasminogen activaaon by EGF. Cultured villous 
trophoblasts (2 x 10.5 per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and EGF at varying concentrations., in the presence or absence 
of 0.28 J..LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm.. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S .E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no EGF addition. 
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Fig. 4.19. Stimulauon of trophoblast plasminogen activation by TGF-a. Cultured villous 
trophoblasts (2 x 1 O' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and TGF-a at varying concentrations., in the presence or 
absence of 0.28 J,LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 run. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S .E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no TGF-a addition. 
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Fig. 4.20. MIT reductive cleavage by cultured trophoblasts following EGF stimulation 
of plasminogen activation. PA activity of cultured villous trophoblasts was determined 
as described in Chapter 2. Subsequently, the cultures were washed twice with indicator-
free medium and incubated with MIT for 2 h. After solubilization the absorbance of the 
blue formazan was measured at 595 nm. The data shown are the mean and S.E. from 4 
wells. 
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Fig. 4.21. Effect of anti-EGF on plasminogen activa1ion by trophoblasts. Cultured villous 
trophoblasts (2 x I o' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and anti-EGF at vacying concentrations~ in the presence or 
absence of 0.28 J.LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no antibody addition. 
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Fig. 4.22. Effect of TGF-Pl on plasminogen acuvaaon by trophoblasts. Cultured villous 
trophoblasts (2 x l o" per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and TGF-~1 at varying concentrations, in the presence or 
absence of 0.28 ~-tM Glu-plasminogen. Hydrolysis of S-225 I was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no TGF-f31 addition. 
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Fig. 4.23. Effect of IGF-H on plasminogen activation by Crophoblasts. Cultured villous 
trophoblasts (2 x 105 per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and IGF-II at varying concentrations~ in the presence or 
absence of 0.28 J.LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no IGF-11 addition. 
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Fig. 4.24. Effect of IL-lj3 on plasminogen activaaon by trophoblasts. Cultured villous 
trophoblasts (2 x 10' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and IL-1(3 at varying concentrations~ in the presence or 
absence of 0.28 JJ.M Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S .E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no IL-l~ addition. 
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appreciable effect on trophoblast plasminogen activation. LPS, which is known to increase 
secretion of IL-l rl in trophoblasts (Librach et al.~ 1994 ), did not alter the activation of 
plasminogen either (Fig. 4.25). 
4.2. 7.3 Effeccs of hormones 
Treatment of trophoblast cultures with hCG caused an inhibition of plasminogen 
activation (Fig. 4.26). 
Dexamethasone elicited a dose-dependent decrease in the rate of plasminogen 
activation (Fig. 4.27). A significant decrease was noticed at 1 0-a M. Maximal inhibition 
was reached at 1 0-6 M. 
4.2.7.4 Effect of 8-bromo-cAMP, forskolin and PMA 
Finallyy the involvement of the protein kinase-A and -C pathways in mediating 
regulatory effects on trophoblast plasminogen activation was examined. We found that 
8-bromo-cAl\iP (Fig. 4.28) and forskolin (Fig. 4.29) that increases intracellular cAl\1P 
levels inhibited plasminogen activation. PMA~ howevery which is known to exert effects 
through the protein kinase-C pathway had no effect (Fig. 4.30). 
4.3 DISCUSSION 
Implantation and subsequent placentation are critically dependent on the controlled 
invasion of the maternal uterus by trophoblasts. This process is accomplished through 
coordinated interactions of several classes of molecules expressed at the matemo-fetal 
interface. Among these molecules, trophoblast-secreted proteases appear to play a central 
role in mediating trophoblast invasion, during which extensive ECM breakdown, tissue 
Fig. 4.25. Effect of LPS on plasminogen activation by trophoblasts. Cultured villous 
trophoblasts (2 x IO' per well) were washed and incubated in serum-free medium 
containing 0. 4 mM S-2251 and LPS at varying concentrations,. in the presence or absence 
of 0.28 J..LM Gin-plasminogen. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no LPS addition. 
187 
c 
0 200 
"i 
0.6 ... IJ-~e 150 
...-.... 
I:M)- ~ LPS (J.Lg/mL) c c ln ·- 0 100 0 E u ~ ~~ • 16 < c..~ so 0 8 ~-.._.... 0 
< u 4 0.4 a; 0 • z a= -5 -4 -3 -2 -1 0 1 2 
c.. [J 2 
c..-. 
• I 0 
c 6 0.1 0 
·- • 0.01 ~ 0.2 ~ 
-
v 0.001 0 
c 
• 0.0001 Q.) 0 ¢ Control 
0.0 
0 5 10 15 20 25 30 
Time(hr) 
Fig. 4.26. Inhibition of trophoblast plasminogen acuvation by hCG. Cultured villous 
trophoblasts (2 x 1 O' per well) were washed and incubated in serum-free medium 
containing 0.4 m.M S-2251 and hCG at varying concentrations~ in the presence or absence 
of 0.28 J..LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no hCG addition. 
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Fig. 4.27. Inhibition of ttophoblast plasminogen activation by dexamethasone. Cultured 
villous trophoblasts (2 x IO' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and dexamethasone at varying concentrations, in the presence 
or absence of 0.28 J,LM Gin-plasminogen. Hydrolysis of S-2251 was measured by 
recording the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-
2251 was calculated as the difference between absorbances measured in the presence and 
absence of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no dexamethasone addition. 
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Fig. 4.28. Inhibition of ttophoblast plasminogen activation by 8-bromo-cA.MP. Cultured 
villous trophoblasts (2 x l O' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and forskolin at varying concentrations., in the presence or 
absence of 0.28 J,.LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-225 I was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no 8-bromo-cA.MP addition. 
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Fig. 4.29. Inhibition of trophoblast plasminogen acavaaon by fors.kolin. Cultured villous 
trophoblasts (2 x I O' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and forskolin at varying concentrations~ in the presence or 
absence of 0.28 J,LM Glu-plasminogen. Hydrolysis of S-2251 was measured by recording 
the appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S .E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no forskolin addition. 
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Fig. 4.30. Effect of PMA on plsminogen acuvation by trophoblasts. Cultured villous 
trophoblasts (2 x IO' per well) were washed and incubated in serum-free medium 
containing 0.4 mM S-2251 and PMA at varying concentrations, in the presence or absence 
of 0.28 ~M Glu-plasminogen. Hydrolysis of S-2251 was measured by recording the 
appearance of pNA at 405 nm. Plasminogen-dependent hydrolysis of S-2251 was 
calculated as the difference between absorbances measured in the presence and absence 
of plasminogen. Progress curves of plasminogen-dependent pNA generation were 
constructed by fitting quadratics to the experimental points representing the mean and S.E. 
of quadruplicate cultures. The rates of plasmin generation (inset) were obtained from the 
second derivative of these curves and expressed as percentage of the rate in control 
cultures with no PMA addition. 
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remodelling and fibrin deposition occur. 
We investigated the mechanisms that control PA activity m human villous 
trophoblasts. The method employed for the measurement of trophoblast-mediated 
activation of plasminogen was adapted from Zini et al. (1992) who demonstrated the 
conversion of exogenous plasminogen to plasmin in the presence of trophoblasts,. using 
the synthetic plasmin substrate,. S-2251. In the present study,. human villous 
cytotrophoblasts purified from term placentas were cultured in the presence of fetal calf 
serum for 36 to 72 hours. During this period,. the great majority of mononuclear 
cytotrophoblasts differentiated to multinucleated trophoblast aggregates and syncytial units. 
At this stage the cultures were washed and maintained in serum-free medium during the 
plasminogen activation assay to ensure that serum proteases and protease inhibitors did 
not interfere with plasminogen activation by trophoblasts. Plasminogen activation was 
measured through plasminogen-dependent hydrolysis of S-2251 in the presence of 
trophoblasts. Trophoblasts remained viable during serum-free culture and were not 
adversely affected by increasing concentrations of plasmin generated during the assay. 
This implies that the assay measures only secreted plasminogen activator. and the 
possibility of measuring some plasminogen activator activity resulting from cell death is 
minimal. An advantage of this assay is that it allows continuous monitoring of 
plasminogen activator activity in the presence of added modulator(s) without the necessity 
of collecting and assaying conditioned media. The assay,. however,. was Wlable to detect 
early changes in trophoblast plasminogen activator activity due to low sensitivity of the 
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plasmin substrate~ S-2251. Although the use of more sensitive plasmin-specific 
fluorogenic substrates could possibly overcome this problem~ the relative unavailability 
of an expensive microplate fluorimeter would still hamper the extensive application of 
assays of this type. 
Activation of plasminogen by cultured trophoblasts produced parabolic progress 
curves of pNA accumulation. These curves could be transformed to linear progress curves 
of plasmin formation~ the slopes of which yielded constant rates of plasmin formation. 
Thus~ term villous trophoblasts in culture maintain steady PA activity at their syncytial 
stage. This fmding is consistent with the steady metabolic and non-proliferating state of 
the syncytium (Yui et al.~ 1994; see also Fig. 3.18). Apparently contrasting results have 
been reported by Zini et al. ( 1992 ). These authors found that human term trophoblasts 
in culture expressed gradually declining numbers of urokinase receptors accompanied with 
a parallel reduction in antigenic u-P A concentration of trophoblast conditioned medium. 
This suggests that PA activity may decrease during in vitro differentiation of 
cytotrophoblasts into syncytiotrophoblasts. However~ PA activity is determined by 
complex interactions between several elements of the plasminogen activation syste~ 
including urokinase receptor affinity, PAl activity and the number and affmity of 
plasminogen receptors expressed on the cell surface~ the balance of which may result in 
a steady PA activity. 
PA activity of villous trophoblast cultures was found to result from u-P A but not 
t-PA. Furthermore, cultured trophoblasts demonstrated only u-PA immunoreactivity by 
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immunocytochemistry. These findings confirm earlier observations that human term 
trophoblasts synthesize and secrete u-PA (Queenan et aL. 1987; Zini et al., 1992). 
Production of u-P A by our cultures is entirely due to villous trophoblasts, because lll..A-
positive extravillous cytotrophoblasts, macrophages, endothelial cells and fibroblasts are 
completely eliminated through the immunomagneti.c purification step employed 
Interestingly, we were l.Dlable to detect any u-P A immunoreactivity in trophoblasts in situ. 
By contrast, occasional macrophages in the placental villi expressed u-PA. One 
explanation for the lack of imm1mostaining in trophoblasts in situ may be that paraffin 
embedment of the placental tissue reduced the number of u-P A epitopes on trophoblasts 
below detection level. To our knowledge, no report has been so far published on 
successful localization of u-PA in term trophoblasts .. although u-PA was previously 
detected in villous and non-villous cytotrophoblasts, intermediate trophoblasts and 
syncytiotrophoblasts of early human implantation sites (Hofmann et al., 1994 ). 
In contrast to term trophoblasts .. cultures established from rtrst trimester placentas 
appear to secrete both u-PA and t-PA (Graham et al., 1993, 1994). The reason why these 
invasive extravillous trophoblasts secrete t-PA in addition to u-P A is not clear. However, 
it seems beyond doubt that human trophoblasts produce u-PA at all gestational ages 
(Queenan et al., 1987; Zini et al., 1992; our results). Although we have no indication on 
which of the molecular forms of urokinase have been produced by our cultures, Percoll-
purified human term cytotrophoblasts, which are largely of the villous variety .. are known 
to synthesize urokinase in the single-chain form (prourokinase) (Queenan et al., 1987). 
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Trophoblast-associated pro-u-PA is converted to two-chain u-PA through a primarily 
plasmin(ogen)-depe:ndent mechanism (Zini et al., 1992). This suggests that during 
plasminogen activation tmder serum-free conditions, such as in our plasminogen activation 
assay, plasmin contamination of the plasminogen preparation and/or trace amotmts of 
plasmin associated with the trophoblast surface in serum culture may have an important 
role in initiating the activation of plasminogen by trophoblasts. 
Plasminogen activation in U937 cells has been shown to be more efficient on the 
cell surface than in solution. The enhancement of plasmin generation on the cell surface 
is due primarily to an enhanced plasmin-mediated feedback activation of receptor-bo1Dld 
pro-u-PA (Ellis et al., 1989, 1991; Duval-Jobe and Parmely, 1994). Although accelerated 
conversion of cell-botmd pro-u-PA to u-PA had been also demonstrated in trophoblasts 
(Zini et al., 1992 ), direct evidence for trophoblast-mediated potentiation of plasminogen 
activation was lacking. In this study, we have shown that plasminogen activation initiated 
by exogenous pro-u-P A progressed more rapidly in the presence of villous trophoblasts 
than in solution in the absence of trophoblasts. This finding is consistent with an 
enhanced plasmin-mediated feed-back activation of pro-u-P A on the trophoblast surface. 
Our immunocytochemical results showed that villous trophoblasts express PAI-l 
and PAI-2 both in vivo and in vitro. In addition, PAI-l production has been verified in 
culture, using ELISA. In agreement with previous investigations (Feinberg et al., 1989; 
Estelles et al., 1994), weak PAI-l immunoreactivity was observed in the syncytium of 
term placentas in situ. In culture, however, nearly all trophoblasts showed moderate to 
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strong diffuse as well as punctate PAI-l staining. The staining pattern observed may 
suggest that some PAI-I is associated with focal adhesions, although the extracellular 
location of PAl -1 could not be m1equivocally determined because of permeabilization of 
the cells prior to immunocytochemistry. By contr~ Feinberg et al. (1989) claimed both 
intra- and extracellular location for PAI-l in cultured trophoblasts. 
PA activity of our trophoblast cultures was specifically augmented by a 
neutralizing antibody to PAI-l and inhibited by exogenous PAI-l. This finding suggests 
that the basal u-PA activity is 1.Dlder autocrinelparacrine control by trophoblast-secreted 
PAI-l. The general model of PAI-l modulation of cell-surface proteolytic activity 
proposed by Blasi et al. (1993) may apply to trophoblast plasminogen activation, too. 
Accordingly, receptor-bound u-PA at focal contact sites is inhibited by PAI-l. In this 
process, covalent u-PA:PAI-1 complexes are formecL internalized and degraded. The u-P A 
receptor itself is also internalized but it recycles back to a different position on the cell 
surface. The relocated u-PAR binds another u-PA molecule and the cycle starts again. 
This mechanisms creates continuously changing proteolytically active and adhesion 
promoting areas required for cell movement, adhesion and invasion. Some evidence that 
trophoblast PA activity may also be regulated through u-PA:PAI-1 complex formation has 
come from the work of Zini et al. (1992). After trophoblasts cultured in serum-free 
medium had been incubated with 12'1-prourokinase and plasminogen, the authors 
demonstrated radioactivity that upon SDS-PAGE migrated with sizes corresponding to 
those of u-PA:PAI-1 complexes. 
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In accord with previous investigations (Astedt et al.~ 1986~ Feinberg et al., 1989; 
Estelles et al., 1994) we demonstrated strong PAI-2 immunostaining in the syncytium of 
term placentas in vivo. Interestingly~ cultured trophoblasts stained weakly and very 
inconsistently for PAI-2. Thus, our results are similar to those reported by Feinberg et 
al. ( 1989) who observed a mosaic pattern of PAI-2 immtmoreactivity with variable 
intensity. The role of PAI-2 in the regulation of trophoblast PA activity is not clear. 
Although exogenous recombinant PAI-2 completely inhibited PA activity of cultured 
trophoblasts .. we were tmable to obtain evidence for the involvement of secreted PAI-2 in 
modulating trophoblast PA activity. One possible explanation for this is that PAI-2 is not 
secreted by our cultures in sufficient amount to compete with PAI-l which inhibits u-P A 
with a second order rate constant 10 times higher than that for the interaction of PAI-2 
with u-PA (Andreasen et al ... 1990). In fact .. PAI-2 appears to be secreted at much lower 
concentrations in trophoblast culture, and its secretion starts considerably later than that 
ofPAI-1 (Zini et al ... 1992). 
Regulation of PA activity has not been studied extensively in human trophoblasts. 
Expression of the components of the trophoblast plasminogen activation system is a 
developmentally tightly regulated process.. linked to trophoblast differentiation and 
invasion (Feinberg et al ... 1989; Zini et al ... 1992~ Multhaupt et al ... 1994). Despite the 
obvious importance of the area.. comparatively few studies have been conducted to 
determine the factors that regulate the activation of plasminogen by human trophoblasts 
(Martin and Arias~ 1982; Queenan et al ... 1987; Milwidsky et al ... 1993; Yagel et al ... 1993; 
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Graham et al.~ 1993 ~ 1994 ). In this thesis, various compounds, including proteases, 
growth factors/cytok.ines, and hormones, have been tested for their ability to modulate 
plasmin generation in primary villous trophoblast cultures established from term human 
placentas. 
This study provides evidence that components of the blood coagulation system 
have the potential to modulate trophoblast plasminogen activation. The addition of 
thrombin to trophoblast cultures caused a dose dependent loss of PA activity. A similar 
thrombin-induced reduction in PA activity had been reported earlier in bovine endothelial 
(Loskutoff~ 1979) and human fibrosarcoma HT -1080 cell cultures (Osada et al., 1991 ). 
Thrombin has profound effects on cell-associated fibrinolysis. Most of our knowledge in 
the area has come from investigations conducted in endothelial cell cultures. Exposure 
of cultured human endothelial cells to thrombin stimulates secretion of t-PA (Levin et al.~ 
1984~ Gelehrter and Smyczer-Laszuk, 1986; Hanss and Collen, 1987; Van Hinsbergh et 
al., 1987~ Dichek and Quertermous~ 1989) and u-PA (Van Hinsbergh et al., 1987~ Shatos 
et al., 1995) antigens. The enhanced PA secretion is active site dependent and appears 
to result from increased synthesis (Dichek and Quertennous, 1989~ Shatos et al., 1995). 
Thrombin has also been reported to stimulate acute release (completed in minutes) of t-PA 
and u-PA from human endothelial cells (Booyse et al., 1986; Schrauwen et al., 1995). 
Thrombin enhances PAl -I secretion and synthesis in cultured endothelial ( Gelehrter and 
Smycer-Laszuk~ 1986; Hanss and Collen; Van Hinsbergh et al.., 1987; Dichek and 
Querterm.ous, 1989; Heaton et al., 1992) and vascular smooth muscle cells (Noda-Heiny 
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et al., 1993; Cockell et al., 1995). In addition, experiments carried out with endothelial 
cells have led to the realization that thrombin can directly inactivate and degrade PAI-l 
even in the absence of cells (Hanss and Collen" 1987; de Fouw et aL, 1987). Thrombin 
has been fotmd to modulate u-PA binding at the cell surface. This effect appears to 
involve both new u-PAR synthesis and an increased cleavage of u-PAR by possible 
involvement ofPI-PLC (Miles et al., 1988; Reuning and Bang, 1992; Reuning et al., 1994; 
Li et aL. 1995; Noda-Heiny and Sobel" 1995}. Thrombin induced stimulation of 
plasminogen binding has also been reported (Miles et aL, 1988). Finally, thrombin is 
known to catalyze conversion of prourokinase to an inactive two-chain form that cannot 
be activated by plasmin, plasma kallikrein and factor XIIa (Ichinose et al., 1986). The 
thrombin mediated inactivation of prourokinase is accelerated in the presence of soluble 
thrombomodulin (de Mtmk et al., 1991; Wilhelm et al., 1994 ). From the foregoing it is 
clear that thrombin has the ability to modulate the plasminogen activation cascade at 
numerous levels. At present" nothing is known on the mechanisms that brought about the 
loss of PA activity in trophoblasts. The fibrinolytic system of the trophoblast lining at the 
intervillous surface of placental villi and in spiral arteries probably functions to maintain 
proper nonthrombogenicity" similar to that on the endothelial surface. As 
thrombomodulin, a binding protein for thrombin at the endothelial surface (Esmon, 1995) 
has been also localized in the microvilli of syncytiotrophoblasts (Matsumoto et al., 1987), 
thrombin may directly interact with various components of the fibrinolytic system while 
actually boWld to thrombomodulin on the trophoblast surface. The thrombin induced 
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reduction in trophoblast PA activity may serve as a mechanism that regulates fibrin 
deposition in spiral arteries and intervillous spaces. The significance of such a mechanism 
in the pathogenesis of preeclampsia, where excessive fibrin deposition (Kanfer et al.~ 
1996)~ coagulation activation (de Boer et aL~ 1989; Espana et al.~ 1991) and depressed 
fibrinolysis occur~ also remains to be determined. 
Activated protein C (APC), another component of the coagulation system, 
stimulated PA activity of cultured trophoblasts. Protein C is a vitamin K-dependent 
glycoprotein that circulates in the plasma as the zymogen for the serine proteinase APC. 
Activation of protein C is carried out by the thrombin-thrombomodulin complex. The 
resultant APC possesses both anticoagulant and profibrinolytic properties (Halkier, 1991 ~ 
Comp and Esmon, 1981; Esmon, 1995). APC increased the fibrinolytic activity in cellular 
extracts and conditioned media of cultured endothelial cells. This effect was also 
observed when APC was added to conditioned media collected from untreated cultures 
(Sakata et al., 1985). Moreover, APC treatment of endothelial cell cultures or of 
conditioned medium in the absence of cells caused a rapid decrease in PAI-l activity 
(Sakata et al., 1985; Van Hinsbergh et al., 1985; de Fouw et al., 1987). These results 
suggested a partially or entirely cell-independent decrease in PAI-l activity and a 
consequent increase in the fibrinolytic activity. The APC induced inactivation of PAI-l 
is associated with the formation of APC-PAI-1 complexes (Sakata et al., 1986; de Fouw 
et al., 1987) and with the appearance of a 42 kD irreversibly inactivated form of PAI-l 
(de Fouw et al, 1987). APC does not react with inactive (latent) PAI-l and the active 
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site of APC is also required for the formation of enzyme-inhibitor complexes and for the 
degradation of PAI-l to occur (de Fouw et al.~ 1987). 
At present~ it is difficult to assess the significance of the fmding that APC 
stimulates plasminogen activation by trophoblasts. As the second order rate constant for 
the inhibition of APC by PAI-l is about three orders of magnitude lower than that for the 
inhibition of plasminogen activators, APC can only compete with plasminogen activators 
for complex fomation with PAI-l if its concentration is very much higher than those of 
plasminogen activators~ or the interaction of APC with PAI-l is accelerated with some 
mechanism (Fay and Owen, 1989). Although activation of protein C can occur on the 
surface of the endothelium (Esmon, 1995), cellular potentiation of APC induced PAI-l 
inactivation has not been reported Recently, APC was fotm.d to facilitate basement 
membrane invasion by tumor cells, including a choriocarcinoma cell line (SMT -eel), most 
probably via a mechanism that involves direct inactivation of PAI-l (Kobayashi et al.,. 
1994 ). Hence,. it is possible that APC, formed as a result of coagulation activation,. 
promotes invasion and/or lysis of fibrin by normal trophoblasts in vivo. These proposed 
roles for APC would be consistent with the reduced protein C level observed in 
preeclampsia (Amar et al., 1986) where decreased fibrinolysis and impaired trophoblast 
invasion occurs. 
Epidermal growth factor (EGF) and its structural analog, transforming growth 
factor-a (TGF-a) were found to increase trophoblast PA activity. These rmdings are in 
line with the recently reported stimulatory effect of EGF on u-PA activity of mouse 
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blastocyst outgrowths (Harvey et al.~ 1995). EGF may affect plasminogen activation at 
various levels of the plasminogen activation cascade. Stimulation of PA synthesis has 
been reported in a variety of cell types (Lee and Weinstein~ 1978; Grimaldi et al.~ 1986; 
Stoppelli et al.~ 1986~ Galway et al.~ 1989; Kessler and Markus .. 1991: Mawatari et aL, 
1991; Jarrard et al.~ 1994). Several examples of EGF induced modulation of PAI-l 
(Thalacker and Nilsen-Hamilton .. 1987; Lucore et al.~ 1988) or u-PAR (Boyd, 1989; 
Estreicher et al.~ 1989; LlDld et al ... 1995) expression are also known. EGF may even be 
implicated in the process of initiating the activation of plasminogen .. because its binding 
protein (EGF-BP) .. a serine proteinase .. becomes activated upon releasing from the 
(EGFh(EGF-BPb complex (Taylor et al. .. 1970; Server et al., 1976), and the active 
proteinase is capable of converting pro-u-PA to active u-PA both in solution and on the 
cell surface (Wolf and Brown, 1995). Thus, it is conceivable that the stimulatory effect 
of EGF on trophoblast PA activity results from the regulation of more than one component 
of the plasminogen activation system. Stimulation of PA activity occurs in the absence 
of cellular proliferation (see Fig. 4.20), which suggest that trophoblast plasminogen 
activation and proliferation are not necessarily interconnected. Lack of proliferation in 
our trophoblast cultures upon EGF stimulation confirms the generally accepted view that 
syncytiotrophoblasts do not possess any proliferative potential (Benirschke and Kaufmann, 
1990). Furthermore~ our observations are consistent with those of Morrish et al. (1987) 
who reported EGF induced differentiation of term cytotrophoblasts into 
syncytiotrophoblasts without cell proliferation. Whether induction of PA activity by EGF 
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has relevance to syncytium formation remains to be elucidated 
EGF affects trophoblast ftmction in various ways. It stimulates proliferation of 
cytotrophoblasts in very early ( 4-5 week) placentas (Maruo et al.~ 1992), inhibits cytokine 
induced apoptosis of term cytotrophoblasts and syncytium (Garcia-Uoret et al., 1996), and 
is also involved in trophoblast differentiation (Morrish et aL, 1987~ Maruo et al., 1987, 
1992 ). Of particular interest are the observations suggesting that EGF is implicated in 
implantation and trophoblast invasion. These include: (I) Maternal estrogen induces the 
synthesis of EGF by the murine uterus at the time of implantation. However, EGF is not 
detected in the uterus if implantation has been delayed by ovariectomy (Huet-Hudson et 
al., 1990), (2) EGF receptor protein is downregulated in the blastocyst trophoectoderm 
during delayed implantation caused by ovariectomy, and subsequent estrogen 
administration restores both EGF receptor expression and implantation (Paria et al., 1993 >~ 
(3) Production of trophoblast invasion-promoting proteases such as u-P A and MMP-9 is 
enhanced by trophoblast outgrowths of cultured blastocysts exposed to EGF, at the time 
which coincides with trophoblast invasion in vivo (Harvey et al., 1995), (4) EGF and its 
analog, TGF-a have been also shown to stimulate mouse trophoblast outgrowths in vitro 
(Machida et al., 1995), (5) mouse blastocysts having no EGF receptors die at various 
stages of gestation or shortly after birth (Threadgill et al., 1995; Sibilla and Wagner, 
1995), (6) EGF upregulates invasion of both fust trimester and term cytotrophoblasts 
purified from human placentas (Basset al., 1994). It should be added, however~ that lack 
of effect of EGF and TGF-a on trophoblast invasiveness has also been reported (Lysiak 
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et al.., 1994) so that this question remains to be further investigated Our observation that 
EGF stimulates plasminogen activation by syncytial trophoblasts suggests that this may 
also be the case in invasive trophoblasts. One can also speculate that EGF stimulation of 
plasminogen activation by villous trophoblasts may be involved in controlling intervillous 
fibrin deposition or fusion of cytotrophoblasts into syncytiotrophoblast. 
We have fotmd that TGF-a also stimulates plasminogen activation in human 
villous trophoblasts. This is not surprising, because the biological functions of TGF-a. are 
linked to its ability to activate the EGF receptor (Burgess~ 1989). Other EGF receptor 
ligands so far described include heparin-binding EGF-like growth factor (HB-EGF), 
amphiregulin and betacellulin (Willey et al.~ 1995). One can hypothesize that these 
ligands also have the ability to stimulate trophoblast plasminogen activation. Furthermore, 
it is also conceivable that EGF, HB-EGF, TGF-a and amphiregulin, which are all 
produced in the uterus during the peri-implantation period (Das et al.~ 1994; Cross et al., 
1994~ Willey et al.~ 1995), act in concert to upregulate trophoblast PA activity in a 
paracnne manner. 
Whether upregulation of trophoblast PA activity by EGF and TGF-a is mediated 
via autocrine and/or paracrine mechanisms remains to be determined. Our finding that a 
neutralizing monoclonal antibody to EGF did not affect trophoblast plasminogen activation 
argues against an autocrine mechanism. EGF receptors have been detected in both villous 
and extravillous (invasive) trophoblasts at all gestational ages (Maruo et al., 1987~ 
Hofmann et al., 1992; Miih.lhauser et al., 1993). EGF and TGF-a appear to be 
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synthesized by the mouse endometrium (Huet-Hudson et al.~ 1990; Tamada et al.~ 1991 
Bioi Reprod 45:365) and are also produced in the human decidua (Haining et al., 1991). 
However., the synthesis of these growth factors by trophoblasts is Wlcertain. TGF-a but 
not EGF m.RNA transcripts were detected in whole mouse blastocysts (Rappolee et al., 
1988). In humans., EGF immunostaining has been detected in trophoblasts (Hoffman et 
al.~ 1992; Chia et al., 1995), but there is no consensus as to whether EGF is synthesized 
by trophoblasts themselves (Amemiya et al., 1994; Basset al., 1994; Chia et aL, 1995). 
Similarly., TGF-a is present in trophoblasts (Lysiak et al . ., 1993 )~but no m.RNA transcripts 
could be demonstrated (Bass et al., 1994 ). Taken together, the available information 
suggests that trophoblast PA activity is likely to be controlled through EGFffGF-a 
mediated paracrine (maternal) mechanisms~ although autocrine mechnisms may also exist. 
Other growth factors such as TGF-~ .. IL-1~ .. IGF-ll and known to be relevant to 
trophoblast development., had no appreciable effect on trophoblast PA activity. TGF-f3 
is a major regulator of cell proliferation and differentiation, extracellular matrix 
composition., and pericellular proteolytic activity (Hsuan et al., 1989; Keski-Oja et al.., 
1991). It usually inhibits both cell growth and PA activity~ although growth inhibition in 
association with enhanced PA activity has been also reported (Keski-Oja and Koli., 1992). 
TGF-J3 often simultaneously regulates the secretion of plasminogen activators and their 
inhibitors., and thus the net PA activity reflects a new balance between their altered levels. 
A major mechanism whereby the human decidua limits trophoblast invasiveness involves 
the decidual secretion of TGF-13 (Graham and Lala, 1991; Graham et al.., 1993). As first 
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trimester trophoblasts themselves secrete TGF-Jl. an autocrine invasion regulating loop 
may also function. TGF-~ appears to inhibit invasiveness of normal rust trimester 
trophoblasts in several ways (see Chapter 1), including downregulation of u-PA activity. 
However~ it does not affect PA secretion by malignant trophoblasts cells. In this thesis, 
I have pointed out that TGF-J3 does not have an effect on PA activity by cultured term 
villous syncytiotrophoblasts. One possible explanation for this finding is that PA activity 
of syncytiotrophoblasts may be already inhibited by endogenously secreted TGF-J3. The 
fact that in vivo, villous syncytiotrophoblasts., as opposed to villous and extravillous 
cytotrophoblasts, express TGF-J3 (Lysiak et aL., 1995) gives some support for the idea 
IL-l., a known regulator of plasminogen activation in endothelial cells (Bevilacqua 
et al.~ 1986~ Michel and Quertermous, 1989; Loskutoff, 1991), has been shown to 
stimulate invasion and MMP-9 activity of frrst trimester cytotrophoblasts (Librach et al ... 
1994 ). As cytotrophoblasts produce IL-l~ and express IL-l receptor (Librach et al ... 
1994), and the human decidua is also a source of IL-l (Romero et al . ., 1989) it is likely 
that both autocrine and paracrine mechanisms have roles in regulating invasion and 
protease secretion by trophoblasts. At present., no information is available on whether frrst 
trimester trophoblasts can regulate the activation of plasminogen. However, as our results 
show, IL-l does not have a significant effect on PA activity in term trophoblasts. We also 
fol.Uld that bacterial endotoxin (lipopolysaccharide., LPS) did not alter PA activity of term 
trophoblasts either. IL-l secretion of cultured trophoblasts has been fomd to be 
stimulated by LPS (Taniguchi et al., 1991; Librach et al., 1994 ). Hence .. the inability of 
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LPS to alter PA activity gives further support to our conclusion that IL-l may not regulate 
PA activity in term trophoblasts. 
Our results indicate that IGF IT has no appreciable effect on plasminogen activation 
in term trophoblasts. The insulin-like growth factors (IGF I and IGF II) are single chain 
polypeptides that are structurally homologous to proinsulin (Cohick and Clemmons~ 1993). 
They regulate proliferation,. differentiation (Cohick and Clemmons,. I 993 ),. and migration 
(Manske and Bade,. 1994) of a variety of cell types. IGF-1 induced stimulation of PA 
activity has been also reported (Tranque et al.~ 1994). The IGFs exert most of their 
biological actions through the IGF-1 receptor but also bind to the IGF-IT and insulin 
receptors as well as their specific binding proteins (IGFBPs). The latter inhibit or enhance 
the biological actions of IGFs at the cellular level (Cohick and Clemmons, 1993). IGF-1 
is expressed in syncytiotrophoblasts (Wang et al.,. 1988),. while the expression of IGF-ll 
is cytotrophoblast specific (Ohlsson et al., I 989). Furthermore,. cytotrophoblasts have been 
shown to express both IGF-1 and IGF-II receptors (Ohlsson et al.,. 1989). The expression 
of IGF-II have been also described in the early pregnancy decidua (Giudice et al.,. 1993),. 
and both trophoblasts and the decidua are known to express IGFBPs (Waites et al., 1989~ 
Petraglia et al.,. 1996). Thus,. the localization of the expression of IGFs .. their receptors 
and binding proteins suggest autocrine/paracrine regulation by IGFs of trophoblast 
functions. IGF-II and IGFBP-1 have been reported to stimulate trophoblast invasion 
(Lysiak et al., 1993, 1994) and migration (Irving and Lala,. 199 5 ). In the light of our 
results,. the IGF-ll induced stimulation of trophoblast invasiveness/migration may not be 
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mediated by a mechanism involving plasminogen. 
In this study, I have shown that hCG inhibits PA activity in term trophoblasts. 
Inhibition of trophoblast urokinase activity has been first described in human first 
trimester cultures (Milwidsky et al.., 1993; Y agel et al.., 1993 ), using a methodology 
different from that employed in this thesis. Specifically, urokinase-like activity was 
determined by measuring aprotinin-resistant amidolytic activity with substrate S-2444, in 
the absence of plasminogen. This method is based on the observation that aprotinin, a 
serine protease inhibitor., does not inhibit urokinase activity (Dan" et al., 1985; Mayer et 
al . ., 1986). In addition to its inhibitory effect on urokinase activity, hCG inhibits 
collagenase production by fust trimester trophoblasts (Lala et al., 1989), and this inhibition 
appears to result from decreased urokinase mediated activation of collagenase (Yagel et 
al., 1993). hCG has also been found to retard trophoblast invasion (Yagel et al., 1993), 
consonant with its inhibitory effect on the invasion promoting enzymes, u-PA and 
collagenase. As trophoblasts synthesize large amounts of hCG (Hoshina et al., 1982) and 
express hCG receptors (Licht et al., 1993)., they may have the ability to regulate their own 
invasiveness by an autocrine mechanism involving hCG induced inhibition of trophoblast 
u-P A activity. It is also possible that modulation of trophoblast urokinase activity by hCG 
has also some role in differentiation of cytotrophoblasts into syncytiotrophoblasts, 
considering that hCG is known to promote this process (Shi et al., 1993 ). 
At present, little is known on the role of hCG in the pathology of trophoblasts. 
Elevated hCG levels (Said et al., 1984; Hsu et al., 1994) and excessive suppression of 
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fibrinolytic activity (Bonnar et al., 1971; Yoshimura et al., 1985; Bonnar et al., 1990; 
Kanfer et al., 1996) have been reported in women with preeclampsia These observations 
together with the facts that hCG inhibits trophoblast u-PA activity and trophoblast 
invasion is impaired in preeclampsia (Brosens et al., 1972; Gerretsen et al., 1981; Khong 
et al., 1986; Meekins et al., 1994) suggest that one way in which hCG may be implicated 
in the pathogenesis of preeclampsia is by inhibition of trophoblast and perhaps systemic 
plasminogen activation. 
Addition of the synthetic glucocorticoid dexamethasone to human term trophoblast 
cultures suppressed PA activity in a dose-dependent manner. Glucocorticoids have been 
found to inhibit u-PA activity in nearly all cell types studied The response of t-PA 
activity to glucocorticoids is more variable: suppression., enhancement and lack of effect 
have all been reported (Dan" et al . ., 1985). Glucocorticoids may decrease PA activity in 
three major ways: (1) by inhibiting PA synthesis (Busso et al . ., 1986, 1987; Medcalf et al.., 
1986), (2) by an enhancement of PAl production (Bussa et al . ., 1987; Gelehrter et al . ., 
1987~ Grant and Medcalf, 1990), and by decreasing plasminogen binding on the cell 
surface (Pollanen., 1989). 
Dexamethasone has also been foWld to decrease PA activity of trophoblast cultures 
established from first trimester human placentas (Martin and Arias, 1982). In addition., 
Librach et al. ( 1994) reported that dexamethasone inhibited human cytotrophoblast 
metalloproteinase (MMP-9) activity and invasion. The fact that downregulation of MMP-
9 activity was observed in serum-free cultures suggests that dexamethasone exerts its 
2I6 
effect VIa a mechanism independent of plasminogen activation. Nevertheless. it is 
conceivable that under conditions when plasminogen is present. a reduction in 
metalloproteinase activity is linke~ at least in part, to dexamethasone induced suppression 
of plasminogen activation. 
We have shown that 8-Br-cA.MP and forskolin decrease PA activity in human 
trophoblasts. Elevation of intracellular cAMP level may regulate plasminogen activation 
at several levels. Activation of adenylate cyclase by forskolin or increasing cAMP content 
with 8-Br-cAMP induced t-PA mRNA in rat granulosa cells (Ohlsson et al ... 1988). By 
contrast, forskolin decreased t-PA mRNA levels in HT- I 080 human fibrosarcoma cells 
(Georg et al... I 990 ). Elevation of cAMP level has been reported to downregulate PA 
production in macrophages (Vassali et al., 1976, 1992) Forskolin decreased the synthesis 
of PAI-l in HT-1080 cells (Georg et al ... 1990). Treatment of endothelial cells with 
forskolin .. 3-isobutyl-1-methylxanthine (ffiMX) or dibutyril cAMP reduced P AI -1 secretion 
(Santell and Levin .. 1988). Evidence for the involvement of cyclic AMP dependent 
pathways in the regulation of u-PAR expression has been also presented (Langer et al ... 
1993). 
Agents that enhance the intracellular cAMP level have profowd effects on the 
expression of various endocrine tlmctions in human trophoblasts (Feinman et al. .. 1986; 
Zhou et al ... 1987~ Benoit et al., 1988; Nulsen et al .• 1988; Ringler et al ... 1989). In 
addition .. cultured cytotrophoblasts have been reported to raise their u-P A mRNA levels 
and u-PA secretion upon exposure to 8-bromo-cA:MP . However, this stimulation is 
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limited to the fust 24 h of culture. and u-P A mRNA and u-P A activity declined during 
the subsequent day (Queenan et al., 1987). It has been also shown that 8-bromo-cAMP 
treatment leads to a marked inhibition of ECM degradation by human term trophoblasts 
(Kliman and Feinberg, 1990). Our observation that both 8-bromo-cAMP and forskolin 
inhibit PA activity in trophoblasts is consistent with the above f'mdings and suggests that 
inhibition of plasminogen activation is implicated in the 8-bromo-cAMP induced inhibition 
of trophoblast mediated ECM degradation. Furthermore, our data suggest that cAMP 
dependent pathways are involved in mediating inhibitory effects on trophoblast 
plasminogen activation. 
PMA did not alter PA activity in our trophoblast cultures. Phorbol esters such as 
PMA have been reported to increase the synthesis of several components of the 
plasminogen activation system in various cell types (Dans et al., 1985 ~ Loskutoff et al., 
1989~ Picone et al., 1989 ~ Niiya et al., 1991 ). Thus, it is possible that PMA affects the 
expression of some components of the trophoblast plasminogen activation syst~ yet the 
net balance of these components (i.e. the PA activity) remains unaltered. At present, the 
effects of phorbol esters on the plasminogen activation system in trophoblasts is totally 
lDlknown. 
CIIAPIER5 
CONO,USION AND PERSPECTIVFS 
This study was undertaken to reveal some characteristics of the plasminogen 
activation system in human trophoblasts both in vivo and in culture. We have been 
successful in isolating and culturing pure villous cytotrophoblasts from human term 
placentas~ using a modification of the procedures originally described by Kliman et al. 
( 1986) and Douglas and King ( 1989)~ respectively. Villus cytotrophoblasts~ characterized 
as being cytokeratin positive as well as vimentin, HLA-ABC, HLA-DR and CD68 
negative, were isolated using sequential trypsinJDNase digestions of the selected placental 
villous tissue~ Percoll density gradient centrifugation and immunomagnetic removal of 
contaminating cells. The purity of our trophoblast cultures ensured that plasminogen 
J 
activation by villous trophoblasts could be studied in the absence of contaminating cells. 
We carried out immunocytochemical experiments to investigate the expression of 
the components of the plasminogen activation system in trophoblasts. The results, in 
accordance with previous findings (Feinberg et aL. 1989; Hofmann et al., 1994 ), 
demonstrate that trophoblasts express PAI-l and PAI-2 both in vivo and in vitro. As also 
shown earlier (Zini et al., 1992), u-PA has been expressed in culture, but could not be 
demonstrated in vivo. No immlDloreactive t-PA has been found in trophoblasts. 
Our results also support and extend previous observations (Queenan et al., 1987; 
Zini et al., 1992) that human term trophoblasts produce PA activity that results from u-P A 
but not t-PA secretion. In addition, we demonstrated that plasminogen activation by 
cultured trophoblasts followed Michaelis-Menten type kinetics. We also fom1d that 
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trophoblasts enhanced plasminogen activation initiated by pro-u-PA, which is consistent 
with previous fmdings that trophoblasts accelerate plasmin mediated conversion of pro-u-
PA to u-PA (Zini et al., 1992). 
Our data show that both PAI-l and PAI-2 are efficient inhibitors of trophoblast 
secreted u-PA, and u-PA activity is regulated by PAI-l through an autocrine mechanism. 
We have also shown that plasminogen activation by villous trophoblasts is modulated by 
a variety of agents. Components of the coagulation system appear to have roles in 
modulating trophoblast plasminogen activation, because thrombin inhibited, whereas 
activated protein C stimulated trophoblast PA activity. Of the growth factors/cytokines 
studied, EGF and its analog, TGF-a were found to stimulate plasminogen activation. 
Experiments with a neutralizing antibody to EGF suggest that EGF may not exert an 
autocrine regulatory influence on trophoblast PA activity. Our results are consistent with 
the recently published finding that u-P A activity secreted by cultured mouse blastocysts 
is enhanced by EGF (Harvey et al., 1995). Another important cytokine, TGF-~, which is 
known to inhibit PA activity in ftrst trimester trophoblasts (Graham et aL, 1993, 1994 ), 
has no effect in term trophoblasts. Hormones such as dexamethasone, a synthetic 
glucocorticoid or hCG, an important secretory product of syncytiotrophoblasts inhibit 
activation of plasminogen by trophoblasts. The inhibitory effect of dexamethasone and 
hCG in term villous trophoblasts is consistent with their inhibition of PA activity in first 
trimestertrophoblasts (Martin and Arias, 1982; Milwidsky et al., 1993; Yagel et al., 1993). 
Finally, agents that increase intracellular cAMP levels such as 8-bromo-cAMP and 
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forskolin inhibit trophoblast plasminogen activation~ suggesting that cAMP dependent 
mechanisms are involved in mediating negative regulatory effects on trophoblast 
plasminogen activation. 
Our findings may have relevance to several trophoblast functions. As plasminogen 
activation is implicated in mediating trophoblast invasiveness (Graham and Lala, 1992)., 
modulation of trophoblast PA activity by growth factors., hormones and coagulation 
products suggests that these molecules may have significant roles in controlling 
trophoblast invasion during implantation and placentation. These compotmds may also 
act as regulators of fibrin deposition at the sites of trophoblast invasion and on the luminal 
surface of syncytium covering the chorionic villi. In addition., we suggest that fusion of 
cytotrophoblasts into syncytium may involve the activation of plasminogen. This is an 
intriguing possibility that could be easily tested in vitro using neutralizing antibodies to 
u-P A and PAis., respectively. The above modulators of trophoblast activation may also 
be implicated in trophoblast pathology., especially in preeclampsia where disturbed 
invasion is associated with suppressed plasminogen activation. 
The process of plasminogen activation in trophoblasts 1s far from being 
characterized. A lot of work has to be done to clarify various aspects of the regulatory 
mechanism of plasminogen activation. Currently., very little is known about the regulation 
of u-P A synthesis and secretion (Queenan et al . ., 1987), and virtually no information is 
available regarding the compounds that regulate PAI-l and PAI-2 activity/production. 
Although the u-PA receptor has been characterized on trophoblasts (Zini et al .• 1992; 
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Multhaupt et al., 1994 )~ regulation of the receptor is not known. Mechanisms of 
plasminogen binding by trophoblasts have never been addressed and the details of 
trophoblast plasminogen activation kinetics also remain to be investigated. Determination 
of the kinetic parameters~ characterizing plasmin generation and pro-u-P A activation., could 
help tmderstand how the trophoblast surface may become a preferential site of 
plasminogen activation. Finally., the tmderlying mechanisms of the disordered 
plasminogen activation in trophoblast-related diseases such as preeclampsia need to be 
understood Identification of such mechanisms may have potential pathogenetic and 
therapeutic implications. 
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